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1 Introduction 
1.1 Overview 
Fungi make an enormous contribution to our life. The role of yeast in the production 
of alcohol and bread is well known. We consume fungi directly in the form of edible 
mushrooms and in cheese, which get their characteristic flavour and aroma from the 
presence of fungi. Fungi are also used for the production of antibiotics and enzymes 
for use in the food industry. Over the last decades Fungi have been used for the 
production of recombinant proteins,1-4 some of which have great therapeutic 
potential. Although infrequently recognised as important decomposers of organic 
detritus, Fungi play a significant role in degrading biological matter, such as fallen 
leaves. In a more negative note some fungi (for example member of the genus 
Aspergillus and Candida) are capable of causing serious life threatening infections5-7 
in immuno-compromised patients, and other fungi can be serious environmental 
contaminants. According to a recent publication less than 5% of fungal species are 
currently known,8 suggesting that millions of fungal species and therefore, potentially 
million of fungal bioactive natural products remain to be discovered.  
 
1.2 Fungi as a source of novel bioactive compounds 
Among all known producers of natural products, microorganism in general and fungi 
in particular represent a rich source of biologically active metabolites that find Wide-
ranging applications in medicine. Moreover, according to a more recent review,  of 
the New Chemical Entities to reach the market as drugs (covering all diseases) 
during the period 1981-2002, roughly 60% are either natural products, natural 
product-derived, natural product mimics, or biological (peptides or proteins) of natural 
origin.9,10 This is especially evident in the fields of cancer and infectious diseases, 
where over 60% and 75% of the drugs are of natural origin, respectively. Notable 
examples of these are from fungal origin. Two examples of useful bioactive fungal 
metabolites are lovastatin (1) and cyclosporin (2). 
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Lovastatin was first isolated from the culture broth of Aspergillus terreus  at Merck & 
Co. and has been representing the most successful drugs from nature for several 
years.11 Later the same compound, but named monacolin K, and related metabolites 
were isolated from the culture broth of Monascus ruber,12,13 Penicillium, and 
Aspergillus,14 respectively. Lovastatin is an important metabolite because of its 
activity. It functions by inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, a key enzyme of cholesterol biosynthesis (mevalonate pathway)15,16 
with a Ki value 6.4 X 10-10. Therefore, lovastatin (1) represents an interesting 
therapeutic principle for the treatment of hypercholesterolemia. It was introduced in 
the market by Merck in 1987. 
Cyclosporin A (2), a cyclic nonribosomal peptide was identified at Sandoz in 
Switzerland as an antifungal agent isolated from the culture broth of the fungus 
Tolypocladium inflatum, formerly classified as Trichoderma polysporum.17 In the 
course of more detailed pharmacological studies applying in vivo animal models 
cyclosporin displayed remarkable immunosuppressive properties.18-22 Only seven 
years after its first publication cyclosporin was commercialized by Sandoz (now 
Novartis) under the trade name Sandimmune. Cyclosporin is used in transplantation 
surgery as a drug that prevents organ rejection, without substantially affecting the 
immune response causing protection against bacterial infection. 
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 In our study we focussed mainly on the discovery of new fungal natural products 
acting on clinically relevant targets in inflammatory and infectious (microbial and viral) 
diseases. 
 
1.3 Inflammation  
1.3.1 Definition 
The symptoms of an inflammation (redness, edema, heat, pain and disturbed tissue 
function) result from complex pathological processes that include the increase of 
blood flow and vascular permeability, activation of humoral and cellular defence 
mechanisms, sensibilization etc. These processes are mediated by a variety of 
signalling molecules produced by mast cells, macrophages, granulocytes, platelets, 
lymphocytes, nerve ending, as well as by complement activation factors. The 
mediators belong to different chemical classes, such as biologically active amines 
(histamine, serotonin), proteins and peptides (hydrolytic enzymes, cytokines, growth 
factors, and antibodies), reactive oxygen species (superoxide anion, hydroperoxide, 
hydroxyl radicals) and lipids (platelet activating factors and prostaglandins).23-26 
These mediators initiate, maintain, aggravate, and modulate the course of a vast 
number of human disorders. Besides the huge number of proinflammatory players, 
the complexity of such processes is further increased by the involvement of 
endogenous antiphlogistics and immunomodulatory mechanisms. 
 
1.3.2 Anti-inflammatory drugs and their mechanism of action 
About 3,500 years ago in ancient Egypt, the Ebers papyrus recommended the 
application of a decoction of the dried leaves of myrtle to the abdomen and back to 
expel rheumatic pains from the womb. A thousand years later, Hippocrates 
recommended the juices of the poplar tree for treating eye disease, and those of 
willow bark to relieve the pain of childbirth and to reduce fever. All of these medicinal 
remedies contain salicylates.  Through the Middle Ages, further use of salicylates 
were found, such as plasters to treat wound and various other external and internal 
applications, including the treatment of menstrual pain and the discomfort of 
dysentery.  In China and other parts of Asia, salicylate containing plants have been 
applied therapeutically. The curative effect of Salix and Spirea species for example 
were even known to the early inhabitants of North America and South Africa.27 Due 
to these observations acetylsalicylic acid was synthesized guided by the natural 
Introduction 
 
4
 
salicylic acid, and nearly 100 years later, aspirin features as the most successful drug 
worldwide. However, its mechanism of action remained unclear until Ferreira, 
Moncada and Vane demonstrated in 1971 that aspirin and aspirin-like drugs inhibit 
the biosynthesis of prostaglandins.28  The discovery that each and every chemically 
large group of aspirin-like drugs, so called  non-steroidal anti-inflammatory drugs 
(NSAIDs), all act by inhibiting the enzyme involved in the generation of prostaglandin 
from arachidonic acid (cyclooxygenase, COX) provided an unifying explanation of 
their therapeutic actions and firmly established certain prostaglandins as important 
mediators of inflammatory diseases. Here, it should be noted that arachidonic acid 
leads not only to COX products, but also to leukotrienes via the 5-lipoxygenase 
pathway.29,30 In this context non-steroidal anti-inflammatory drugs such as diclofenac 
and indomethacin, have emerged as the most commonly used anti-inflammatory 
agents, including the therapy of rheumatoid arthritis. Many of these drugs target 
COX-1 rather than COX-2.  But due to the side effect including gastrointestinal 
ulceration and bleeding, renal damage and platelet dysfunction associated only with 
the inhibition of COX-1,31-34 the selective inhibition of enzyme subtypes COX-2 has 
become an important goal. Further works have reported that NSAIDs inhibit 3α-
hydroxy steroidehydrogenase (3α-HSD),35,36  and 12-0-tetradecanoylphorbol-13-
acetate (TPA)-induced edema.37,38 More recently kinases were believed to play also 
a crucial role in the expression and activation of inflammatory mediators.39 
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Fig. 1. The arachidonic acid cascade induced by COX 
 
In contrast with rheumatoid arthritis, gouty arthritis is mediated by the crystallisation 
of uric acid (UA) in the joints.40,41 Gout can be treated with drugs that either increase 
the urinary excretion of UA, or with xanthine oxidase (XO) inhibitors that block the 
terminal step of UA biosynthesis.42,43 The purine analogue allopurinol is yet the only 
XO inhibitor in clinical use. Unfortunately, it seems to be associated with an 
infrequent but severe hypersensitivity.44 Thus, the search for new potent inhibitors of 
these enzymes, which could be useful as lead structures for new anti-inflammatory 
and anti-arthritic therapeutics, plays a pivotal role.  
 
1.3.3 Fungal metabolites as anti-inflammatory agents 
To date only a few fungal metabolites including triterpenes from the culture broths of 
the fungus Penicillium griseofulvum,45 the fruiting body of the fungus Fomitopsis 
pinicola46 and Ganoderma colossum,47  and cyathane diterpenes from the fruiting 
body of the fungus Sarcodon glocaupus48 and Sarcodon scabrosus49 have been 
reported as anti-inflammatory agents. (Fig. 2) 
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Fig. 2. Selected anti-inflammatory fungal metabolites 
 
All these compounds exhibited their anti-inflammatory activity with diverse 
mechanisms of action. Fomitopinic acid A (3) and B (4) from the fruiting body of the 
fungus Fomitopsis pinicola have been reported to inhibit the activities of COX-1 and 
COX-2 with a significant selectivity for COX-2 for fomitopinic acid A (3); 
Colossolactone A (5) and D (6) from the fruiting body of the fungus Ganoderma 
colossum inhibited the enzyme 3α-hydroxysteroid dehydrogenase (3α-HSD); and the 
cyathane diterpenes glaucopine A (7), glaucopine B (8) from the fruiting body of the 
fungus Sarcodon glocaupus, as well as those isolated from the mushroom Sarcodon 
scabrosus, 19-O-oleoylsarcodonin A (9), 19-O-stearoylsarcodonin A (10) and 19-O-
linoleoylsarcodonin A (11) exhibited significant inhibitory activities towards the 12-0-
tetradecanoylphorbol-13-acetate (TPA)-induced edema of mouse ear. 
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2 Aim of the study 
The aim of this work is to examine selected fungi (filamentous fungi and mushrooms) 
from special habitats for their metabolic profiles and to evaluate their biological 
activities (anti-inflammatory, antimicrobial and antiviral, etc.). This includes: 
 
-The selection of strains on the basis of biological pre-screenings.  
 
-The cultivation and the optimisation of the cultivation conditions (nutrient type, pH, 
temperature and fermentation duration for filamentous fungi) of selected strains and 
fermentation on a big scale in order to have a large amount of crude extract. 
 
-The isolation and the purification of secondary metabolites from the extracts of 
microbial fermentation or from those of the fruiting bodies using chromatographic 
methods (i.e. Sephadex, silica gel column chromatography, PTLC, HPLC etc.). 
 
-The elucidation of the structures of purified metabolites using spectroscopic 
techniques such as ESI-MS, MS/MS, IR, UV, 1H NMR, 13C NMR, HMBC, COSY, 
HMQC and NOESY. 
 
-The evaluation of characterised secondary metabolites (known or new) for their 
inhibitory activity against enzymes involved in inflammation processes such as 3α-
hydroxysteroid dehydrogenase (3α-HSD), cyclooxygenase I (COX-1), 
cyclooxygenase II (COX-II), xanthine oxidase (XO), serine protease (α-
chymotrypsin), as well as for their inhibitory activity against growth promotion of 
various micro-organisms. 
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3 Results and discussion 
3.1 Evaluation and selection of the strains 
The selection of strains was based on biological pre-screening (we used 3α-HSD 
assay for the screening of anti-inflammatory compounds and agar diffusion assay for 
the pre-screening of antibacterial and antifungal metabolites) and chemical screening 
using analytical techniques such as TLC, HPLC and HPLC/MS. This procedure led to 
the selection of eight strains, Trichoderma crassum HKI 0471, Epicoccum sp. HKI 
0470, Lepista nebularis HKI 0411, Aspergillus sp. HKI 0472, Inonotus sp., Pholiota 
squarrosa, Phellinus pini DSM 5238 and Piptoporus betulinus. The results of pre-
screenings are showed in table 1. 
 
Activity Strain 
3α-HSD Antibacterial Antifungal 
Trichoderma crassum HKI 0471 - ++ +++ 
Epicoccum sp. HKI 0470 ++ + + 
Lepista nebularis HKI 0411 - +++ +++ 
Aspergillus sp. HKI 0472 ++ + + 
Inonotus sp.  +++ + + 
Pholiota squarrosa +++ + + 
Phellinus pini DSM 5238 +++ + + 
Piptoporus betulinus +++ ++ ++ 
-      not active  ++   active 
+     moderate active +++ strong active 
 
Table 1. Pre-screening’s results of selected strains 
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Trichoderma crassum
60 l Fermention
Mycelium Filtrate
Silica gel
CHCl3/MeOH 1-7:3
Sephadex LH-20
MeOH
Prep HPLC
ACN/water
Silica gel
CHCl3/MeOH 9:1
Sephadex LH-20
and HPLC ACN/ water
Silica gel
CHCl3/MeOH 8:2
Prep HPLC
ACN/water
Silica gel
CHCl3/MeOH 1-7:3
Sephadex LH-20
MeOH
Prep HPLC
ACN/water
 α-viridin (13) CAF 603 (19) 9α-D-arabinofuranoside (20) β-viridin (13)Cerebroside C (21)
3.2 Secondary metabolites from selected strains 
3.2.1 Trichoderma crassum 
The fungal genus Trichoderma contains cosmopolitan soil-borne fungi, also 
frequently  found on decaying wood,50 some of which are economically important 
producer of industrial enzymes1 and antibiotics or have application as biocontrol 
agents against plant pathogens. In our effort to isolate some active metabolites from 
fungal strains, we investigated the species Trichoderma crassum, which have not yet 
been studied. 
 
3.2.1.1 Cultivation, extraction and isolation 
Well grown agar cultures of Trichoderma crassum HKI 0471 served to inoculate 60 
liters of malt medium. The flasks were incubated at 25 ºC during 28 days. The culture 
broth was filtered and extracted with ethyl acetate. The dark brown crude extract was 
applied to Sephadex LH-20 and silica gel column chromatography, eluting with a 
chloroform-methanol gradient. Further purification of fractions using HPLC led to the 
isolation of the known β-viridin (13), α-viridin (14), CAF (603) (19), 9α-D-
arabinofuranoside and cerebroside C (21) 
 
 
 
 
 
 
  
 
 
 
 
 
  
Fig. 3. work up scheme of Tichoderma crassum HKI 0471 
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3.2.1.2 Structure elucidation of β-viridin (13) 
13 was isolated as a pale yellow powder. The yield was 0.4 mg/l of the culture filtrate 
of the fungus. On the basis of HR-ESIMS and 13C NMR spectroscopic data, the 
molecular formula was determined as C20H18O6. DEPT data indicated the presence 
of two oxymethines. Three ketone functions were indicated by carbon resonances at 
δ 173.2, 189.0, and 206.3. The structural fragments C(1)HOH-C(2)HOCH3; 
C(11)H=C(12)H; and C(15)H2-C(16)H2 were deduced through analysis of its 1H-1H 
COSY and HMQC spectra and from the chemical shift considerations. These 
fragments were connected to other carbon atoms by analysis of long range HMBC 
correlation as follows: The methoxy methyl protons correlated with C-2 and the H-2 
proton correlated with the methoxy carbon, indicating that the methoxy group is 
attached to C-2. The methyl protons H-18 correlated with C-1, C-5, C-9, and C-10, 
indicating that the carbon C-9 is attached to C-1, C-5, C-10 and C-18. The 
connection of C-4 to the three carbons C-3, C-5 and C-20 was revealed by the 
correlation of H-20 with C-4, C-5 and C-6. The connection of C-13 with the three 
carbons C12, C14 and C-17 was deduced by the correlation of the aromatic proton 
H-12 with C-14, C-17, as well as the correlation of the methylene proton H-16 with C-
13 and C-17. The aromatic proton H-11 correlated with C-8, C-9 and C-10, indicating 
the connection of C-10 to C-8, C-9, and C-11. The correlation of the methylene 
proton H-15 with C-8, C-13 and C-14 established the connection of C-14 to C-8, C-13 
and C-15. The most important correlations were the four bond correlations of the 
aromatic protons H-11 and H-20 with the carbonyl carbon C-7. These correlations 
unambiguously helped locating one of the carbonyl group at position 7. (Fig. 4) Thus, 
the structure was found to be that of β-viridin (13), which has three chiral centres. 
The stereochemistry was deduced from the NOESY spectrum, which showed a 
strong correlation between H-1 and H-2, and a weak correlation between H-1 and H-
18. Furthermore, the coupling constant between H-1 and H-2 was measured, and 
found to be J = 5.0 Hz, confirming their cis-configuration.  
O
OH
O O
MeO
O
1
2
3
4
5
6
7
89
10
11
12
13
14 15
16
1718
19
20
     
13   
Results and discussion 
 
11
 
O
OH
O O
MeO
O
 
key HMBC correlations
 
Fig. 4. Structure of β-viridin based on 2D NMR 
                                                                                     
3.2.1.3 Structure elucidation of α-viridin (14) 
14 was isolated from the same fraction as β-viridin described above. The two 
metabolites (13 and 14) share the same molecular weight (m/z = 353 [M+H]+) The 
analysis of the spectra of 14 including 1H NMR, 13C NMR and DEPT 135 
spectroscopic data of 14 showed that they share also the same molecular formula 
(C20H18O6), suggesting that they are isomers. As in the above described molecule, 
three carbonyl carbons were indicated by 13C NMR spectrum at δ 173.2, 186.9 and 
206.3. Therefore, the structure was deduced using NOESY spectrum, which 
indicated a correlation between the methyl proton H-18 and H-1. Correlations were 
shown neither between the methyl proton H-18 and H-2 nor between H-1 and H-2. 
This unambiguously revealed the trans-configuration of the protons H-1 and H-2. 
Supporting information was derived from the coupling constant of these protons, 
which was found to be J = 9.5 Hz. Thus, 14 was identified as the known α-viridin 
(14). 
O
OH
O O
MeO
O
 
14 
 
β-Viridin (13) and α-viridin (14)  were first isolated from the culture broth of the fungus 
Gliocladium virens,51-54 which was incorrectly described as Trichoderma viride in the 
early literature.55 Their structures were determined by UV, IR, mass spectrometry, 
and chemical transformations. α- and β-viridin are members of the structurally 
closely-related class of steroidal furanoids, which include viridiol (15), wortmannin 
(16), wortmannolone (17) and demethoxy viridiol (18).56 
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β-Viridin (13) and α-viridin (14) showed significant antifungal activity against Candida 
albicans ATCC 18804 and Penicillium notatum JP 36 and antibacterial activity 
against Bacillus subtilis ATCC 6633 with an inhibition of growth of 24, 26 and 25 mm, 
respectively at a concentration of 1 mg/ml. 
 
3.2.1.4 Structure elucidation of CAF 603 (19) 
19 was isolated after various chromatography techniques including preparative TLC, 
CC, sephadex LH-20 and HPLC. On the basis of HR-ESIMS, 13C NMR and DEPT 
135 spectroscopic data the molecular formula was found to be C15H26O2. The IR 
spectrum showed an absorption band at 3383 nm, indicating the presence of 
hydroxyl groups. In the 1H NMR spectrum of 19 one olefinic proton and one 
oxymethine proton were visible due to their chemical downfield shift at δ 5.34 and  
3.85, respectively. Four methyl protons were also observed at δ 0.85, 0.94, 1.00 and 
1.73. Their connections with the rest of the molecule were deduced from long range 
HMBC experiments. According to the observed HMBC and NOESY correlations, the 
structure was established to be 8-daucene-3,4-diol, also known as CAF 603 (19). 
This metabolite is related to the carotane sesquiterpenes, and was first isolated by 
Watanabe et al.57 19 shows a strong antifungal activity against Sporobolomyces 
salmonicolor SBUG 549 and moderate activity against Candida albicans ATCC 
18804 with a diameter of inhibition of 30 and 18 mm, respectively, at a concentration 
of 1 mg/ml. 
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3.2.1.5 Structure elucidation of adenoside 9α-D-arabinofuranoside (20) 
The molecular formula of 20 was found to be C10H13N5O4 on the basis of HR-ESIMS 
(m/z = 268 [M+H]+), 13C NMR and DEPT 135 spectroscopic data. 13C NMR 
suggested the presence of 5 sp2 carbons and 5 oxygenated sp3 carbons. The 
analysis of the long range HMBC and NOESY spectra helped identifying the 
structure as the known adenoside 9α-D-arabinofuranoside, which has been reported 
as herbicide58 and as a potent anti-cancer agent.59 
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3.2.1.6 Structure elucidation of cerebroside C (21)  
Cerebroside C (21) was obtained as a colourless powder. Its molecular formula was 
found to be C43H79NO9 on the basis of HR-ESIMS (m/z = 776 [M+Na]+), 13C and 
DEPT 135 NMR spectroscopic data. Its structure was elucidated by comparison of its 
NMR data with those of cerebroside C already reported in the literature.60 
Cerebrosides have already been isolated from various fungal sources and have been 
reported as antifungal agents,60 as stimulants of fruiting body formation in fungi61 and 
recently as elicitors of hypersensitive cell death and phytoalexin accumulation in rice 
plants.62 
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3.2.2 Epicoccum sp. HKI 0470 
The genus Epicoccum has already been studied for its natural products content 
leading to the discovery of epicorazines A (22) and B (23),63-65 triornicin (24),66 3822-
B (25)67 and Epicocconone (26).68 All are produced by Epicoccum nigrum (E. 
purpurascens), indicating that some members of the genus Epicoccum might have a 
highly developed and diverse secondary metabolism. To date the investigated strains 
were isolated from soil samples or from the marine sources such as sediments, wood 
algae or, as in the case of Epicoccum, from marine animals. In the present study the 
strain Epicoccum sp. was isolated from the hat of the mushroom of the fungus 
Pholiota squarrosa. 
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3.2.2.1 Cultivation and extraction 
Epicoccum sp. HKI 0470 strain was first cultivated on solid malt medium (agar plates) 
at 23o C for 21 days. One part was directly extracted with ethyl acetate, and the other 
part was used to inoculate 20 l of liquid malt medium as a stand culture. The resulting 
extracts were chromatographied using open column chromatography on Sephadex 
and silica gel and reverse-phase HPLC, affording a new phenolic compound, 
epicoccone B (29), a new and highly oxygenated coumarin polyketide, epicoccalone 
(30) and the known epicoccamide (27), epicoccine (28) and orevactaene (31). 
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Fig. 5. Work up scheme for Epicoccum sp. HKI 0472 
 
3.2.2.2 Structure elucidation of epicoccamide (27) 
The EIS-MS mass spectrum of 27 showed the molecular ion peak at m/z 580 
[M+Na]+. Its molecular formula was determined as C29H51NO9 based on HR-ESIMS 
and 13C NMR spectroscopic data. The IR spectrum of 27 showed absorption bands 
for hydroxyl groups at 3367 cm-1, three carbonyl carbons at 1709, 1646, and 1612 
cm-1. This observation was confirmed by the 13C NMR spectrum, which indicated 
carbonyl carbon signals at δ 173.1, 191.9 and 194.5. The 1H NMR spectrum 
indicated three methyl protons signals at δ 1.13 (d, J = 6.9, H-23), δ 1.34 (d, J = 6.9, 
H-5) and δ 2.92 (s, H-6). An aliphatic chain (14 x CH2), as well as the glycosyl proton 
signals were also indicated at δ 1.18 and 3.44 - 4.46, respectively. The long range 
HMBC correlation observed between the methyl protons δ 1.13 (d, J = 6.9, H-23) and 
C-7 (δ 194.5), C-8 (δ 36.0) and C-9 (δ 33.7), as well as the correlation of the methyl 
proton signals δ 1.34 (d, J = 6.9 Hz, H-5) with C-4 (δ 59.5) and C-3 (δ 191.9), and the 
correlation of the methyl proton signals δ 2.92 (s, H-6) with C-4 (δ 59.5) and C-1 (δ 
173.3) established the structure of the aglycone moiety as a tetramic acid with the 
long chain CH2 connected to C-8. This tetramic acid moiety can be presented in three 
tautomeric forms. (Fig. 6) 
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Fig. 6.Tautomeric forms of the tetramic acid part of epicoccamide 
 
The sugar part of the 27 was identified as mannose by comparison of the 1H and 13C 
NMR data with those reported.69 While the aglycone part and sugar were identified, it 
was necessary to determine the stereochemistry of the glycosidic linkage. The 
coupling constant between the anomeric proton H-1’ and the proton H-2’ was found 
to be JH-1’, H-2’ = 0 Hz, indicating that 27 contained a β-mannose. Further confirmation 
of the structure was obtained from the MS/MS mass spectrometry, which clearly 
revealed the daugther ion peak for aglycone moiety (m/z = 396). 
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Database reaches led to the recently isolated epicoccamide (27) from Epicoccum 
purpurascens.70 Epicoccamide showed weak antibacterial activity against Bacillus 
subtilis ATCC 6633 and Staphylococcus aureus ATCC 511 and moderate antifungal 
activity against Sporobolomyces salmonicolor SBUG 549 at a concentration of 1 
mg/ml. 
 
3.2.2.3 Structure elucidation of epicoccine (28) 
On the basis of HR-ESIMS and 13C NMR data the molecular formula of 28 was 
determined as C9H10O4. It was obtained as yellow oil with the yield of 0.1 mg/l of the 
culture filtrate of the fungus. The IR spectrum of 28 showed absorption bands for 
hydroxyl groups at 3280 cm-1, and for aromatic rings at 1627 and 1510 cm-1. A signal 
attributable to methyl protons at δ 1.91 (3H, s, H-H-8), two oxymethylene proton 
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signals at δ 4.83 (2H, s, H-1)) and δ 4.87 (2H, s, H-3), respectively, as well as three 
hydroxyl proton signals at δ 8.02 (1H, s), 8.06 (1H, s) and 8.45 (1H, s) were deduced 
from the 1H NMR spectrum of 28. The analysis of 13C NMR and DEPT 135 spectra 
indicated the presence of 6 fully substituted sp2 carbons and two oxygenated sp3 
carbons. The long range HMBC correlations observed between the methyl protons 
H-8 (δ 1.91) and C-7 (δ 108.2), C-7a (δ 132.5) and C-6 (δ 143.9), as well as Those 
observed between the oxymethylene protons and C-4a (δ 115.6), C-7a (δ 128.4), C-4 
(δ 137.6), C-5 (δ 132.5) C-6 (δ 143.9) and C-7 (δ 108.2) enabled the elucidation of 
the structure of 28 as the known 1,3-dihydro-7-methyl-4,5,6-trihydroxy-
isobenzofurane (epicoccine) (28) from Apergillus terreus. It has been reported to be 
an antioxidant that efficiently inhibits the oxidation of linoleic acid by sardine flesh 
lipoxygenase (LOX).71 
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3.2.2.4 Structure elucidation of epicoccone B (29) 
Epicoccone B 29 was obtained as yellow oil with a yield of 0.1mg/l of the culture 
filtrate of the fungus. The IR spectrum of the metabolite showed absorption bands for 
hydroxyl groups at 3420 cm-1 and 3134 cm-1, for carboxyl groups at 1725 cm-1, and 
for aromatic rings at 1628, 1515 and 1481 cm-1. On the basis of HR-ESIMS and 13C 
NMR data, 29 has the molecular formula C9H8O5. The 1H NMR spectrum of 29 
showed two signals attributable to methyl proton signals at δ 1.96 (1H, s) and to a 
methylene proton signal at δ 5.09 (1H, s). The remaining three protons were 
attributable to phenolic exchangeable hydroxyl protons. As in the 1H NMR spectrum 
of epicoccine (28), the absence of the aromatic proton signals in the 1H NMR 
spectrum of 29 suggested that the aromatic part of its structure is fully substituted. 
The 13C NMR and DEPT 135 spectra of 29 showed two sp3 carbon signals (one 
methyl carbon at δ 10.7 and one oxymethylene carbon at δ 67.6) six quaternary sp2 
carbons, as well as a carboxyl carbon at δ 169.8. The protonated carbons and their 
corresponding protons and the full connection of compound 29 were established 
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using HMQC and HMBC experiments. The long range HMBC showed the 
correlations between the methyl protons H-8 (δ 1.96) and C-4 (δ 109.1), C-4a (δ 
138.0), and C-5 (δ 151.1). The correlations between the oxymethylene protons δ 5.09 
(2H, s) and C-1 (δ 169.8), C-4 (δ 109.1), C-4a (δ 138.0), C-5 (δ 151.1), C-7 (δ 143.0), 
and C-7a (δ 102.7) were also visible. Thus, 29 was elucidated as 4-methyl-5,6-7-
trihydroxy-1(3H)-isobenzofuranone, a new natural product. 
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The newly described metabolite named epicoccone B (29) is an isomer of 
epicoccone A72 in which the methyl carbon is attached to C-7. Further confirmation of 
the structure of 29 was derived from the NOESY spectrum, which showed a strong 
correlation between the methyl protons and the oxymethylene protons. 
In the anti-inflammatory assay epicoccone B (29) exhibited moderate inhibitory 
activity towards 3α-hydroxysteroid dehydrogenase.  
 
3.2.2.5 Structure elucidation of epicoccalone (30) 
The ESI-MS mass spectrum of 30 indicated the molecular ion peak at m/z 321 
[M+H]+. Its molecular formula was determined as C16H16O7 based on HR-EISMS 
(found [M-H]-: 319.0814 calcd. for C16H16O7: 319.0818) and the 13C NMR spectra. 
The IR spectrum of 30 showed absorption bands for hydroxyl groups at 3244 cm-1, 
for carbonyl groups at 1699 cm-1, and for aromatic rings (1598, 1562 and 1465 cm-1). 
The 1H NMR spectrum of 30 revealed three signals attributable to the methyl groups 
at δ 1.23 (3H, d, J = 7.1 Hz), 2.22 (3H, s) and 2.28 (3H, s), one oxymethylene at δ 
4.68 (2H, s) and two methine protons including an olefinic proton at δ 4.71 (1H, q) 
and 8.89 (1H, s), respectively.  The remaining three protons were attributable to the 
phenolic exchangeable hydroxyl protons. Similar to the compounds 28 and 29, the 
absence of the aromatic proton signals in the 1H NMR spectrum suggested that the 
aromatic part of the structure is fully substituted. The 13C NMR and DEPT 135 
spectra of 30 indicated 5 sp3 carbon signals (three methyl groups, one oxymethylene 
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and one methine), 8 sp2 carbon signals including 7 quaternary sp2 carbon signals 
(three of which are oxygenated), as well as two carbonyl signals and one carboxyl 
carbon signal at δ 194.0, 206.2 and 159.2, respectively. The protonated carbons and 
their corresponding protons and the full connection of 30 were established using 
HMQC and HMBC experiments. The correlation of the methyl proton H-5’ (δ 1.23) 
with the carbons C-1’ (δ 194.0), C-2’ (δ 57.3) and C-3’ (δ 206.2), the correlation of the 
proton H-4’ (δ 2.28) with the carbons C-2’ (δ 57.3), and C-3’ (δ 206.2) and the 
correlation of the proton H-2’ (δ 4.71) with the carbon C-1’ (δ 194.0), C-3’ (δ 206.2) 
and C-5’ (δ 12.1) revealed the 2-methylbutan-1,3-dione as a side chain of the 30.  
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For the identification of the second part of 30, long range HMBC played an important 
role. The correlation of the proton of the oxymethylene carbon H-9 (δ 4.68)  with C-4a 
(δ 109.9), C-5 (δ 131.6) and C-6 (δ 122.4) and the correlation of the methyl protons 
H-10 with C-5 (δ 131.6), C-6 (δ 122.4) and C-7 (δ 151.6) suggested the connection of 
the oxymethylene carbon C-9 (δ 55,6) and the methyl carbon C-10 (δ 11.3) at the C-5 
and C-6, respectively. The most important correlation was that of the olefinic proton 
H-4 (δ 8.89) with C-2 (δ 159.2), C-3 (δ 116.5) C-5 (δ 131.6) and C-8 (δ 130.2). All 
these correlations enabled the elucidation of the second part of the molecule as 5-
hydroxymethylene-6-methyl-7,8-dihydroxycoumarin.  
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Due to the correlation observed between the olefinic proton H-4 (δ 8.89) and the 
carbonyl carbon C-1’, it was evident that the two parts are connected at C-3. Thus, 
30 was elucidated as 3-(3-methylbutan-1,3-dione)-5-hydroxymethylene-6-methyl-7,8-
dihydroxycoumarin, a new natural product named epicoccalone (30). Further 
confirmation of the structure was obtained from the MS/MS spectrum, which showed 
peak fragments at m/z = 221, 203 and 175 in negative mode. These fragments are 
the result of the cleavage of the side chain moiety, (m/z = 221) followed by the 
Results and discussion 
 
20
 
elimination of H2O (m/z = 203) and the loss of the carbonyl of the carboxyl moiety 
(m/z = 175). (Fig. 11) 
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Fig. 7. Structure of epicoccalone based on 2D NMR 
 
 
Fig. 8. 1H NMR spectrum of epicoccalone 
 
 
 
Fig. 9. 13C NMR spectrum of epicoccalone (30) 
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Fig. 10. HMBC spectrum of epicoccalone (30) 
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Fig. 11. Fragmentation mechanism of epicoccalone (30) 
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3.2.2.6 Biological activity of epicoccalone 
In the antimicrobial assays epicoccalone showed no detectable activity against Gram 
positive, Gram negative bateria and fungi.  
In the enzyme inhibition assays epicoccalone exhibited moderate inhibition activity 
towards 3α-HSD but proved to be a potent α-chymotrypsin inhibitor with an IC50 
value of 27 µg/ml (Fig. 12). It should be noted that α-chymotrypsin is a serine 
protease73-75 that plays critical roles in several physiological processes including 
digestion, blood coagulation, complement activation, fibrinolysis and reproduction. 
However, it is well known that serine proteases are not only a physiological 
necessity, but can be of potential hazard if present in excessive quantities. Therefore, 
serine proteases are responsible of vascular clotting and cerebral and coronary 
disorders. The excessive activity of this enzyme can also cause skin disease, 
including glomerulonephritis, pancreatitis and other disorders that could be controlled 
by its inhibition.76 There is increasing evidence that serine protease inhibitors 
regulate inflammation by inhibiting the proteolytic activity of serine protease released 
by leucocytes. They may also contribute directly or indirectly to the defence against 
invading microorganisms.77  
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Fig. 12. Inhibition activity of epicoccalone (30) towards α-chymotrypsin  
 
3.2.2.7 Structure elucidation of orevactaene (31) 
Orevactaene (31) was isolated as yellow oil. It has the molecular weight of 613 
[M+H]+ and the molecular formula of C34H44O10 based on HR-ESIMS. The IR 
spectrum revealed strong absorption band for hydroxyl groups and for a conjugated 
carbonyl at 3251 and 1671 cm-1, respectively. The UV spectrum showed the 
absorption maxima at 430 nm, indicating the presence of a polyene. The analysis of 
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13C and DEPT 135 revealed the presence of 34 carbons, including two carboxyl 
carbons, 18 sp2 carbons (1 of which is oxygenated), 14 sp3 carbons (5 oxymethines, 
and 1 oxymethylene) and two carboxyl carbons. The presence of carboxyl carbons 
was confirmed by the 13C NMR data, which showed two signals at δ 162.2 and 169.3. 
The 1H-1H COSY revealed the alignment H-9/H-10/H-11/H-12/H-13/H-14/H-15/H-
16/H-17/H-18, H-22/H-23/H-24/H-25/H-26/H-27 and H-3/H-4/H-5/H-32/H-33/H-34. 
The long range HMBC (Fig. 13) helped connecting the rest of the molecule. For 
example the correlation of the proton H-20 (δ 6.11) with C-30 (δ 169.3) and the 
correlation of the proton H-22 (δ 5.55) with C-30 enabled the connection of the 
carboxyl carbon at C-21 (δ 131.4). The correlations of H-3 with C-1 (δ 162.2), C-2 
and C-6 (δ 167.7) were also visible. Thus, the structure of 31 was determined as 
shown below. The confirmation of the structure was derived from the MS/MS 
spectrum, which showed the pseudo molecular ion at m/z 403, 447, 491, and 521 in 
negative mode. These fragments are result of the cleavage of the hydroxylated side 
chain moiety, followed by the cleavage of the dihydroxypyranne ring and by the 
decarboxylation (Fig. 14) 
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The search for this structure in the database revealed the known orevactaene, which 
has been reported to be a binding inhibitor of HIV-1 Rev protein to the Rev response 
element (RRE) with an IC50 value of 3.6 µM from Epicoccum nigrum WC47880.78 
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Fig. 13. Structure of orevactaene (31) based on 2D NMR 
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Fig. 14. Fragmentation mechanism of orevactaene based on MS/MS spectrum 
 
3.2.3 Lepista nebularis 
3.2.3.1 Cultivation and extraction 
The strain Lepista nebularis HKI 0411 collected in Siberia appeared to produce 
antimicrobial metabolites as revealed by an initial screening with the crude extract. It 
was then cultivated under the condition of surface fermentation at 25 oC in 500 ml 
Erlenmeyer flasks containing 100 ml of MPG medium as shake culture. After 
cultivation for 28 days the mycelium cake from culture medium (60 l) was harvested 
and extracted twice with ethyl acetate and methanol (each 10 l). The culture broth 
was thoroughly extracted with ethyl acetate and the combined extracts were dried 
and the solvents were evaporated. The residue (3.2 g) was subjected to column 
chromatography on Sephadex and silica gel with stepwise CHCl3 and CHCl3/MeOH 
(9:1, 1:1, v / v) as eluent. Active components were isolated through bioassays guided 
purification. Final purification was achieved by preparative HPLC, yielding 7 active 
metabolites, nebularic acid A (32), nebularone (33), nebularic acid B (34), 
nebularilactone A (35), nebularilactone B (36), N-acetyltyramine (46) and diatretyne 
(47). 
 
 
 
 
 
 
 
 
 
 
Fig. 15. Work up scheme of Lepista nebularis HKI 0411 
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3.2.3.2 Structure elucidation of nebularic acid A (32) 
32 was obtained as a white powder. Its molecular formula was determined as 
C14H20O3 based on HR-ESIMS (found [M+H]+: 237.1480, calcd. for C14H21O3: 
237.1485) and 13C NMR spectroscopic data. The 1H NMR spectrum showed 19 non 
exchangeable protons including one olefinic proton at δ 8.02 and three methyl 
protons at δ 0.88, 0.92 and 1.14. Analyses of 13C, DEPT 135 and HMQC NMR 
spectra of 32 indicated the presence of two methine carbons (one of which is sp2 
hybridized) four methylene carbons, three methyl carbons and three quaternary 
carbons (one of which is sp2 hybridized), a carboxyl carbon at δ 164.0 and a carbonyl 
carbon at δ 204.3. The presence of carboxyl and carbonyl groups was confirmed by 
the IR spectrum, which showed strong absorption bands at 1742 cm-1 and 1632 cm-1. 
The 1H-1H COSY spectrum revealed the coupling system H-1/H-2/H-3, and H-5/H-6. 
By means of HMBC all connections were fully assigned. The geminal arrangement of 
the methyl groups C-14 (δ 20.9) and C-15 (δ 32.6) was established by the correlation 
of H-14 (δ 0.92) and H-15 (δ 0.88) with C-4 (δ 33.0), C-3 (δ 40.7) and C-5 (δ 49.4). 
Similarly, the correlation of H-13 (δ 1.14) with C-10 (δ 38.3), C-1 (δ 36.8) and C-9 (δ 
175.4) revealed the connection of the methyl group C-13 (δ 17.1) with C-10 (δ 38.3). 
Another important correlation was observed between the olefinic proton H-9 (δ 8.02) 
and C-8 (δ 123.5), C-7 (δ 204.3) and C-12 (δ 164.0), which helped unambiguously 
identifying the position of the carboxyl and carbonyl groups. The correlation of H-6 (δ 
2.65, 2.50) with C-5, C-7, C-4 and C -8 was also observed. Thus, 32 was identified 
as 7-oxo-11-nordrim-8-en-12-oic acid (nebularic acid A) 
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Fig. 16. Structure of nebularic acid 
based on 2D NMR 
 
3.2.3.3 Structure elucidation of nebularone (33) 
1H and 13C NMR spectra of 33 were almost identical with those obtained from 32. 
However, it appeared from the analyses of 13C, DEPT 135 and HMQC NMR spectra 
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of 33 that it contained two hydrogenated olefinic carbons. This was confirmed by the 
1H NMR spectrum, which indicated the olefinic protons signals at δ 5.72 (d, J = 9.8 
Hz, H-8), and 6.59 (d, J = 9.8 Hz, H-9). Furthermore, the 13C NMR spectrum 
indicated a carbonyl carbon signal at δ 201.5. No carboxyl carbon signal was 
detectable, suggesting that 33 was a decarboxylation product of 32. This finding was 
strongly supported by mass spectra, as well as IR spectra, which showed a mass 
difference of 44 units compared to 32, and an absorption band for carbonyl carbon at 
1709 cm-1, respectively. Thus, 33 was elucidated as bisnor-11,12-drim-8-en-7-one 
named nebularone (33). 
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Fig. 17. Structure of nebularone 
based on 2D NMR 
 
This is the first time that nebularone was isolated as natural product. However, it had 
already been prepared as an intermediate for the synthesis of the drim-8-en-7-one 
starting with decalone.79 
 
3.2.3.4 Structure elucidation of nebularic acid B (34) 
1H and 13C NMR spectra of 34 were almost similar with those obtained for 32 and 33. 
However, it appeared from the analyses of 13C, DEPT 135 and HMQC NMR spectra 
that 34 contained no olefinic carbon. The two olefinic carbons present in 32 were 
replaced by a methine and by a quaternary sp3 carbon. According to their chemical 
downfield shifts δ 69.5 and 62.2, both of them are oxygenated. Supporting 
information was obtained from mass spectra, which showed a mass difference of 16 
units compared to 32. The pseudo molecular ion peak obtained by HR-ESIMS 
accounted for a molecular formula of C14H20O4 (found [M-H]-: 251.1262, calcd.: 
251.1264). Therefore, 34 was identified as 7-oxo-8,9-epoxy-11-nordriman-12-oic acid 
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(34) (nebularic acid B). The relative configuration of 34 was established using 
NOESY experiments, which showed a correlation between the methine proton H-5 
and the oxymethine proton H-9. 
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Fig. 18. Structure of nebularic acid B based 
on 2D NMR 
 
3.2.3.5 Structure elucidation of nebularilactone A (35) 
The molecular formula of nebularilactone A (35) was determined as C15H22O3 based 
on HR-ESIMS (found [M+H]+: 251.1642, calcd. for C14H23O3: 251.1650) and 13C NMR 
spectroscopic data. The 1H NMR spectrum of 35 showed 22 non exchangeable 
protons including one olefinic proton at δ 6.85 and three methyl groups at δ  0.78, 
0.94 and 1.34. 13C, DEPT and HMQC NMR spectra of 35 indicated the presence of 
four methine carbons (two of which are sp2 hybridized and oxygenated according to 
their chemical downfield shifts δ 79.8 and 135.2, respectively), four methylene 
carbons (one of which is oxygenated δ 69.2), three methyl carbons, three quaternary 
carbons (one of which is sp2 hybridized), and a lactone carbon δ 170.1. The presence 
of the lactone group was confirmed by the IR spectrum, which indicated a strong 
absorption band at 1729 cm-1. The 1H-1H COSY spectrum revealed the coupling 
system H-1/H-2/H-3, H-5/H-6/H-7 and H-9/H-11. The other connections were fully 
assigned by means of the long range HMBC spectrum. The geminal arrangement of 
the methyl groups C-14 (δ 21.5) and C-15 (δ 32.5), and the connection of the methyl 
C-13 were established in the same manner as described for compounds 33 and 34. 
The lactone ring was connected according to the correlation of H-7 (δ 6.85) with C-8 
(δ 127.6), C-9 (δ 50.1) and C-12 (δ 170.1), the correlation of H-9 with C-8, C-11 (δ 
69.2) and C-12 and the correlation of the oxymethylene protons H-11 (δ 4.15) with 
the carbons C-8, C-9 and C-12. The most important correlations were the correlation 
of H-9 with C-1 (δ 79.8), the correlation of H-13 with C-1 and that of H-1 (δ 3.39) with 
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C-10 (δ 39.5), C-13, and C-9. These correlations helped identifying the position of the 
hydroxyl group. The relative sterochemistry was established using NOESY 
experiments, which indicated correlations between H-1/H-5, H-1/H-9 and H-5/H-9. 
Thus, 35 was identified as 1β-hydroxydrim-7-en11,12-olide, designated 
nebularilactone A (35). 
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Fig. 19. Structure of nebularilactone A based 
on 2D NMR 
 
 
 
 
Fig. 20. 1H NMR spectrum (CDCl3) of nebularilactone A (35) 
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Fig. 21. 13C NMR spectrum (CDCl3) of nebularilactone A (35) 
 
 
 
 
 
Fig. 22. Key HMBC correlations of nebularilactone A (35) 
 
3.2.3.6 Structure elucidation of nebularilactone B (36) 
36 was obtained as a colourless oil. Its molecular formula was determined as 
C15H22O3 based on HR-ESIMS (found [M+H]+ 251.1642, calcd. for C14H23O3: 
251.1650 ) and 13C NMR. 1H, 13C, DEPT 135 and HMBC spectra of 36 were almost 
identical with those obtained from 35. However, it appeared from the analyses of 
NOESY spectrum of 36 that the proton H-1 (δ 3.51) correlated with the methyl 
protons H-13 (δ 0.78). No correlation was found between the proton H-1, H-5 (δ 1.75) 
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and H-9 (δ 3.58). Thus, 36 was identified as 1α-hydroxydrim-7-en-11,12-olide 
(nebularilactone B). 
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Fig. 23. Structure of nebularilactone B based 
on 2D NMR 
 
This is the first isolation and full characterization of componds 32-36 as natural 
products. However, it should be noted that the detection of the methyl ester of 32 
from the methylated extract of Lepista glaucocana has been reported previously.80 
Nebularic acid A appears to be the biogenetic progenitor of nebularone and nebularic 
acid B, which features an unusual α,β-epoxy moiety for drimane.  
 
3.2.3.7 Model for the biosynthesis of drimane sesquiterpenoids 
In analogy to the majority of sesquiterpenoids, the drimane sesquiterpenoids are 
biosynthesised by an enzyme-mediated solvolysis of the pyrophosphate group of 
farnesylpyrophosphate (FPP) (37),81-83 which is cyclized and converted to the final 
products by hydrolysis and oxidation. Therefore, the co-occurrence of drimanes and 
nor drimanes may arise through decarboxylation of drimanic acid from drimenol (39). 
(Fig. 24) 
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Fig. 24. Proposed biosynthesis of nebularone, nebularic acids and nebularilactones 
 
3.2.3.8 Biological activity of isolated drimanes 
Nebularone (33), nebularic acids A (32) and B (34) as well as nebularilactones A (35) 
and B (36) have been tested in various bioassays system, including antimicrobial, 
anti-inflammatory and antiviral assays. Nebularic acid B, nebularilactones A and B 
exhibited no significant activity. Conversely, nebularic acid A exhibited a strong 
antiviral activity against coxsackievirus, which has been found to be one of the main 
causes of certain debilitating or life-threatening diseases such as the inflammation of 
the heart muscle, the so-called myocarditis84 with an IC50 value of 6 µM. (Fig. 25) 
A number of antiviral drimane sesquiterpenoids have already been reported including 
epi-albrassitriol (40),85 which exhibited a moderate activity in in vitro tests against  
influenza A and mixovirus (MIC 44.4 µm/ml), kuehneromycin-A (41),86 which proved 
to be a non-competitive inhibitor of the reverse transcriptase of avian myeloblastosis 
virus (IC50 75 µg/ml), and a weak inhibitor for HIV-1 reverse transcriptase (IC50 185 
µg/ml) and mniopetals A-D (41-45),87 which inhibited the reverse transcriptase of 
avian myeloblastosis virus and moloney murine leukemia virus with IC50 values  of 
41-77 µM and 1.7-7 µM, respectively. 
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Fig. 25. Inhibition of coxsackievirus B3-induced CPE in HeLa cells of nebularic acid 
A (32) 
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3.2.3.9 Structure elucidation of N-acetyltyramine (46) 
The molecular formula of 46 was determined as C10H13O2 based on HR-ESIMS (m/z 
= 180 [M+H]+). The IR spectrum showed an absorption band for a carboxamide 
carbon at 1635 cm-1. The 1H NMR spectrum indicated two proton signals assigned to 
an AA’ BB’ spin coupling for a para-subtituted phenyl moiety. The analysis of 13C and 
DEPT 135 NMR spectra revealed the presence of 6 sp2 carbons and three sp3 
carbons including two methylene carbons. Thus, the structure of 46 was assigned as 
N-acetyltyramine according to the HMBC correlation. This compound was already 
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reported from bacterial strains including marine Streptomycetes and Mycobacterium 
tuberculosis. 
H
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46 
 
3.2.3.10 Structure elucidation of diatretyne (47) 
47 was obtained after various bioassay guided chromatographic purification steps 
including TLC, CC (Silica gel and Sephadex LH-20) and HPLC. Its molecular formula 
was determined as C8H3NO2 based on HR-ESIMS (m/z 144 [M-H]-). The IR spectrum 
showed an absorption band of a carboxyl carbon at 1685 cm-1 and the UV (MeOH) 
spectrum revealed various maxima (λmax 230, 239, 268, 284, 302, 322 nm), 
suggesting the presence of  a polyine. The 1H NMR spectrum indicated the presence 
of two trans disubstituted protons at δ 6.60 (d, J = 16.2 Hz) and  6.77 (d, J = 16.2 Hz). 
The long range HMBC of these protons with other carbons led to the elucidation of 
47 as 7-cyano-hept-2-ene-4,6-diynoic acid (47). 
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The search for this structure in the database revealed that 47 is a known 
antimicrobial compound named diatretyne, which has been reported from the fungus 
Clitocybe diatreta.88,89 
 
3.2.3.11 Biological activity of diatretyne (47) 
The activity of diatretyne was evaluated in various bioassay test systems including 
antimicrobial, cytotoxic (HeLa cells) and antiproliferative assays (murine fibroblast 
cell line L-929 and human leukemia cell line K-562). For all these tests diatretyne 
was found to be highly active. (table 2, 3 and Fig. 26) 
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MIC (µg/ml) 
 MRSA 
134/94 
VRSA 
1528 
E.coli 
ATCC 
25922 
Staphylococcus 
aureus 
1719/00 
Mycobacterium 
Vaccae 
Candida 
albican 
Diatretyne  1.56 1.56 6.25 1.56 6.25 25 
Ciproflox. 25 0.8 0.05 25 0.4 - 
Amp. - - - - - 0.2 
 
Table 2. MIC value of antimicrobial activity of diatretyne (47) 
 
Diatretyne 
Antiproliferative activity Cytotoxicity 
L-929 GI50(µg/ml) K-562 GI50(µg/ml) HeLa CC50 (CC10) (µg/ml) 
2.4 0.8 4.7 (3.6) 
 
Table 3. Antiproliferative and cytotoxic data of diatretyne (47) 
 
 
Fig. 26. Antiproliferative and cytotoxic activity of diatretyne (47) 
 
3.2.4 Aspergillus sp. HKI 0472 
Apergillus sp. HKI 0472 was isolated from a soil sample (compost) collected in 
Bafoussam, a region situated in west Cameroon. It showed a good agreement with 
the microscopic characteristics of Aspergillus. It was deposited in the strain collection 
of the Leibniz-Institute for Natural Product Research and Infection Biology, HKI, Jena 
(Germany). 
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3.2.4.1 Cultivation and extraction 
The strain Aspergillus sp. was cultivated and extracted in the same way as described 
above for Lepista nebularis to afford a new phenolic metabolite with an unusual 
conformation, funalenine (48) and the known TMC-256C2 and TMC-256A1. 
 
3.2.4.2 Structure elucidation of funalenine (48) 
The 1H NMR spectrum of 48 displayed two singlet proton signals at δ 2.68 and  3.67, 
which are attributable to a methyl and a methoxy groups, respectively. Moreover, two 
singlet proton signals at δ 18.39 and 18.42 attributed of protons putatively involved in 
intramolecular resonance assisted hydrogen bonds were visible. The presence of the 
methyl and methoxy groups was supported by the DEPT spectrum, which showed 
eleven aromatic quaternary carbon signals in addition to the signals of methyl and 
methoxy. For the assignment of the other constituting protons and carbons 13C, 1H 
long range coupled NMR spectra (HMBC) were particulary helpful. The connection of 
the methoxy residue to C-2 (δ 130.4) was suggested by the correlation of the 
methoxy protons H-10 (δ 3.67) with C-2 (δ 130.4). The correlation of the protons at δ 
18.39 and 18.42 with C-2 (δ 130.4), C-3 (δ 169.0), C-3a (δ 106.9), C-4 (δ 171.3), C-5 
(δ 116.4) and C-1 (δ 169.9), C-2, C-8 (δ 98.9), C-9 (δ 173.3), and C-9a (δ 102.7) (Fig. 
27), respectively, afforded the alignment C-8, C-9, C-9a, C-1, C-2, C-3, C-3a, C-4, 
and C-5. This was evidence of strong intramolecular hydrogen bonds in the 
molecule. The other alignment C-5, C-6 (δ 143.7), C-6a (δ 106.7), C-7 (δ 163.3) and 
C-8 (δ 98.9) as well as the connection of C-11 (δ 25.0) were suggested as shown in 
Fig. 27. Supporting evidence was given by the long-range 1H-1H COSY and NOESY 
between H-5 (δ 6.32) and the methyl protons H-11 (δ 2.68), between 7-OH and H-8 
(δ 6.04) and between the hydroxyl proton 9-OH, respectively. Therefore, the structure 
of 48, was determined as funalenine (48), in which the pi -electron in the A, B, C rings 
are totally delocalized. 48 was found to be a conformer of funalenone (49),90 which 
was produced by an Aspergillus niger strain from a soil sample collected in 
Funabashi City, Chiba, Japan.92 They share the same molecular weight and the 
same molecular formula. The comparison of the 13C NMR data of 48 and 49, which 
have been measured using the same solvent (DMSO-d6) indicated some 
disagreements, particularly with the C-3 and C-4 signals, which appeared at δ 169.0 
and 171.3 for 48, and δ 163.0 and 164.9 for 49, respectively. Moreover, other 
disagreements were found in the IR spectra, which indicated an absorption band at 
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1584 cm-1 for 48  (attributable to the aromatic double bonds) and an absorption band 
at 1616 cm-1 for 49 (attributable to the ketone function). These comparisons indicated 
that 48 have a weak carbonyl character for the carbon C-1 (δ 169.9), C-3 (δ 169.0), 
C-4 (δ 171.3) and C-9 (δ 173.3) and therefore, strongly supported the structure of 48. 
The tautomer form 49 is stabilized by the intramolecular resonance assisted 
hydrogen bonds (RAHB). This concept has been introduced by Gilli et al. to explain 
the observed strong hydrogen bonding in the oxygen analogue.91,92 In this model a 
strong hydrogen bonding is possible if a bond allows charge flow through covalent 
bonds from a donor to the acceptor atom. In addition, it should be noted that 
intramolecular hydrogen bonds are implicated in the control of the conformation of 
many biological molecules and are known to contribute to the interactions necessary 
for efficient molecular recognition.93,94 
The treatment of 48 with diazomethane afforded only the 7-methoxy derivative, and 
thus, the great stability of 48 was confirmed. 
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Fig. 27. Structure of funalenine based on 2D NMR 
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Fig. 28. 1H NMR spectrum (DMSO-d6) of funalenine (48) 
 
 
 
Fig. 29. 13C NMR spectrum (DMSO-d6) of funalenine (48) 
 
 
 
Fig. 30. Key HMBC correlation spectrum of funalenine (48) 
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3.2.4.3 Biological activity of funalenine 
As funalenone (49), funalenine (48) showed no antimicrobial activity against a series 
of Gram-postive bacteria, Gram-negative bacteria and fungi at concentration >500 
µg/ml. However, funalenine (48) displayed potent anti-inflammatory activity by 
inhibiting the enzyme 3α-hydroxysteroid dehydrogenase (Fig. 31), COX-1 and COX-2 
with an IC50 value of 52 µM, 36 µM and 45 µM, respectively. Indomethacin was used 
as standard. It should also been noted that fungal phenalenones have been reported 
recently as inhibitor of HIV-1 integrase.95 
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Fig. 31. Inhibition of 3α-HSD by funalenine (48)  
 
3.2.4.5 Structure elucidation of TMC-256C2 and TMC-256A1 
TMC-256C2 (50) and TMC-256A1 (51) were identified in comparison with the 
spectroscopic data of the known TMC-256C2 (asperxanthone) and TMC-256A1 from 
Aspergillus niger,96 respectively. 
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51 is known as an inhibitor of IL-4 driven luciferase and germine Cε mRNA with IC50 
values of 25 µM and 6.6 µM, respectively. 
 
Results and discussion 
 
39
 
Inonotus sp. (fruiting bodies) 25 g
Extraction with ethanol 
and CHCl3/MeOH 1:1
Crude extractPowder
Silica gel
CHCl3/MeOH 1:1
Silica gel
CHCl3/MeOH ) 95:5
Prep HPLC
ACN/water
Inonotic acid methyl ester (52)
Silica gel
CHCl3/MeOH ) 9:1
Sephadex LH-20
MeOH
(E)-4-(3,4-Dihydroxyphenyl)but-3-en-2-one (56)
hispidin (57)
Silica gel
CHCl3/MeOH ) 8:2
Prep HPLC
ACN/water
Inotilone (53) isohispidin (58)
3.2.5 Inonotus sp. (fruiting body) 
The fruiting body of Inonotus sp. was collected in Vietnam. Its identity was verified by 
Prof. Thrinh Tam Kiet from the Mycological Research Centre, Hanoi State University, 
Vietnam, where a specimen was deposited. 
 
3.2.5.1 Extraction and isolation 
100 g of fresh fruiting body was cut into small pecies, dried and crushed. The 
resulting powder was extracted three times with ethanol and CHCl3:MeOH (3 x 2 l, 3 
days each). The combined extracts (5 g) of a brown solid was subjected to a pre-
screening, which revealed the presence of potent inhibitors of key enzymes involved 
in inflammatory processes, including 3α-HSD, COX and xanthine oxidase, as well as 
the presence of some moderate antibacterial components. For the isolation of the 
active components the extract was subjected in various chromatographic separation 
techniques. Bioassay-guided separation using open column and preparative HPLC 
yielded three new  phenolic metabolites, inonotic acid methyl ester (52), inotilone 
(53), isohispidin (58) and the known (E)-4-(3,4-dihydroxyphenyl)but-3-en-2-one (56) 
and hispidin (57).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32. Work up scheme for the isolation of phenolic components from Inonotus sp. 
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3.2.5.2 Structure elucidation of inonotic acid methyl ester (52) 
The ESI-MS mass spectrum of 52 showed a molecular ion peak at m/z 277 [M-H]-. 
Based on HR-EIMS and the 13C NMR spectrum, the molecular formula of 52 was 
determined as C14H14O6. The IR spectrum showed absorption bands for hydroxyl 
groups (3183 cm-1), for a conjugated carbonyl (1632 cm-1), for a carboxyl carbon 
(1733 cm-1), and for aromatic rings (1567, 1513 and 1435 cm-1). The 1H NMR 
spectrum showed also signals attributable to the ABX spin coupling system of a 
trisubstituted phenyl moiety at δ 6.77 (1H, d, J = 8.1 Hz, H-12), 7.02 (1H, dd, J = 8.2, 
1.8 Hz, H-13), 7.07 (1H, d, J = 1.8 Hz, H-9), a trans disubstituted double bond at δ 
7.45 (1H, d, J = 15.8 Hz, H-7) and 6.50 (1H, d, J = 15.8 Hz, H-6), as well as two 
exchangeable phenolic hydroxyl protons at δ 9.15 and 9.65, and one chelated proton 
at δ 15.20. Analyses of 13C, DEPT 135 and HMQC NMR spectra of 52 indicated 14 
carbon signals including six sp2 methines, four quaternary sp2 carbons  (three of 
which are oxygenated), one methylene carbon (δ 45.6), a methoxy carbon (δ 51.8) a 
carbonyl carbon (δ 191.8) and a carboxyl carbon (δ 167.9). For the connection of all 
these carbons HMBC was very helpful. The correlation of H-9 (δ 7.07) with C-7 (δ 
141.0), C-8 (δ 126.2), C-10 (δ 145.6), C-11 (δ 148.4), the correlation of H-12 (δ 6.77) 
with H-8, H-10, H-11, H-13 and the correlation of H-13 (δ 7.02) with C-7, C-8, C-9, C-
11 and C-12 revealed an ortho substitution of the phenolic hydroxyl protons. Another 
important correlation was that of the methylene protons with C-1 (δ 167.9), C-3 (δ 
191.8) and C-4 (δ 100.3). Therefore, the structure of 52 was assigned as 7-(3,4-
dihydroxy-phenyl)-5-hydroxy-3-oxo-hepta-4,6-dienoic acid methyl ester, named 
inonotic acid methyl ester (52). 
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3.2.5.3 Structure elucidation of inotilone (53) 
53 was obtained as a yellow oil. The IR spectrum of 53 showed absorption bands for 
hydroxyl groups at 3183 cm-1, for a conjugated carbonyl (1681 cm-1), and for 
aromatic rings (1588, 1516 and 1434 cm-1). The ESI-MS mass spectrum showed the 
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molecular ion peak at m/z 217 [M-H]-. Its molecular formula was determined as 
C12H10O4 based on HR-ESIMS and the 13C NMR spectrum. The 1H NMR  spectrum 
showed signals attributable to the ABX spin coupling system of a trisubstituted 
phenyl moiety at δ 6.80 (1H, d, J = 8.2 Hz, H-11), 7.17 (1H, dd, J = 2.0, 8.2 Hz, H-12) 
and 7.35 (1H, d, J = 2 Hz, H-8). Two olefinic protons δ 6.49 (1H, s, H-6), 5.82 (1H, d, 
J = 0.6, H-3) and a methyl proton signal δ 2.39 (3H, s, H-13) were also observed. The 
remaining two protons were attributable to the phenolic exchangeable hydroxyl 
protons. The 13C NMR and DEPT135 spectra of 53 showed 11 sp2 carbon signal 
including five methines, and three quaternary oxygenated carbons. The presence of 
the carbonyl moiety was also confirmed by the 13C NMR spectrum, which showed 
one carbon signal of C-4 (δ 186.6). The protonated carbons and their corresponding 
protons and the full connection of the structure of 53 was established using HMQC 
and HMBC experiments, respectively. The correlation of the methyl protons with C-2 
(δ 180.4), C-3 (δ 105.4) and the correlation of the olefinic proton (H-3) at δ 5.82 with 
C-2 (δ 180.4), C-4 (carbonyl moiety) δ 186.6 and C-5 (δ 144.3) unambiguously 
revealed a disubstituted dihydrofuranone moiety. The correlation of the olefinic 
proton H-6 (δ 6.49) with C-4 (δ 186.6), C-5 (δ 144.3), C-7 (δ 122.9), C-8 (δ 117.9) and 
C-12 (δ 124.7) enabled the connection of the dihydrofuranone moiety with the rest of 
the molecule. The stereochemistry of the C-5 double bond was carried out using 
molecular modeling and the NOESY spectrum, which showed a correlation between 
H-1’ (δ 6.49) and H-3 (δ 5.82) and the correlation between the protons H-3’ (δ 7.35) 
and H-7’ (δ 7.17) with the methyl protons at δ 2.39. Thus, the structure was 
established as a new 2-(3,4-dihydroxybenzylidene)-5-methyfuran-3-one named 
inotilone (53). 
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Fig. 33. Structure of inotilone (53) based on 
2D NMR 
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Fig. 34.  1H NMR spectrum (DMSO-d6) of inotilone (53) 
 
 
 
Fig. 35. 13C NMR spectrum (DMSO-d6) of inotilone (53) 
 
 
 
Fig. 36. HMBC spectrum of inotilone (53) 
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Recently, related 5-methyl-3(2H)-furanone metabolites including philligridin G (54)97 
and philligridin E (55)98 have been reported from the fruiting body of Phellinus 
igniarius.  
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3.2.5.4 Structure elucidation of (E)-4-(3,4-dihydroxyphenyl)but-3en-2-one (56) 
The molecular formula of 56 was determined as C10H10O3 based on HR-ESIMS and 
the 13C NMR spectrum. The IR spectrum indicated absorption bands for hydroxyl 
groups at 3459 cm-1, for a conjugated carbonyl (1597 cm-1) , and for aromatic rings 
(1596, 1533 and 1442 cm-1). Similar to that of inotilone, the 1H NMR  spectrum of 56 
showed signals attributable to the ABX spin coupling system of a trisubstituted 
phenyl moiety at δ 6.78 (1H, d, J = 7.78 Hz, H-19), 6.98 (1H, dd, J = 1.9, 8.2 Hz, H-
10) and 7.07 (1H, d, J = 1.9 Hz, H-8), as well as a trans disubstituted double bond at 
δ 6.53 (1H, d, J = 16.1 Hz, H-3) and 7.52 (1H, d, J =16.1 Hz, H-4), and a methyl 
proton signal. Therefore, the structure of 56 was identified as the known (E)-4-(3,4-
dihydroxyphenyl)but-3-en-2-one (56).98 
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3.2.5.5 Structure elucidation of hispidin (57) 
57, the major product of the mushroom Inonotus sp. was obtained as a yellow 
powder. The IR spectrum indicated absorption bands for hydroxyl groups (3093 cm-
1), for a conjugated carbonyl (1650 cm-1), and for aromatic rings (1594, 1544 and 
1449 cm-1). The ESI-MS mass spectrum showed the molecular ion peak at m/z 245 
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[M-H]-. Its molecular formula was determined as C13H10O5 based on HR-ESIMS, 13C 
NMR and DEPT 135 spectra. The 1H NMR spectrum indicated signals attributable to 
the ABX spin coupling system of a trisubstituted phenyl moiety at δ 6.75 (1H, d, J = 
8.4 Hz, H-13), 6.93 (1H, dd, J = 2.1, 8.4 Hz, H-14), 7.01 (1H, d, J = 2.1 Hz, H-10), a 
trans di-substituted double bond at δ 6.63 (1H, d, J = 15.9 Hz, H-7) and 7.13 (1H, d, J 
= 15.9 Hz, H-8) and three exchangeable phenolic hydroxyl protons at δ 9.02, 9.40 
and 11.60. Analyses of 13C, DEPT 135 and HMQC NMR spectra of 57 showed 13 
sp2  carbon signals (four of which are oxygenated), and a carboxyl carbon at δ 162.3. 
The long range correlation of H-7 (δ 6.63) with C-6 (δ 159.7) and C-5 δ 100.4, the 
correlation of H-5 (δ 6.14) with C-3 (δ 89.1), C4 (δ 170.3), C-6 (δ 159.7) and C-7 (δ 
116.3) and  the correlation of H-3 (δ 5.26) with C-2 (δ 162.3), C-4 (δ 170.3) and C-5 
(δ 100.4) enabled the identification of 57 as 6-(3,4-dihydroxystyryl)-4-hydroxy-2-
pyrone, also known as metabolite hispidin (57), early reported from Polyporus 
hispidus.99 A variety of activities including antimicrobial  and antioxidant activities, as 
well as the inhibition of protein kinase C (PKC) βI and βII isoforms (IC50 2µM) have 
been reported for hispidin.100,101 Recent studies have demonstrated that highly-
purified synthetic hispidin is cytotoxic at the range of 10-5 to 10-7 mol/l towards normal 
human MRC-5 fibroblasts and towards two human cancer cell lines, SCL-1 
(keratinocytes) and capan-1 (pancrealitic duct cells).102 
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3.2.5.6 Structure elucidation of iso-hispidin (58) 
The mass spectrum of 58 exhibited the molecular ion at m/z 245 [M-H]-. Based on the 
HR-ESIMS the molecular formula was established as C13H10O5. The IR spectrum 
showed absorption bands for hydroxyl groups (3359 cm-1), for a conjugated carbonyl 
(1644 cm-1) and for aromatic rings (1590, 1505 and 1414 cm-1). The 1H NMR 
spectrum of 58 showed signals similar to those of hispidin (57). But compared to 
those of hispidin their chemical shifts were quite different. This suggested that 58 
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was the tautomeric form of 57. This assumption was confirmed by the 13C NMR 
spectrum, which showed a signal for a conjugated carbonyl (δ 179.1) attributable to 
the carbon C-4. Therefore, the structure of 58 was elucidated as the highly stable 6-
(3,4-dihydroxystyryl)-2-hydroxy-4-pyrone, designated iso-hispidin (58). 
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58      Fig. 37. Structure of iso-hispidin based on  
2D NMR 
 
 
 
 
Fig. 38. 13C NMR spectrum (DMSO-d6) of iso-hispidin (58) 
 
3.2.5.7 Biogenetic relation of the isolated metabolites from Inonotus sp. 
The structures of compounds 52, 53 and 58, as well as that of the known compounds 
56 and 57 suggest that all metabolites share the same biosynthetic origin. All 
compounds represent linear or cyclized polyketides derived from caffeyl-CoA (59). 
While 56 appears to be a shunt product resulting from a premature release from the 
polyketide synthase, 52, 53, 57 and 58 are the result of two rounds of elongation. 
The structurally unusual 53 could be the product of a decarboxylation-radical ring 
closure sequence via the known metabolite hispolon 64.103 A related sequence could 
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be involved in the formation of the tri- and tetrahydroxyaurone aglycones of 
sulphurein and cernuosides. 104,105 
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Fig. 39. Structures of Inonotus sp. metabolites and model for their biosynthesis 
 
3.2.6 Pholiota squarrosa 
The fruiting body of Pholiota squarrosa was isolated in Jena (Germany) and its 
taxonomic identification was verified by Dr. Martin Roth, from the Leibniz-Institute for 
Natural Product and infection biology, HKI, Pilot Plant for Natural Products, where a 
specimen was deposited. Similar to that of Inonotus sp., the crude extract of the 
mushroom Pholiota squarrosa exhibited significant inhibitory activities against 3α-
HSD, COX and XO. 
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3.2.6.1 Extraction and isolation 
The fruiting body of Pholiota squarrosa (15 g dry weight) was treated the same way 
as those of Inonotus sp. to afford a related phenolic metabolite, squarrosidine (65). 
 
3.2.6.2 Structure elucidation of squarrosidine (65) 
The molecular formula of 65 was determined as C27H20O9 based on HR-ESIMS and 
13C NMR data. The 1H NMR spectrum showed three signals attributable to the 
characteristic ABX spin coupling system at δ 6.72 (1H, d J = 8.1 Hz, H-13), 6.88 (1H, 
dd J = 1.8, 8.1 Hz, H-14), 6.96 (1H, d J = 1.8 Hz, H-10). In addition, two signals were 
assigned to an AA’BB’ spin coupling system of a para-disubstituted phenyl moiety at 
δ 6.76 (2H, d, J = 8.7 Hz, H-11’ and H-13’), 7.43 (2H, d, J = 8.7 Hz, H-10’ and H-14’). 
Furthermore, the presence of two trans-disubstituted double bonds at δ 6.52 (1H, d, J 
= 15.9 Hz, H-7), 6.97 (1H, d, J = 15.9 Hz, H-8), 6.62 (1H, d, J = 15.9 Hz, H-7’) and 
7.06 (1H, d, J = 15.9 Hz, H-8’) was established.  
 
 
 
Fig. 40. 1H NMR spectrum (DMSO-d6) of squarrosidine (65) 
 
The 13C NMR and DEPT spectra showed one methylene sp3 and 26 sp2 carbon 
signals including 11 methines, 13 quaternary carbons (7 of which are oxygenated) 
and two carboxyl carbons. The presence of the carboxyl carbons was confirmed by 
IR, which showed the absorption band for a conjugated carboxyl carbon at 1661 cm-
1
. HMQC and HMBC experiments helped resolving the structure (see figure 41). In 
the HMBC spectrum the correlation of H-10 with  C-9, C-11, C-12, and C-14, the 
correlation of H-13 with C-9, C-11, C-12 and C-14 and the correlation of H-14 with C-
Results and discussion 
 
48
 
9, C-10, C-12 and C-13 confirmed the presence of the 11,12-dihydroxystyryl moiety. 
Moreover, the correlation of H-8 with C-6, C-9, C10, and C-14, that of H-7 with C-5, 
and the three-bond correlations of H-5 with C-3 revealed hispidin (57)  as a 
substructure of 65. This observation was confirmed by comparison of the 13C NMR 
data with those of 57. For the connection of the second part of 65, HMBC was once 
more very helpful. The correlation of H-10’ with C-10’ and of H-11’ with C-11’ 
established the para-hydroxystyryl moiety. Furthermore, the correlation of H-7’ with 
C-6’, C-9’, C-10’, C-14’; the correlation of H-7’ with C-5’ and the correlation of H-5’ 
with C-4’ and C-3’ helped identifying bisnoryangonin (66) as the second part of the 
molecule. It is remarkable that bisnoryangonin has been previously reported as a 
metabolite of Pholiota squarrosa-adiposa.106 HMBC data (correlation of H-15’ with C-
2, C-2’, C-3, C-3’ C-4 and C-4’) finally revealed that the two parts are connected 
through the C-15’ methylene. Thus, 65 was elucidated as an unprecedented 
methylene-bridged bisstyrylpyrone derivative designated squarrosidine.  
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Fig. 41. Selected HMBC correlations of squarrosidine (65) 
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Fig. 42. HMBC spectrum of squarrosidine (65) 
 
3.2.6.3 Model for the biosynthesis of squarrosidine 
The formation of squarrosidine can be rationalized by the nucleophilic vinylogous 
addition of the enol of 57 to a tautomeric form of a methylated bisnoryangonin 
derivative 67 (or vice versa). (Fig. 43)  
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Fig. 43. Biosynthesis of squarrosidine (65) 
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The only known methylene bridged bis-pyrone compounds are heliopyrone (68),107 
dicoumarol (69),108 gerberinol (70),109 and 1,13-dimethyl-6H,7H,8H-
chromeno[3’,4’:5,6]pyrano[3,2-c]chromene-6,8-dione (71).110  
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3.2.7 Phellinus pini DSM 5238  
Phellinus pini was retrieved from the fungal collection of the Leibniz-Institute for 
Natural Product Research and Infection Biology, HKI. 
 
3.2.7.1 Cultivation, extraction and isolation 
Well grown agar plates of the Phellinus pini DSM 5238 were used to inoculated 30 l 
of liquid malt medium as a stand culture. The dark brown crude extract from the ethyl 
acetate extraction of the culture broth exhibited significant inhibitory effect against 
3α-HSD, COX and XO. It was therefore, applied on Sephadex and silica gel for the 
purification of active metabilites, using 300 ml portions of CHCl3, CHCl3/MeOH (9:1), 
and CHCl3/MeOH (7:3). Further purification led to the isolation of three metabolites, 
pinillidine (72), pinillic acid (73), and hypholomine B (74). The work up scheme of the 
extract of the Phellinus pini DSM 5238 strain was the same as for Trichoderma 
crassum. 
 
3.2.7.2 Structure elucidation of pillidine (72) 
72 was obtained as an orange oil The IR spectrum showed absorption bands for 
hydroxyl groups (3071 cm-1), for conjugated carbonyl (1672 cm-1) and for aromatic 
rings (1601, 1548 and 1429 cm-1). The mass spectrum exhibited the molecular ion at 
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m/z 517 [M-H]-. The HR-ESIMS established the molecular formula as C13H10O5. The 
1H NMR spectrum of 72 was similar to that of hispidin (57), except for the presence of 
an additional doublet and quartet signals (δ 1.45, and 4.55, respectively). In the 13C 
NMR spectrum of 72, signals were observed at δ 16.5 and 25.5 in addition to those 
similar to 57. According to the mass (m/z = 518), it became obvious that 72 
represents a bis-hispidin derivative. The structure of 72 was then established as bis-
hispidinylethane. This compound has not yet been described in the literature. 
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3.2.7.3 Structure elucidation of pinillic acid (73) and hipholomine B (74) 
The molecular formula of 73 was determined as C17H14O5 based on HR-ESIMS and 
13C NMR data. The 1H NMR spectrum showed three signals attributable to the 
characteristic ABX spin coupling system at δ  7.18 (1H, d, J = 2.0 Hz, H-5), 6.93 (1H, 
d, J = 8.7 Hz, H-8), 7.12 (1H, dd, J = 2.0, 8.7 Hz, H-9). In addition, two signals were 
assigned to an AA’BB’ spin coupling system of a para-disubstituted phenyl moiety at 
δ 7.28 (2H, d, J = 8.5 Hz, H-4’ and H-8’), 6.83 (2H, d, J = 8.5 Hz, H-5’ and H-7’). 
Furthermore, the presence of a trans-disubstituted double bond at δ 6.34 (1H, d, J = 
15.9 Hz, H-2), 7.59 (1H, d, J = 15.9 Hz, H-3) was also established. The 13C NMR 
spectrum showed a carboxylic acid carbon signal, as well as 12 sp2 carbon signals 
(three of which are oxygenated) and two oxygenated sp3 carbon including one 
oxymethine (δ 76.2) and one oxymethylene (δ 70.5). The oxymethylene protons 
appeared as two diastereotopic protons at δ 4.04 (H-1’a, dd, J = 8.8, 11.5 Hz, 1H) 
and 4.36 (H-1’b, dd, J = 2.3, 11.5 Hz, 1H). Moreover, the COSY spectrum revealed 
the alignment H1’/H2’. These observations were evidence of the presence of an 
assymetric centre at C-2’ (δ 76.2). The HMBC spectrum enabled the elucidation of 
the final structure as follows: the correlation of H-2 (δ 6-34, d, J = 15.9 Hz, 1H) and 
H-3 (δ 7.59, d, J = 15.9 Hz, 1H) with C-1 (δ 170.7), and the correlation of H-3 with C-
5 and C-6 helped identifying caffeic acid (substructure 1) as a substructure of 73. 
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The substructure 2 of 73 was also established according to the correlation of H-2’ 
with H-4’. Finally the observed strong correlation between H1’a and H-7 led to the 
elucidation of the structure of 73 as that of a new natural product, belonging to the 
class of lignan secondary metabolites. The relative steochemistry of 73, designated 
pinillic acid (73), was established using NOESY, which showed correlations between 
H-1’a and H-8, H-1’a and H1’b and between H-1’a and H-2’. 
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Fig. 44. Structure of pinillic acid based on 2D NMR 
 
 
 
 
 
Fig. 45. 1H NMR spectrum (CD3OD) of pinillic acid (73) 
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Further confirmation of the structure was derived from the MS/MS spectrum, which 
indicated the peak fragments at m/z = 253, 177, 133 and 119 in negative mode. 
These fragments are the result of a decarboxylation (m/z = 253) and the cleavage of 
the dioxane moiety through a retro-Diels-Alder mechanism, (m/z = 177 and 119) 
followed by the decarboxylation (m/z = 133). (Fig. 46) Related metabolites have been 
isolated from plant including Grewia bilamellata,111 Silybum marianum112 and 
Hibiscus syriacus.113 
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Fig. 46. Fragmentation mechanism of pinillic acid based on MS/MS 
 
3.2.7.4 Model for the biosynthesis of Pinillic acid  
The biosynthesis of pinillic acid can be rationalized by a peroxidase catalysed 
cycloaddition between p-hydroxyvinylbenzene and caffeic acid. (Fig. 47) 
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Fig. 47. Proposed biosynthesis of pinillic acid (73) 
 
All the spectroscopic data of 74 proved to be that of the diasteroisomer mixture of the 
known hypholomine B (74). 114  
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3.2.7.5 Biological activity evaluations of the metabolites from Inonotus sp. and 
Pholiota squarrosa  
All phenolic metabolites from Inonotus sp, Pholiota squarrosa and Phellinus pini were 
evaluated for their inhibitory activities towards the enzymes 3α-hydroxysteroid 
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dehydrogenase (3α-HSD), COX-1, COX-2 and XO. Their inhibitory potencies, 
expressed as IC50 values, are shown in table 4 and are compared with those of the 
standards, indomethacin and allopurinol. The results in the present study 
demonstrate that phenolic compounds exhibit strong COX inhibitory effects with 
prevalence for COX-2 in the case of the compounds 52, 53, 56, 57. Interestingly, 
hispidin (57) and the new inotilone (53) selectively inhibit COX-2 at a level 
comparable with those of the marketed selective inhibitors meloxicam and nimesulide 
with an IC50 ratio (COX-2/COX-1) value of 0.08 µM both. In all cases, except for 
compound 53, strong 3α-HSD inhibitory effects were noted, as well as moderate 
inhibitory effects towards XO, except hispidin (57), which exhibited an inhibitory 
activity at a level comparable with that of the standard allopurinol. As far as the 
tautomeric compounds 57 and 58 are concerned, it seems that the α-pyronne is 
more active than the γ-pyrone. In summary, we have isolated and characterized five 
new phenylpropanoid-derived polyketides with potent COX and XO inhibitory 
activities from the mushrooms Inonotus sp., Pholiota squarrosa, and Phellinus pini 
DSM 5238. Apart from their anti-inflammatory activities, the structures of the 
dihydrofuranone-substituted and dioxane-substituted caffeyl derivative 53 and 73 and 
the unusual bisstyrylpyrones 65 are most notable. 
 
Compound IC50 (µM) 
 3α-HSD COX-1 COX-2 COX-1/COX-2 XO 
52 16.1 0.46 0.21 0.4 7.1 
53 50.4 0.3 0.03 0.08 9.1 
56 8.9 0.03 0.01 0.3 10.1 
57 8.1 0.01 0.0008 0.08 4.4 
58 12.1 0.05 0.13 2.6 13.8 
65 8.1 0.02 0.04 2.0 8.1 
72 5.8    5.8 
73 - - -  - 
74 25.5    6.5 
Indomethacin 15.8 0.1 6 60 n.a 
Allopurinol n.a n.a n.a  4.4 
 
Table 4. Inhibitory activities of 52, 53, 56, 57, 58, 65, 72, 73 and 74 towards 3α-HSD, 
COX-1, COX-2 and XO. 
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3.2.8 Piptoporus betulinus (fruiting body) 
The fruiting bodies of Piptoporus betulinus were collected in a forest district near 
Jena (Thuringia, Germany) and deposited in the strain collection of the Leibniz-
Institute for Natural Product Research and Infection Biology, HKI. 
 
3.2.8.1 Extraction and isolation 
The mushroom of the fungus Piptoporus betulinus was cut into small pecies, dried 
and crushed. The resulting powder was extracted three times with ethyl acetate, 
chloroform and methanol. The ethyl acetate extract of a brown solid, which was 
found to have a strong anti-inflammatory effect (significant inhibitory activity against 
3α-HSD), was subjected to silica gel chromatography and preparative HPLC, 
affording five lanostanoids-like triterpenes (two of which are new) namely,  
polyporenic acid A (75), acetylpolyporenic acid A (76), (25S)-(+)-12α-hydroxy-3α-
methylcarboxyacetate-24-methyllanosta-8,24(31)-diene-26-oic acid (77), (25S.3‘S)-
(+)-12α-hydroxy-3α-(3‘-hydroxy-4‘-methoxycarbonyl-3‘-methylbutyryloxy)-24-
methyllanosta-8,24(31)-dien-26-oic acid (78) and Polyporenic acid C (79). 
 
3.2.8.2 Structure elucidation of polyporenic acid A (75) 
The molecular formula of 75 was determined as C31H50O4 based on HR-ESI-MS. The 
1H NMR spectrum of 75 showed 50 non exchangeable protons, including two olefinic 
protons and seven methyl groups. Analyses of the 13C NMR, DEPT 135 and HMQC 
spectra of 75 further identified the presence of seven methyl carbons, ten methylene 
carbons (one of which is sp2 hybridized), six methine carbons (two of which are 
oxygenated), six quaternary carbons (two of which are sp2 hybridized) and a carboxyl 
carbon δ 178.7. This was also confirmed by the IR spectrum, which showed 
absorption at 1708 cm-1. The sequences of couplings H15/H16/H17/H20; 
H21/H20/H22/H23/H31, H6/H7, H1/H2/H3 was obtained by 1H-1H COSY spectra. For 
the assignment of the other constituting protons and carbons 13C, 1H long range 
coupled NMR spectra (HMBC) were particularly helpful. The correlation of H-31 (δ 
4.89, brs, 2H) with C-24 (δ 151.6) and C-23 (δ 33.2), the correlation of H-25 (δ 3.16, 
q, J = 7.0 Hz, 1H)  with C-26 (δ 178.7), C-27 (δ 16.2) , C-23 (δ 33.2) , C-24 (δ 151.6) 
and C-31 (δ 110.0)  and the correlation of H-27 (δ 1.25, d, J = 7.0, Hz, 3H) with C-24 
(δ 151.6), C-25 (δ 48.3) and C-26 (δ 178.7) were evidence of the connection of the 
carboxyl carbon in C-25. Another important aspect of the analyses was the observed 
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HMBC correlations of H-12 (δ 4.00, d, J = 8.1 Hz, 1H) with C-9 (δ 134.7), C-11 (δ 
32.9), C-13 (δ 50.7) and C-14 (δ 50.6). These correlations helped identifying the 
position of the hydroxymethine. 75 was then elucidated as the known polyporenic 
acid A. The spectral data were found to be in good agreement with those 
reported.115,116  
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3.2.8.3 Structure elucidation of 3α- acetylpolyporenic acid A (76) 
76 was obtained as a colourless oil [α]22D+30o (MeOH; c 0.18). Its formula was 
determined as C33H52O5 based on HR-ESIMS. The 1H NMR spectrum of 76 was 
similar to that of polyporenic acid A (75) except for the presence of an additional 
singlet at δ 2.06 (s, 3H). In the 13C NMR spectrum two additional signals were 
observed at  δ 171.0 (carboxyl carbon signal), and  21.3 (methyl carbon signal). The 
long range HMBC helped connecting these additional carbons by showing a 
correlation of the methine proton H-3 (δ 4.65, brs, 1H) and the methyl proton H-2’(δ 
2.06, s, 3H) with the carboxyl carbon C-1’ (δ 171.0). This indicated that the carbon C-
3 is connected to an acetate group. Consequently, 76 was identified as 3α-
acetylpolyporenic acid A (76). 
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Fig. 48. 13C NMR spectrum (CDCl3) of 76 
 
3.2.8.4 Structure elucidation of (25S)-(+)-12α-hydroxy-3α-
methylcarboxyacetate-24-methyllanosta-8,24(31)-diene-26-oic acid (77) 
In the 1H and 13C NMR spectra of 77, which was obtained as a colourless oil 
[α]22D+19.2o (MeOH; c, 0.50), all the signals assignable to 75 were almost identical. 
But the C-3 (δ 79.7) of 77 was substituted by another functional group. The 1H NMR 
spectrum revealed the presence of two additional singlets at δ 3.39 (s, 2H) and  3.70 
(s, 3H). In the 13C NMR spectrum, additional signals were also observed at δ 41.7 
(CH2), 52.3 (CH3O), 166.0 ppm (C=O) and 167.2 (C=O). The long range HMBC 
spectrum data helped elucidating the additionnal moiety by showing the correlation of 
the protons of the additional methylene with the two additional carboxyl carbons, and 
the correlation of the protons of additional methoxy moiety with the carboxyl carbon 
at δ 167.2. Thus, the substituent at C-3 (δ 79.7) could be identified as methyl 
malonate (-CO2CH2CO2CH3), which was supported by the IR spectrum (strong 
absorption at 1722 cm-1) and MS data (pseudo molecular ion peak at m/z 609.3756 
[M+Na]+). Consequently, compound 77 was identified as (25S)-(+)-12α-hydroxy-3α-
methylcarboxyacetate-24-methyllanosta-8,24(31)-diene-26-oic acid (77). 
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Fig. 49. 13C NMR spectrum (CDCl3) of 77 
 
This is the first isolation and full characterization of 76 and 77. However it is 
important to note that their methyl ester derivatives have been isolated from the 
methylated extract of Piptoporus betulinus.117 
 
3.2.8.5 Structure elucidation of (25S.3’S)-(+)-12α-hydroxy-3α-(3’-hydroxy-4’-
methoxycarbonyl-3’-methylbutyryloxy)-24-methyllanosta-8,24(31)-dien-26-oic 
acid (78) and Polyporenic acid C (79) 
Similar to those of 76 and 77, the 1H and 13C NMR spectra of 78 indicated all signals 
assignable to polyporenic acid A (75). The ESI-MS exhibited a molecular ion peack 
at m/z = 667 [M+Na]+, suggesting that the C-3 of 78 was substituted by a functional 
group other than acetate or methyl malonate. A signal due to an oxygen-bearing 
quaternary carbon was observed at δ 69.7 in the 13C NMR spectrum. Three 
correlations from the methyl protons at δ 1.39 to the quaternary carbon C-3’ (δ 69.7), 
to the methylene carbon C-2’ (δ 45.0) and to the other methylene carbon C-4’ (δ 44.8) 
were observed from the HMBC spectrum. Finally the two additional carbon signals 
attributable to the carboxyl carbons, enabled the identification of 78 as the O-(3-
hydroxy-3-methylglutaryl) derivative of 75: ((25S.3’S)-(+)-12α-hydroxy-3α-(3’-
hydroxy-4’-methoxycarbonyl-3’-methylbutyryloxy)-24-methyllanosta-8,24(31)-dien-26-
oic acid). The absolute configuration of O-(3-hydroxy-3-methylglutaryl)118 was 
determined by comparing the optical rotation with literature data. All physicochemical 
and spectrometric data obtained for compounds 79 proved to be identical with those 
reported for polyporenic acid  C.118  
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3.2.8.6 Biological activity of the isolated metabolites from Piptoporus betulinus 
 
3.2.8.6.1 Anti-inflammatory activity 
76-79 were tested for their ability to inhibit the key enzymes involved in the 
inflammatory processes including COXs and 3α-HSD. While 76-79 exhibited only 
weak inhibition activity of COX-1, they proved to be promising anti-inflammatory 
agents in the 3α-hydroxysteroid dehydrogenase (3α-HSD)-assay according to the 
method described by Penning.119 Most remarkably, 76, 78 and 79 inhibited 3α-HSD 
at the level comparable to indomethacin reference and 77 exhibited a stronger 
activity than that of indomethacin. (Fig. 50 and table 5) 
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Fig. 50. Inhibition of 76, 77, 78 and 79 towards 3α-HSD 
 
 
 76 77 78 79 indomethacin 
IC50 (µg/ml) 8.5 4.0 5.5 17.5 6.5 
 
Table 5. Inhibitory activity of 76-79 against 3α-HSD (IC50 values) 
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3.2.8.6.2 Anti-hyaluronidase activities  
Anti-hyaluronidase activities were measured spectrophotometrically based on the 
precipitation of undigested hyaluronane by N-cetyl-N,N-trimethylammoniumbromide 
(CTA) and the measurement as turbidity (E600nm) using the method described by Di 
Ferrante.120 Although 76-79 showed no activity against bovine hyaluronidase (Fig. 51 
and table 6) they are potent inhibitors of hyaluronate lyase from Streptococcus 
agalactiae. This enzyme acts as surface antigen, which is responsible of the 
degradation of hyaluronane (hyaluronic acid), the most abundant matrix of the 
connective tissues, predominantly into disaccharide units. This degradation facilitates 
the invasion of bacterial pathogens, mostly Gram-positive Streptococci into the host 
tissues.121,122 Strikingly, the methylated derivatives of 78 and 79 exhibited no 
inhibition towards the bacterial hyaluronate lyase, and bovine hyaluronidase, 
suggesting that the carboxyl moieties of 76-79 are essential for activity. To date only 
saccharic acid is known to selectively inhibit bacterial hyaluronate lyase, while not 
affecting the enzymatic activity of testicular hyaluronidase.123 Thus, 76-79 appear to 
be a new class of compounds possessing a similar selectivity. 
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Fig. 51. Inhibition of 76, 77, 78 and 79 towards hyaluronat lyase 
 
 
 76 77 78 79 
IC50 (µM) 40.0 3.5 51.0 12.5 
 
Table 6. Inhibitory activity of 76-79 against Streptococcus agalactiae hyaluronate 
lyase (IC50 values) 
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4 Summary 
 
The present study is mainly focused on the discovery of new fungal natural products 
acting on clinically relevant targets in inflammatory and infectious (microbial and viral) 
diseases. 
 
4.1 Anti-inflammatory compounds 
Rheumatoid arthritis is a chronic debilitating inflammatory disease that affects up to 
1% of the population with a 3:1 prevalence in women over men but has no known 
cure. While a number of small-molecule drug therapies exist to ease symptoms, they 
often demonstrate limited efficacy and many adverse side effects. The therapy based 
on the inhibition of the key enzymes (3α-HSD, COX-1 and COX-2) involved in the 
biosynthesis of prostaglandins has been shown to be a relatively safe and effective 
therapy for the treatment of various inflammatory diseases. In contrast with 
rheumatoid arthritis, gouty arthritis is mediated by the crystallisation of uric acid (UA) 
in the joints. Its therapies are based either on the increase of the urinary excretion of 
UA, or on the blockage of the terminal step of the biosynthesis of UA using xanthine 
oxidase (XO) inhibitors. Allopurinol, the only XO inhibitor in clinical use, seems to be 
associated with a severe side effect.  On the basis of these therapies, it is highly 
desirable to develop the next generation of small-molecule targeting with these 
enzymes, which could be useful as lead structures for the new generation of anti-
inflammatory and anti-arthritic drugs.  
To achieve this goal, six fungal strains, Epicoccum sp HKI 0470, Aspergillus sp HKI 
0472. Inonotus sp, Pholiota squarrosa, Phellinus pini DSM 5238 and Piptoporus 
betulinus were selected based on the pre-screening assay. We used 3α-HSD assay 
as a pre-screening for anti-inflammatory compounds. 
 
Epicoccum sp. HKI 0470 
Two new metabolites, epicoccone B (29) and epicoccalone (30) in addition to three 
known metabolites, epicoccamide (27), epicoccine (28) and orevactaene (31), were 
isolated from Epicoccum sp HKI 0470. 
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While 29, 30 and 31 displayed only weak inhibition effect towards 3α-HSD, 30 was 
identified as a serine protease (α-chymotrypsin) inhibitor. Here it should be noted that 
there is increasing evidence about possible involvement of the serine protease 
inhibitors in the regulation of inflammation, host defence against infection, tissue 
repair and extra cellular matrix synthesis. 
 
Aspergillus sp. HKI 0472 
From the strain Aspergillus sp. three compounds were isolated, namely funalenine 
(48), TMC-256C2 (50) and TMC-256A1 (51). While TMC-256C2 (50) and TMC-
256A1 (51) exhibited no anti-inflammatory activity, the new funalenine, with an 
unusual conformation, proved to be a potent anti-inflammatory drug by inhibiting 3α-
HSD, COX-1 and COX-2 with IC50 values of 52 µM, 36 µM and 45 µM, respectively. 
H
O
OO
H
O
CH3O
CH3 OH
H
O
O
OH
OCH3
H3CO
         
O
OOHOCH3
HO
 
                              48                                              50                                                       51 
 
 
 
Summary 
 
64
 
Inonotus sp. (fruiting body) 
In the pre-screening assay the ethyl acetate extract of mushroom Inonotus sp. 
exhibited a strong anti-inflammatory activity. The bioassay guided purification led to 
the isolation of 5 compounds, three of which are new, namely inonotic acid methy 
ester (52), inotilone (53), and isohispidin (58). The known compounds are (E)-4-(3,4-
dihydroxyphenyl)but-3-en-2-one (56) and hispidin (57).  
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All these compounds exhibited strong COX inhibitory effects with prevalence for 
COX-2 in the case of 52, 53, 56 and 57. It should be highlighted that 53 and 57 
selectively inhibited COX-2 at concentrations as low as those of the marketed 
selective inhibitors meloxicam and nimesulide. In all cases, except for 53, strong 3α-
HSD inhbitory effects were noted, as well as moderate inhibitory effects towards XO, 
except 57, which exhibited an inhibitory activity at the level comparable with that of 
the standard allopurinol. 
 
Pholiota squarrosa (fruiting body) 
The new compound named squarrosidine (65) is the only metabolite we have 
isolated from the mushroom Pholiota squarrosa using bioassay guided separation. It 
is a bishispidin derivative with an unusual methylene bridge. 65 displayed significant 
3α-HSD, COX-1, COX-2 and XO inhibitory effect with an IC50 values of 8.1, 0.02, 
0.04 and 8.1 µM, respectively. The ratio COX-1/COX-2 value was 2, indicating that 
65 is a non-selective COX inhibitor. 
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Phellinus pini DSM 5238 
Three compounds were isolated from the filamentous fungus Phellinus pini DSM 
5238. These are pinillidine (72) (a known structure, which has not yet been described 
in the literature), pinillic acid (73) a new lignan metabolite, and the known 
hypholomine B (74). While 73 displayed no anti-inflammatory activity, 72 and 74 
exhibited significant inhibitory effects towards 3α-HSD and XO.  
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Piptoporus betulinus (fruiting body) 
Bioassay guided fractionation of ethyl acetate extract of the mushroom Piptopurus 
betulinus led to the isolation of 5 lanostanoid-like triterpenes, two of which are new, 
acetylpolyporenic acid A (76) and (25S)-(+)-12α-hydroxy-3α-methylcarboxyacetate-
24-methyllanosta-8,24(31)-diene-26-oic acid (77)). The known compounds are 
polyporenic acid A (75), (25S.3’S)-(+)-12α-hydroxy-3α-(3’-hydroxy-4’-
methoxycarbonyl-3’-methylbutyryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid 
(78) and Polyporenic acid C (79). 76 and 77 exhibited remarkable inhibitory effects 
towards 3α-HSD. Most remarkably 77 exhibited a stronger activity than that of the 
reference (indomethacin). 
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In conclusion, the screening for the search for new anti-inflammatory compounds led 
to the isolation of 22 compounds, 10 of which are new. Among the new compounds 7 
proved to be promising anti-inflammatory agents. These are funalenine (48), inonotic 
acid methyl ester (52), Inotilone (53), isohispidin (58), squarrosidine (65), 
acetylpolyporenic acid A (76) and (25S)-(+)-12α-hydroxy-3α-methylcarboxyacetate-
24-methyllanosta-8,24(31)-diene-26-oic acid (77). It should be noted that hispidin 
(57), (E)-4-(3,4-dihydroxyphenyl)but-3-en-2-one (56), pinillidine (72) and 
hypholomine B (74) are described here for the first time as anti-inflammatory agents. 
 
4.2 Anti-infectious compounds 
Despite the successes in the treatment of some infectious diseases during the past 
three decades, the search for new antimicrobial or antiviral drugs remains an area of 
active investigation. Effective treatment is not available for many infectious diseases. 
Moreover, the selection of resistant and cross-resistant mutants caused partially by 
the narrow spectrum of the mechanism of activity, as well as potential toxic side-
effects demand the discovery of new drugs. 
To meet this objective, two strains, Trichoderma crassum HKI 0471 and Lepista 
nebularis HKI 0411 were selected based on pre-screening assays on agar plates. 
 
Trichoderma crassum HKI 0471 
Three known active metabolites, β-viridin (13), α-viridin (14) and CAF 603 (19) were 
isolated from Trichoderma crassum HKI 0471. These metabolites exhibited strong 
anti-fungal activity against Candida albicans ATCC 18804 and Sporobolomyces 
salmonicolor SBUG 549, respectively. 
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Lepista nebularis HKI 0411 
In addition to the new antiviral metabolite (nebularic acid A (32)), a known strong 
anti-microbial metabolite (diatretyne (47)) was isolated from Lepista nebularis HKI 
0411. 
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32 exhibited a strong anti-virale activity against cosackievirus with an IC50 value of 6 
µM, and diatretyne (47) exhibited significant anti-fungal and bacterial activities 
against Candida albicans ATCC 18804 (MIC = 25 µg/ml) multi-resistant 
Streptococcus aureus (MIC = 1.56 µg/ml) and Mycobacterium vaccae (MIC = 6.25 
µg/ml). Diatretyne exhibited also cytotoxic and antiproliferative activities.
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5 Experimental section 
5.1 General experimental procedures 
Melting point and decomposition points were adjusted with the Wagner & Munz 
melting point apparatus and were not corrected.  
IR spectra (film) were recorded on a Sattelite FTIR spectrometer equipped with a 
ATR device and on a JASCO FT/IR-4100 spectrometer equipped with ATR a device. 
UV spectra were measured with a Specord 200 Carl Zeiss technology spectrometer 
(Analytik Jena AG, Jena) and with a HP UVIS (Desaga GmbH, Wiesloch) apparatus 
for TLC. 
Optical rotations were mesured with a Propol Digital Automatic Polarimeter. 
1H NMR spectra were recorded on a Bruker Avance 500 DRX spectrometer (Bruker, 
Kalrlsruhe, Germany) at 300 MHz. Coupling constants (J) in Hz. Abbreviations: s = 
singulet, d = doublet, dd = double doublet, t = triplet , q = quartet, m = multiplet, brs = 
broad.  
13C NMR spectra including DEPT were recorded on a Bruker Avance 500 DRX 
spectrometer (Bruker, Karlsruhe, Germany) at 75 MHz. Chemical shifts were 
measured relative to tetramethylsilane as standard.  
2D-NMR spectra  
1H-1H COSY (1H, 1H-correlated spectroscopy), HMBC (Heteronuclear Multiple Bond 
Connectivity), HMQC (Heteronuclear Multiple Quantum Coherence) and NOESY 
(Nuclear Overhauser Effect Spectroscopy) 
Electrospray Ionisation Mass Spectroscopies (ESI-MS/Tandem-MS (MS/MS) 
were performed on a VG Quattro with an ASI source (VG Biotech Atrincham, 
England) apparatus, eluent: MeOH/H2O = 99:1, rate: 15 µl/min, temperature: 65 oC. 
ESI-MS/Tandem-MS (MS/MS)/MSn were recorded on a Benchtop Mass 
spectroscopy apparatus Finnigan LCQ (Finnigan, Bremen). 
High-Resolution Electrospray Ionisation Mass Spectroscopies (HR-ESIMS) 
were recorded on a AMD 402 double-focusing mass spectrometer with BE geometry 
(AMD, Intestra, Harpstedt, Germany).  
LC/MS were recorded on a Finnigan TSQ quantum ULTRA AM apparatus equipped 
with a Finnigan Surveyor PDA detector, a Finnigan Surveyor Autosampler plus, and 
a Finnigan Surveyor LC pump plus. 
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High Performance Liquid Chromatography (HPLC). 
Intrument-1. Analytical HPLC was recorded on a SHIMADZU (Kyoto, Japan) 
multiwavelength detector SPD-M 10AVP (DAD), equipped with two pumps type LC-
10AT, System controller type: SCL-10AVP mixing chamber, injection valve (type 
rheodyne) with sample loop 20 µl, hardware: class VP 54.0. Analytical column: 1) 
Eurochrom 4.6 x 125 mm without pre-column: stationary phase: Hypersil, ODS 120 x 
5 µm; 2) Vertex 4.6 x 250 mm, stationary phase: Nucleosil NP 100-C-18, particle size 
5 µm.  
Intrument-2. Preparative HPLC was performed using a Gilson binary gradient HPLC 
system equipped with a UV detector (UV/VIS -151), two pumps type Gilson 305 and 
306, Gilson 811C dynamic mixer and a Gilson 806 manometric module.  
Intrument-3. Preparative HPLC was performed using a Shimadzu, Kyoto, Japan 
equipped with two pumps type LC-8A, detector: SPD-10A system-controller: SCL-8A, 
fractions collector: FCV-100B preparative column: Vertex 16 x 250 mm with 16 x 30 
mm pre-column, stationary phase: Eurospher C-18 Rp 100 x 5 µm; 2); Vertex 16 x  
250 mm with 16 x 30 mm pre column, stationary phase: Nucleosil NP 100-C-18, 
particle size 5 µm, pore diameter 100 Å (Macherey-Nagel & Co.). HPLC-solvents: 
acetonitrile/water-azeotrope (83% acetonitrile / 17% water bp. 74-80 oC) the 
azeotrope was redistilled with a Fischer LABODEST 107 solvent recycling apparatus.  
Lyophilizer drying: All water contained in the fractions was lyophiolized with a Virtus 
Sentry (The Virtus Company Gardiner, New York 12525) apparatus. 
 
Materials  
Thin layer and preparative thin layer chromatographies (TLC and PTLC) were carried 
out with silica gel 60 F254 20 x 20 cm plates Merck KGaA Darmstadt, Germany. 
Column chromatographies (CC) were performed on silica gel (60, Merck; 0.063-0.2 
µm) and Sephadex LH-20 (Pharmacia). 
 
Spray reagents 
Vanillin/sulphuric acid: 2.5 g vanillin was added to a solution containing 425 ml 
methanol, 50 ml acetic acid and 25 ml sulphuric acid. 
Anisaldehyd/sulphuric acid: 1ml anisaldehyde was added to 100 ml solution 
containing 85 ml methanol, 14 ml acetic acid and 1 ml sulphuric acid. 
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Ehrlich’s Reagent:  1 g of 4-dimethylaminobenzaldehyde was dissolved in a mixture 
of 25 ml hydrochloric acid (37%) and 75 ml methanol. 
 
Microbiological materials 
Fermenter: 200 l fermenter (B. Braun Biotech International, Melsungen) consisted of 
a culture container, magnet-couplet propeller stirrer, cooler with thermostat, control 
unit with pH and antifoam regulation, Control unit: pH regulator, antifoam regulator 
and air regulator.  
Storage of strains: deep-freeze storage in a Dewar vessel, Fa. -Capillaries for deep-
freeze storage: diameter 1.75 mm, length 80 mm, Fa. Hirschmann Laborgeräte, 
Eberstadt. 
Laboratory Shaker: ISF-1-w Adolf Kühner AG. Basel  
Autoclave: Albert Dargatz Autoclave, volume 119 l, working temperature 121 oC, 
working pressure 1.2 kg/cm2. 
Antimicrobial assay disc: 9 mm diameter, Schleicher & Schuell No. 321 261.  
Culture media: Glucose, bacto peptone, bacto agar, dextrose, soybean, mannit 
yeast extract and malt extract were from Merck. 
Laminar-Flow-Box: Haraeus instrument (Germany) 
 
Ingredients of different media 
All the microbiological work was performed under sterile conditions as unsual. 
The ingredients of medium were consisted of: 
Malt extract, Glucose, Caseine peptone, Merck. 
Degreased soybean flour, Henselwerk GmbH. 
Yeast extract, Oxoid 
Oatmeal (Holo Hafergold), Neuform 
BiTek Agar-Agar, Difco 
Glucose, AppliChem 
Maltose, Fluka 
Biomalt, Villa Natura 
. 
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Recepies for media 
All the culture media were autoclaved at 1.2 bar and 121 oC for 35 min 
 
Malt medium (liquid medium) (g/l)    Zeolith medium (g/l) 
Malt extract   20    Glycerine   5 
Yeast extract  2    Glucose   30 
Glucose   10    Peptone  5 
(NH4)2HPO4   0.5    NaCl   2 
Agar   1 
pH 7.0 
 
 
MPG-medium (shake culture)(g/l)  Sbo1-Medium (shaking culture) (g/l) 
Glucose   10    Glucose  10 
Malt extract   20    Saccharose  10 
Soybean flour 2              Yeast extract 0.8 
Yeast extract  1    Caseine peptone 2 
KH2PO4   1    Soybean flour 5 
MgSO4.7H2O  0.5    (NH4)2HPO4  0.5 
pH  5.5      CaCO3  0.3 
       (NH4)2SO4  5 
       pH   6.5 
 
 
5.2 Microbiological and analytical methods 
Storage of strains 
All strains (filamentous fungi) were stored in liquid nitrogen for a long time. The 
strains were inoculated in agar plates with suitable media at 25 oC. 
 
Pre-screening 
The fungal isolates were cultivated in a 1 l scale in 500 ml  Erlenmeyer flasks 
containing 200-300 ml of  malt medium, MPG medium, Sbo1, medium, and zeolith 
medium. The flasks were shacked for about one month after which the entire 
fermentation broth was freeze-dried and the residues were extracted with ethyl 
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acetate. The extracts were evaporated to dryness and used for antimicrobial tests at 
a concentration of 100-1000 µg/ml. 
 
5.3 Biological screening method 
5.3.1 Antimicrobial screening 
Antimicrobial activities were determined qualitatively by agar diffusion tests according 
to: Deutsches Arzneibuch,124 9th Edition, 1986, 47-48 and 424-430, Deutscher 
Apotheker Verlag Stuttgart. Test organisms (Bacillus subtilis ATCC 6633, Escherichia 
coli SG 458, Streptococcus aureus BB 271, Micrococcus luteus SG 125 A, 
Mycobacterium vaccae IMET 10670, Saccharomyces cerevisiae Gi300, 
Sporobolomyces salmonicolor SBUG 549, Candida albicans ATCC 18804, 
Penicillium notatum JP 36, Fusarium culmorum JP 15, Phoma destructiva i 1015, 
Aspergillus fumigatus ATCC 46645, Aspergillus terreus etc. were suspended in the 
melted agar medium and poured into Petri dishes. Holes of 9 mm in diameter were 
cut in the agar and filled with 50 µl of a 100 mg/l or a 1000 mg/l solution of the crude 
extract. Inhibition zones were measured with a ruler after overnight incubation. 
 
5.3.2 Antiviral screening assay 
The antiviral assays were carried out by Dr. Michaela Schmidtke from the institute of 
virology of the University of Jena. 
 
Material 
HeLa cell (Human cervix carzinoma cell line (USA) 
Coxsackievirus B3 strain Nancy (Institut for poliomyelitis Moskow Russia) 
Minimal essential Medium/Earle (MEM) SIGMA, Deisenhofen 
Trypsin Berlinchemie, Berlin 
Tricin Serva Heidelberg 
 
Method 
Virus stocks of the coxsackie virus B3 strain Nancy (Coxsackie virus B3; Institute of 
Poliomyelitis and virus Encephalitides, Moscow, Russia) the influenza virus A strain 
Hong Kong/68 (H3N2; Schaper and Brümmer, Salzgitter, Germany), and the 
acyclovir- and phosphonoformic acid-sensitive laboratory herpes simplex virus type 1 
strain (HSV-1; kindly provided by W. Hampl Universität Ulm, Germany) were 
prepared in HeLa Ohio, MDCK and GMK cells, respectively. About 50 µl aliquots of 
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the virus stocks were stored at –70 oC until use. The titre of the virus was determined 
by plaque assay on the respective monolayers. 
 
Plaque reduction assays 
The plaque reduction assays were carried out as described by Schmidtke et al.125 
Briefly, after removal of the cell growth medium, confluent 2-day-old cell monolayer in 
6 well plates (Flacon 3046) were inoculated with 1 ml of the respective virus 
suspension in the test medium (coxsackie virus on HeLa; influenza virus A on MDCK; 
HSV-1 K1 on GMK cells) containing approximately 100 plaque forming units (pfu) in 
the absence of serial twofold dilutions of the test compounds. After adsorption at 37 
oC for 1 h, the inoculum was aspirated and 2 ml of the respective test medium 
containing 0.4% agar and the appropriate concentrations of the drugs were added. 
Each compound concentration was tested in duplicate. The tests were incubated at 
37 oC for 48 h (coxsackie virus B3 and influenza virus A or 72 h for HSV-1 K1 until 
plaques appeared and then fixed and stained with formalin (3% v / v) and ethanol 
(1.67% v / v) in water overnight. Plaques were counted over a light box after removal 
of the agar overlay. The average plaque count from two compound treated wells at 
each concentration was plotted against the average plaque count of three untreated 
virus-infected wells. The concentration required to reduce the plaque number by 50% 
(IC50) was calculated from the mean dose-response curves of at least three plaque 
reduction assays. 
 
5.4 Enzyme inhibition test assays 
5.4.1 α-Chymotrypsin inhibitory assay 
The α-Chymotrypsin inhibitory assay was carried out by Dr. Keishi Ishida from the 
Leibniz-Institute for Natural Product Research and Infection Biology, HKI, 
Biomolecular Chemistry. 
 
Material 
Chymotrypsin: α-Chymotrypsin from bovine pancreas (C4129, SIGMA). 
N-succinyl-phenylalanine-p-nitroanilide (35572, SERVA) 
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Method 
The chymotrypsin inhibitory activity was determined by the method of Cannell et 
al.126 Each assay mixture containing 30 µL of 50 mM Tris-HCl buffer (pH 7.6), 50 µl of 
chymotrypsin solution (150 U/ml in 50 mM Tris-HCl buffer (pH 7.6)) and 20 µl of test 
solution were added to each cuvette and pre-incubated at 37 oC for 5 min.  Each 
reaction was started with the addition of 100 µl of substrate solution (N-succinyl-
phenylalanine-p-nitroanilide in Tris-HCl (pH 7.6, 1 mg/ml)).  The absorbance of the 
reaction mixture was immediately measured at 405 nm.  The change colour was 
measured after 30 min incubation at 37 oC. 
 
5.4.2 3α-Hydroxysteroid dehydrogenase (3α-HSD) inhibition assay  
Test principle 
3α-HSD from rat liver cytosol can be inhibited by non-steroidal antiphlogistics. 3α-
HSD catalyses the reduction of 5β-dihydrocortisone with consumption of NADPH. 
The NADPH consumption is determined photometrically as a decrease of extinction 
at 340 nm. Indomethacin and ibuprofen are used as standard compounds. 
 
Material 
Aqua dest. (purest) 
1 M Phosphatbuffer (pH 6.0) 
9 mM NADPH (SIGMA) 
5 mM 5β-dihydrocortisone (SIGMA) 
UV visible spectrophotometer (UV 160A, Shimadzu, 340 nm) 
 
Procedure 
This assay was conducted spectrophotometrically according to the method described 
by T. M Penning.119 
 
5.4.3 Cyclooxygenase inhibition assays 
Test Principle 
The chemical chemiluminescent COX (ovine) inhibitor screening assay utilizes the 
heme-catalyzed hydroperoxidase activity of ovine cyclooxygenases to generate 
luminescence in the presence of a cyclic naphthalene hydrazide and the substrate 
arachidonic acid. 
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Material 
Assay Buffer (Cyaman Chemical) 
Heme (Cyaman Chemical) 
COX-1 (ovine) (Cyaman Chemical) 
COX-2 (ovine) (Cyaman Chemical) 
Arachidonic acid (Cyaman Chemical) 
Potassium Hydroxide (Cyaman Chemical) 
Chemiluminescent substrate (Cyaman Chemical) 
96 well plate (Cyaman Chemical) 
Plates cover (Cyaman Chemical) 
 
Method 
Background Wells-10 µl of heme, 10 µl of assay buffer, and 10 µl of solvent (DMSO) 
were added to three wells 
100% Initial Activity Wells- 10 µl of heme, 10 µl of enzyme (either COX-1 or COX-2), 
and 10 µl of solvent were added to three wells. 
Inhibitor Wells- 10 µl of heme, 10 µl of enzyme and 10 µl of inhibitor were added to 
three wells. 200 µl of buffer was then added to all of the used wells. The plate was 
inserted into the luminometer, which has been dispensed with 10 µl of the 
chemiluminiscence substrate, immediately 50 µl of arachidonic acid was dispensed 
to all the using wells. The total volume of this assay was 290 µl in all wells. After 
inhibition by NSAIDs, the direct residual activity of COX was measured by addition of 
a proprietary luminescent substrate and arachidonic acid. Light emission starts 
immediately and is directly proportional to the COX activity in the sample. The 
chemiluminescent signal was measured over 5 seconds. One unit of COX activity is 
defined as the amount of enzyme needed to consume 1 nM of oxygen per minute. 
 
5.4.4 Xanthine oxidase assay 
The test was conducted according to the method described by Pierce et al.130 
 
Test Principle 
The superoxide anion radicals can be quantified as relative light units (RLU) by use 
of the chemiluminescent detector lucigenin. Allopurinol (1,5-dihydro-4H-pyrazol[3,4-
d]pyrimidin-4-one) inhibits xanthine oxidase, and it is used as a therapeutic agent in 
the treatment of gout and as standard compound in this assay. 
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Material 
HBSS (10x) (Hank’s solution without Ca und Mg; GIBCO BRL) 
Aqua dest. 
Lucigenin (Sigma Chemical Co.) 
Allopurinol (SIGMA Chemical Co.) 
Hypoxanthine (SIGMA Chemical Co.) 
Xanthine oxidase (SIGMA Chemical Co.) 
 
Procedure 
100 µl lucigenin (5 x 10-4 M) was added to a well, followed by 50 µl xanthine oxidase 
grade III (sigma, 0.1 units/ml) and an appropriate solution of the test compound. After 
equilibration of the plate at 37 oC for 15 min, background CL reading were made 
every 5 mn intervals for 15 min before 50 µl hypoxanthine (Sigma, 10 mg/ml) was 
added to start the reaction. The results were expressed as the percentage decrease 
in the total CL produced in the presence of the test compound 30 mn after addition of 
hypoxanthine to the plate. Chemiluminescence was measured continuously for 10 
min and was expressed as relative light unit (RLU) per minute. 
3α-HSD, COX and XO assays were performed by Dr. Albert Härtl from the Leibniz-
Institute for Natural Product Research and Infection Biology, HKI.  
 
5.4.5 Assay for hyaluronat lyase (Streptococcus agalactiae) activity 
There are many different assays for hyaluronidase activity based on spectrometric, 
radiochemical, fluorogenic, enzymimmunological, chemical, physicochemical and 
zymographic analysis. The simple assay used is based on the precipitation of 
undegested hyaluronane by N-cetyl-N-,N,N-trimethylammoniumbromide and the 
measurement of turbidity (E600nm). It has been adapted to an automated 96-well-
microplate format .120 The test was performed by Dr. Waltraud Hertel from the 
Leibniz-Institute of Natural Product and Infection Biology, HKI. 
 
Procedure 
The incubation solution containing hyaluronic acid in acetate buffer (pH 6), 
hyaluronate lyase of a defined activity and the inhibitory solution (1 mg/ml DMSO) 
was carried out for 30 min at 37 oC. After incubation, N-cetyl-N-,N,N-
trimethylammoniumbromide was added. The optical density at 600 nm of the reaction 
mixture was measured by spectrophotometer. 
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Inhibitory effects of the test compounds were calculated as follows: 
 
    
 
 
 
5.4.6 Antiproliferative and cytotoxic assays 127,128 
The test compounds were dissolved in ethanol (10 mg/ml) before dilution with RPMI 
1640. The test compounds were assayed against cell lines K-562 (human chronic 
myeloid leukemia) and L-929 (mouse fibroblast) for their antiproliferative effects. The 
adherent cells of L-929 were harvested at the logarithmic growth phase after soft 
trypsinization, using 0.25% trypsin in PBS containing 0.02% EDTA (Biochrom KG 
L2163). For each experiment with K-562, L-929, and HeLa approximately 10,000 
cells were seeded with 0.1 ml RPMI 1640 (GIBCO BRL 21875-034), containing 25 
µg/ml gentamicin sulfate (BioWhittaker 17-528Z), but without HEPES, per well of the 
96-well microplates (K-562: NUNC 163320, L-929, HeLa: NUNC 167008).  
 
Cells and culture conditions 
Cells of established non-adherent cell lines K-562 (DSM ACC 10) and adherent L-
929 (DSM ACC 2) were cultivated in RPMI 1640 medium (GIBCO BRL), 
supplemented with 25 µg/ml gentamicin sulfate (Cambrex), 10% heat inactivated 
fetal bovine serum (GIBCO BRL), and GlutaMAX (GIBCO BRL) at 37 oC in high 
density polyethylene flasks (NUNC 156340). HeLa (DSM ACC 57) cells were grown 
in RPMI 1640 culture medium (GIBCO BRL 21875-034) supplemented with 25 µg/ml 
gentamicin sulfate (BioWhittaker 17-528Z), and 10% heat inactivated fetal bovine 
serum (GIBCO BRL 10500-064) at 37 oC in high density polyethylene flasks (NUNC 
156340). 
 
Condition of incubation 
Cells of L-929, K-562, and HeLa were incubated for 72 hours at 37 oC under a 
humidified atmosphere and 5% CO2. 
 
Methods of evaluation 
Suspension cultures of K-562 in microplates were analysed by an electronic cell 
analyser system (CASY 1 SCHÄRFE, Reutlingen, Germany). 
A600nm sample  
A600nm control  
x 100  %of inhibition = 
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The 0.2 ml content of each well in the microplate was diluted to 1:50 with CASYTON 
(SCHÄRFE, Reutlingen, Germany) (NaCl: 7.93 g/l; EDTA disodium salt dihydrate: 
0.38 g/l; KCl: 0.4 g/l; NaH2PO4 x 1 H2O: 0.22 g/l; NaH2PO4 x 2 H2O: 2.45 g/l; NaF: 0.3 
g/l). Every count/ml was automatically calculated from the arithmetic mean of three 
successive counts of 0.4 ml each. From the dose response curves, the GI50 values 
(concentration which inhibited cell growth by 50%) were calculated with the software 
for data evaluation CASYSTAT (SCHÄRFE, Reutlingen, Germany). At the same 
incubation time, the adherent L-929 and HeLa cells were fixed by glutaraldehyde and 
stained with a 0.05% solution of methylene blue for 15 min. After gently washing the 
stain was eluted by 0.2 ml of 0.33 N HCl from the wells. The optical densities were 
measured at 660 nm in SUNRISE microplate reader (TECAN). Comparisons of the 
different values were performed with software Magellan (TECAN). 
 
5.5 Isolation and identification of metabolites 
5. 5.1 Trichoderma crassum HKI 0471 
The strain Trichoderma crassum HKI 0471 was obtained from the strain collection of 
HKI. Fifteen days malt agar-plate cultures were prepared and the well grown agar-
plate cultures were used to inoculate malt liquid medium. The surface cultivation was 
carried out under sterile conditions in 500 ml Erlenmeyer flasks containing 300 ml 
medium. The whole culture broth was extracted twice by two volumes of ethyl 
acetate. The residue (10 g) of the evaporated ethyl acetate extract from 20 l of 
culture was first pre-screened and then applied to a silica gel column in chloroform. 
Elution was performed with 500 ml portions of CHCl3, CHCl3/MeOH (9:1), and 
CHCl3/MeOH (7:3). The fractions obtained were separated using Sephadex LH 20 
and HLPC on reverse phase column (RP18 Spherisorb, 25 mm x 250 mm) using a 
binary gradient (water/acetonitrile 95:5 to 5:95; 30 min). The individual peaks were 
collected and purified by the same preparative procedure. 
 
5.5.1.1 Pre-screening 
Chemical screening by TLC revealed a remarkable yellow zone. In addition 
numerous UV absorbing bands were observed. The most of them were coloured 
violet after have been sprayed with vanillin/sulphuric acid. In the antimicrobial pre-
screening the crude extract exhibited strong antifungal activity particularly against 
Candida albicans. 
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β-Viridin (13) (C20H16O6) was obtained as yellow crystals by open column 
chromatography on Sephadex LH-20 and silica gel using MeOH and CHCl3/MeOH  
(v / v = 95 : 5) as eluent, respectively. Further purification was achieved by HPLC 
using gradient (water/acetonitrile 95:5 to 5:95; 30 min) Rt = 19.2 min. Upon spraying 
with vanillin/sulphuric acid or Emmerie-Engel’s reagent a strong greenish- brown spot 
was obtained on the TLC plate.  
 
Mp: 222~224 
[α]20D -224 
ESI-MS: 353 [M+H]+, 407 [M+MeOH+Na]+,  
727 [2M+Na]+ 
UV (MeOH): λmax 240, 302 nm 
IR (film) 3276, 3092, 1705, 1673, 1621, 1586, 1529,1122, 1061, 1010, 977 cm-1 
 
1H NMR (CDCl3, 300 MHz): δ 4.26 (d,  J = 10 Hz, 1H, H-1), 4.15 (d, J = 10 Hz, 1H, H-
2), 8.61 (d, J = 8.3 Hz, 1H, H-11), 7.95 (d, J = 8.3 Hz, 1H, H-12), 3.66 (m, H-15), 2.73 
(m, H-16), 1.71 (s, H-18), 3.84 (s, H-19), 8.26 (s, H-20) 
 
13C NMR (CDCl3, 75 MHz): δ 75.4 (d, C-1), 85.9 (d, C-2), 189.0 (s, C-3), 122.1 (s, C-
4), 142.0 (2, C-5), 146.7 (s, C-6), 173.2 (s, C-7), 137.3 (s, C-8), 41.7 ( s, C-9), 154.9 
(s, C-10), 128.3 (d, C-11), 127.5 (d, C-12), 129.8 (s, C-13), 155.6 (s, C-14), 27.2 (t, 
C-15), 36.3 (t, C-16), 206.3 (s, C-17), 28.4 (d, C-18), 61.7 (s, C-19), 148.5 (d, C-20) 
 
α-Viridin (14) (C20H16O6) was obtained as yellow crystals by open column 
chromatography on Sephadex LH 20 and silica gel using MeOH and CHCl3/MeOH (v 
/ v = 95 : 5) as eluent, respectively. Further purification was achieved by HPLC using 
gradient (water/acetonitrile 95:5 to 5:95; 30 min) Rt = 20.1 min . Upon spraying with 
vanillin/sulphuric acid or Emmerie-Engel’s reagent a strong greenish- brown spot was 
obtained on the TLC plate.  
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Mp: 140oC 
[α]20D +50 
ESI-MS: m/z 353 [M+H]+, 407 [M+MeOH+Na]+,  
727 [2M+Na]+  
UV (MeOH): λmax 240, 302 nm 
IR (film): 3276, 3092, 1705, 1673, 1621, 1586, 1529,  
1122, 1061, 1010, 977 cm-1 
 
1H NMR (CDCl3, 300 MHz): δ 4.26 (dd, J = 5.0, 10.6 Hz, 1H, H-1), 3.87 (d, J = 5.0 
Hz, 1H, H-2), 8.64 (d, J = 8.2 Hz, 1H, H-11), 7.95 (d, J = 8.2 Hz, 1H, H-12), 3.61, 
3.85 (m, H-15), 2.72 (m, H-16), 1.66 (s, H-18), 3.73 (s, H-19), 8.28 (s, H-20) 
 
13C NMR (CDCl3, 75 MHz): δ 73.2 (d, C-1), 83.5 (d, C-2), 186.9 (s, C-3), 121.6 (s, C-
4), 142.9 (2, C-5), 147.0 (s, C-6), 173.2 (s, C-7), 137.2 (s, C-8), 41.9 ( s, C-9), 156.4 
(s, C-10), 127.8 (d, C-11), 127.6 (d, C-12), 129.8 (s, C-13), 157.9 (s, C-14), 29.7 (t, 
C-15), 36.3 (t, C-16), 206.3 (s, C-17), 28.4 (d, C-18), 60.9 (s, C-19), 149.3 (d, C-20) 
 
8-Daucene-3,4-diol (CAF 603) (C15H26O2) was obtained as a colourless oil by open 
column chromatography on silica gel and Sephadex LH-20 using CHCl3/MeOH 95:5 
and MeOH as eluent, respectively. Further purification was achieved by HPLC using 
gradient (water/acetonitrile 95:5 to 5:95; 30 min) Rt = 25.6 min. Upon spraying with 
vanillin/sulphuric acid a strong blue spot was obtained on the TLC plate, suggesting a 
terpenoid. 
 
[α]D20 -26 
ESI-MS: m/z 261 [M+Na]+, 256, [M+NH4]+, 499 [2M+Na]+  
MS/MS: m/z 221 [M-H2O]+, 203 [M-2H2O]+,    
IR (film): 3383, 2951, 1450, 1381, 1317 cm-1 
 
1H NMR (CDCl3, 300 MHz):  δ 1.60 (m, 2H, H-2), 4.02 (dd, J = 1.4, 7.5 Hz, 1H,  H-3), 
1.47 (m, 1H, H-5), 1.55 (m, 2H, H-6), 2.06 (m, 2H,  H-7), 5.34 (dd, 1H, H-9), 1.75, 
1.85 (m, 2H, H-10), 1.80 (m, 1H, H-11), 0.85 (d, J = 6.9 Hz, 3H, H-12), 0.96 (d, J = 
6.9 Hz, 3H, H-13), 1.75 (s, 3H, H-14), 1.00 (s, 3H, H-15) 
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13C NMR (CDCl3, 75 MHz): δ 42.2 (d, C-1), 50.3 (t, C-2), 72.4 (d, C-3), 84.3 (s, C-4), 
58.4 (d, C-5), 20.7 (t, C-6), 34.4 (t, C-7), 139.0 (s, C-8), 122.4 (d, C-9), 42.8 (t, C-10), 
35.1 (d, C-11), 17.7 (q, C-13), 17.0 (q, C-12), 27.3 (q,  C-14), 21.1 (q, C-15)   
 
Adenine-9α-D-arabinofuranoside (C10H13N5O4) was obtained as white solid crystal 
by open column chromatography on silica gel using and CHCl3/MeOH 80:20. Further 
purification was done by HPLC using gradient (water/acetonitrile 95:5 to 5:95; 30 
min) Rt = 9.5 min. Upon spraying with vanillin/sulphuric acid a strong red spot was 
obtained on the TLC plate.  
 
MP: 258~260 
ESI-MS: m/z 268 [M+H]+, 290 [M+Na]+  
IR (film): 3315, 3154, 2914, 2845, 1662, 1602, 1570, 1466, 13330,  
1299, 1106 cm-1 
 
1H NMR (DMSO-d6, 300 MHz): δ 8.33 (s, 1H, H-2), 7.25 (s, 2H, NH2), 8.10 (s, 1H, H-
6), 5.86 (d, 1H, J = 6.2 Hz, 1H, H-1’), 4.25 (dd, J = 5.1, 10.3 Hz, 1H, H-2’), 4.15 (dd, 
H-3’), 3.95 (dd, 1H, H-4’), 3.60 (s, 2H,  H-5’), 5.54 (dd, J = 7.6, 2.5 Hz, 1H, OH), 5.47 
(d, overlapped, 1H, OH), 5.25 (d, J = 4.17 Hz, 1H, OH). 
 
13C NMR (DMSO d6, 75 MHz): δ 140.3 (s, C-2), 156.3 (s, C-4), 119.5 (s, C-4a), 152.7 
(d, C-6), 149.2 (s, C-7a), 88.2 (d, C-1’), 73.8 ( d, C-2’), 70.9 (d, C-3’), 86.2 (d, C-4’), 
61.9 (t, C-5’). 
  
Cerebroside C (C43H79NO9) was obtained as colourless crystals by open column 
chromatography on CHCl3/MeOH 70:30 using CHCl3/MeOH 70:30 as eluent . Further 
purification was done by HPLC using gradient (water/acetonitrile 95:5 to 5:95; 30 
min). Upon spraying with vanillin/sulphuric acid a strong red spot was obtained on the 
TLC plate.  
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Mp: 159~169oC 
[α]D20 -6.2o  
ESI-MS: m/z 754 [M+H]+, 776 [M+Na]+ 
IR (film): 3268, 2918, 2849, 1638, 1530, 1466, 1229, 1154, 1082, 1032 cm-1 
 
1H NMR: (CD3OD, 300 MHz): δ 3.71, 4.1 (m, 2H,  H-1), 3.98 (m, 1H, H-2), 3.62 (m, 
1H, H-3), 5.71 (m, 1H, H-4), 5.45 (m, J = 5.1 Hz, 1H,  H-5), 1.96 (m, 2H, H-6), 2.01 
(m, 2H, H-7), 5,15 (m, 1H, H-8), 1.52 (s, 3H, H-10), 1.40 (m, overlapped, 2H, H-11-H-
17), 0.80 (t, 3H, H-18), 4.41 (d, J = 6.2 Hz, 1H,  H-2’), 5.73 (m, 1H, H-3’), 5.49 (m, 
1H, H-4’), 2.01 (m, 2H, H-5’), 2.01 (m, J = 5.1 Hz, 2H  H-6’), 1.40 (m, overlapped, 2H, 
H-11’-H-17’), 0.80 (t, 3H, H-18’), 4.27 (d, J = 7.71 Hz,1H,  H-1’’), 4.10 (m, 1H, H-2’’), 
3.30 (m, 1H, H-3’’), 3.27 (m, 1H, H-4’’), 2.85 (m, 5.1, 1H,  H-5’’), 3.68 (m, 2H, H-6’’) 
 
13C NMR (CD3OD, 75 MHz): δ 69.6 (t, C-1), 54.6 (d, C-2), 72.9 (d, C-3), 134.5 (d, C-
4), 131.0 (d, C-5), 33.4 (t, C-6), 33.7 (t, C-7), 124.8 (d, C-8), 136.7( s, C-9), 16.1 (q, 
C-10), 40.7-23.7 (t, C-11-C-18), 14.4 (q, C-19) δ 175.4 (t, C-1’), 74.1 (d, C-2’), 134.7 
(d, C-3’), 129..0 (d, C-4’), 33.4 (t, C-5’), 33.7-23.7 (t, C-6-C-17’), 14.4 (q, C-18’), 
104.7 (d, C-1’’), 72.9 (d, C-2’’), 77.9 (d, C-3’’), 71.6 (d, C-4’’), 75.0 (d, C-5’’), 62.7 (t, 
C-6’’) 
 
5.5.2 Epiccoccum sp. HKI 0470 
The strain Epicoccum sp. HKI 0470 was isolated from the hat of the basidiomycete 
Pholiota squarrosa. Fifteen days malt agar-plate cultures (25o) were prepared and 
the well grown agar plate cultures were used to inoculate a liquid malt medium. The 
surface cultivation was carried out under sterile conditions in 500 ml Erlenmeyer 
flasks containing 300 ml medium. The whole culture broth was extracted twice by two 
volumes of ethyl acetate. The residue (7.5 g) of the evaporated ethyl acetate extract 
from 30 l of culture was first pre-screened and then applied to a silica gel column in 
chloroform. Elution was performed with 300 ml portions of CHCl3, CHCl3/MeOH (9:1), 
CHCl3/MeOH (7:3) and MeOH. The fractions obtained were separated using 
Sephadex LH 20 and HLPC on reverse phase column (RP18 Spherisorb, 25 mm x 
250 mm) using a binary gradient (water/acetonitrile 95:5 to 5:95; 30 min). The 
individual peaks were collected and purified by the same preparative procedure to 
Experimental section 
 
83
 
OHO
O
HO
N
O
O
OH
HOHO
1'
1
323
5
6222
6'
8 7
101214161820
afford the new compounds, epicoccalone and epicoccone B, and the already known 
compounds, epicoccamide, epicoccine and orevactaene. 
 
5.5.2.1 Pre-screening 
Chemical screening by TLC showed a remarkable yellow zone. In addition, 
numerous UV absorbing bands were observed. The most of them were coloured 
violet after have been sprayed with vanillin/sulphuric acid. In the biological screening, 
the crude extract exhibited significant inhibitory activity against 3α-hydroxysteroid 
dehydrogenase, showing that the extract contained some anti-inflammatory products. 
Furthermore, the antimicrobial pre-screening of the crude extract exhibited moderate 
anti-fungal anti-bacterial activity. 
 
Epicoccamide (C29H51NO9) was obtained as colourless oil by open column 
chromatography on Sephadex LH-20 and silica gel using CHCl3/MeOH 95:5 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 40 min) Rt = 33.8. Upon spraying with vanillin/sulphuric acid brown spot was 
obtained on the TLC plate.  
 
 
 
 
ESI-MS: m/z 580.4 [M+Na]+, 1137 [2M+Na]+, 556[M-H]- 
MS/MS: m/z 557.9, 396.1 
[α]D20 -10.3 (c = 0.10 EtOH) 
UV (EtOH): λmax 282 nm 
IR (film): 3367, 2922, 2852, 1709, 1646, 1612, 1487, 1448, 1339, 1235, 1067 cm-1 
  
1H NMR (CD3OD, 300 MHz): δ 3.52 (br, 1H, H-4), 1.30 (d, 3H, J = 6.9, H-5), 2.91 
(brs, 3H, H-6), 3.78 (1H, m), 1.27, 1.72 (m, 2H, H-9), 1.24, 1,36 (m, 2H, H-10-19), 
1.42 (m, 2H, H-20), 1.64 (m, 2H, H-21), 3.56 (ddd, 1H, J = 2.9, 6.8, 9.8 Hz, H-22), 
3.98 (dt, 1H, J = 6.8, 6.8, 9.8 Hz, H-22), 1.02 (d, J = 6.2 Hz, H-23), 4.55 (brs, 1H, H-
1’) 3.88 (brs d, J = 3.2 Hz, H-2’), 3.48 (dd, 1H, J = 3.2, 9.5, H-3’), 3.62 (t, 1H, J =9.5, 
9.5, H-4’), 3.26 (ddd, J = 3.0, 5.6, 9.5 Hz, H-5’), 3.75 (dd, 1H, J = 5.6, 11.8 Hz, H-6’) 
3.94 (dd, 1H, J = 3.0, 11.8 Hz, H-6’). 
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13C NMR (CD3OD, 75 MHz): δ175.3 (s, C-1), 101.6 (s, C-2), 197.7 (s, C-3), 61.8 (d C-
4), 16.0 (q, C-5) , 26.5, (q, C-6), 201.1 (s, C-7), 40.8 (d, C-8), 35.0 (t, C-9), 30.8-31.0 
(t, C-10-19), 27.2 (t, C-20), 30.8 (t, C-21), 70.6 (t, C-22), 18.0 (q, C-23), 101.7 (d, C-
1’), 72.5 (d, C-2’), 75.3 (d, C-3’), 68.5 (d, C-4’), 78.1(d, C-5’), 62.8 (t, C-6’). 
 
Epicoccin (28) (C9H10O4) was obtained as colourless crystal by open column 
chromatography on Sephadex LH-20 and silica gel using CHCl3/MeOH 95:5 as 
eluent. Further purification was done by HPLC using a binary gradient 
(water/acetonitrile 95:5 to 5:95; 40 min) Rt = 14.5 min. Upon spraying with 
vanillin/sulphuric acid or Emmerie-Engel’s reagent a strong greenish-brown spot was 
obtained on the TLC plate.  
 
ESI-MS: m/z 205 [M+Na]+, 387 [2M+Na]+, 181[M-H]-  
Mp: 205~207 oC  
UV (MeOH): λmax 248 nm 
 
1H NMR (DMSO-d6, 300 MHz): δ 4.83 (s. 2H, H-1), 4.87 (s, 2H, H-3), 8.45 (s, brs 1H, 
OH-4), 8.06 (s, brs 1H, OH-5), 8.02 (s, brs, 1H, OH-6), 1.91 (s, 3H, H-8) 
 
13C NMR (DMSO-d6, 75 MHz):  δ 72.5 (t, C-1), 71.7 (t, C-3), 137.6 (s, C-4), 132.5, (s, 
C-5), 143.9 (s, C-6), 108.2 (s, C-7), 115.6, (s, C-4a), 128.4 (s, C-7a), 12.1 (q, C-8). 
 
Epicoccone B (29) (C9H8O5) was obtained as colourless oil by open column 
chromatography on Sephadex LH-20 and silica gel using CHCl3/MeOH 95:5 as 
eluent. Further purification was done by HPLC using a binary gradient 
(water/acetonitrile 9:1 to 5:95; 30 min) Rt = 14 min. Upon spraying with 
vanillin/sulphuric acid or Emmerie-Engel’s reagent a strong greenish- brown spot was 
obtained on the TLC plate.  
 
ESI-MS: m/z 197 [M+Na]+, 219 [M+Na]+, 195[M-H]- 
IR (film): 3420, 3134, 1725, 1628, 1514, 1249, 1104, 879 cm-1 
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1H NMR (DMSO-d6, 300 MHz): δ 5.09 (s. 2H, H-3), 1.96 (s, 3H, H-8). 
 
13C NMR (DMSO-d6, 75 MHz):  δ 169.8 (s, C-1), 67.6 (t, C-3), 109.1 (s, C-4), 138.0 
(s, C-4a), 151.1 (s, C-5), 132.8 (s, C-6), 143.0 (s, C-7), 102.7 (s, C-7a), 10.7 (t, C-8) 
 
Epicoccalone (30) (C16H16O7) was obtained as yellow powder by open column 
chromatography and sephadex LH 20 and silica gel using CHCl3/MeOH 85:15 as 
eluent. Further purification was done by HPLC using a binary gradient 
(water/acetonitrile 8:2 to 5:95; 30 min) Rt = 15.8 min. Upon spraying with 
vanillin/sulphuric acid or Emmerie-Engel’s reagent a strong greenish-brown spot was 
obtained on the TLC plate.  
 
ESI-MS: m/z 321 [M+Na]+, 343 [M+Na]+ 663 [2M+Na]+,  
319 [M-H]- 
MS/MS: m/z 221, 203, 175 
HR-ESIMS (found [M-H]-; 319.0814 calcd.  
for C16H61O7: 319.0818) 
UV (MeOH): λmax 269, 390, 463 nm 
IR (film): 3244, 2925, 1699, 1598, 1562, 1465, 1268, 1197, 1107, 895 cm-1 
 
1H NMR (DMSO-d6, 300 MHz): δ 8.89 (s. 1H, H-4), 4.68 (s, 2H, H-9), 2.22 (s, 3H, H-
10), 4.71 (q, 1H, H-2’), 2. 28 (s, 1H, H-4’), 1.23 (d, J = 7.1 Hz 3H, H-5’) 
 
13C NMR (DMSO-d6 75 MHz)  δ 159.2 (s, C-2),  116.5 (s, C-3), 147.0 (d, C-4), 131.6 
(s, C-5), 109.9 (s, C-5a),  122.4 (s, C-6), 151.6 (s, C-7), 130.2 (s, C-8), 144.0 (s, C-
8a), 55.6 (t, C-9), 11.3 (q, C-10), 194.0 (s, C-1’), 57.3 (d, C-2’), 206.2 (s, C-3’), 28.7 
(q, C-4’), 12.1 (q, C-5’). 
 
Orevactaene (31) (C34H44O10) was obtained as yellow oil by open column 
chromatography on Sephadex LH-20 and silica gel using CHCl3/MeOH 9:1 as eluent. 
Further purification was done by HPLC using gradient (water/acetonitrile 95:5 to 5:95; 
40 min) Rt = 25.1 min . Upon spraying with vanillin/sulphuric acid brown spot was 
obtained on the TLC plate.  
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ESI-MS: m/z 613 [M+H]+  
MS/MS: m/z 521, 447, 403 
UV (MeOH): λmax 430, 452 nm 
IR (film): 3251, 2957, 2923, 1671, 1539, 1417, 1200, 1134, 1045, 1000 cm-1 
 
1H NMR (DMSO-d6, 300 MHz) δ 4.23 (d, 1H, J = 9.5 Hz H-3), 4.10 (dd, 1H, J = 9.5, 
9.3 Hz, H-4), 3.27 (dd, 1H  J = 9.3, 2.8 Hz, H-5), 6.16 (s, 1H, H-7), 6.31 (d, 1H, J = 
15.2 Hz, H-9), 7.00 (dd, 1H, J = 15.2 Hz, 11.4, H-10), 6.43 (dd, 1-H, overlapped, H-
11), 6,70 (dd, 1H overlapped, H-12), 6.42 (dd, 1H overlapped, H-13), 6.50 (dd, 1H, 
overlapped, H-14), 6.40 (dd, overlapped, H-15), 6..48 (dd, 1H, overlapped, H-16), 
6.40 (dd, overlapped, H-17), 6.41 (dd, 1H, overlapped, H-18), 6.11 (s, 1H, H-20), 
5.55 (d, 1H, 10.3, H-22), 2.88 (m, H-23), 1.08,1.24 (m, 2H, H-24), 1.20 (m, 1H), 1.10, 
1.20 (m, 2H, H-26), 0.80 (t, 3H, J = 7.6 Hz, H-27), 0.78 (d, 3H, J = 7.2 Hz, H-28), 0.96 
(d, J = 7.1 Hz, 3H, H-29), 8.01 (brs, 1H COOH), 1.79, (s, 3H, H-31), 3.70 (dd, 1H, J = 
6.2, 2.8 Hz, H-32), 3.37 (m, 1H, overlapped), 3.39, 3.42 (m, 2H, H-34). 
 
13C NMR (DMSO-d6, 75 MHz): δ 167.6 (s. C-1), 101.4 (s, C-2), 74.5 (d, C-3), 67.9 (d, 
C-4), 75.3 (d, C-5), 162.1 (s, C-6), 101.5 (d, C-7), 157.6 (s, C-8), 122,7 ( d, C-9), 
134.6 (d, C-10), 131.8 (d, C-11), 138.7 (d, C-12), 129.0 (d, C-13), 136.4 (d, C-14), 
133.1 (d, C-15), 135.5 (d, C-16), 132.8 (d, C-17), 139.1 (d, C-18), 134.7 (s, C-19), 
130.6 (d, C-20), 131.4 (s, C-21), 146.7 (d, C-22), 31.5 (d, C-23), 44.1 (t, C-24), 32.2 
(d, C-25), 29.7 (t, C-26), 11.3 (q, C-27), 18.9 (q, C-28),  21.4 (q, C-29), 169.6 (s, C-
30), 13.3 (q, C-31), 69.1 (d, C-32),  79.3 (d, C-33), 60.9 (t, C-34). 
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5.5.3 Lepista nebularis HKI 0411 
The strain Lepista nebularis was collected as mycelia culture (derived from the tissue 
plugs of the fruiting body) in Siberia. The taxonomy of the fungus was verified by Dr. 
Heinrich Dörfelt of the Institute for Nutrition and Environment, Friedrich-Schiller-
University, Jena. A specimen (HKI 0411) was deposited in the fungal collection of the 
Leibniz-Institute for Natural Product Research and Infection Biology, HKI, Jena, 
Germany. 
 
5.5.3.1 Cultivation and extraction 
Twenty eight days agar-plate cultures were prepared as inoculum using a medium 
composed as follows (g/l): malt extract 40, yeast extract 4, agar 15, deionised water , 
pH 6.0. Agar chips (4-5 cm2) of the plate cultures were used to inoculate a liquid 
MPG medium. The surface cultivation was carried out under sterile conditions in 500 
ml Erlenmeyer flasks containing 300 ml medium. The whole culture broth was 
extracted twice by two volumes of ethyl acetate. The residue (5 g)  of the evaporated 
ethyl acetate extract from 60 l of culture was first pre-screened and then applied to a 
silica gel column in chloroform. Elution was performed with 500 ml portions of CHCl3, 
CHCl3/MeOH (9:1), and CHCl3/MeOH (7:3). The fractions obtained were then 
separated using Sephadex LH-20 and HLPC on reverse phase column (RP8 
Spherisorb, 25 mm x 250 mm) using a binary gradient (water/acetonitrile 95:5 to 
5:95; 30 min). The individual peaks were collected and purified by the same 
preparative procedure to afford the new natural compounds: nebularone, nebularic 
acid A, nebularic acid B, nebularilactone A, nebularilactone B and the known 
compounds N-Acetyltyramine and diatretyne.    
 
5.5.3.2 Pre-screening 
Chemical screnning by TLC indicated a considerable number of compounds. 
Furthermore numerous UV absorbing bands were observed. The most of them were 
coloured after have been sprayed with vanillin/sulphuric acid, indicating the presence 
of terpenoids. In the biological pre-screening, the crude extract exhibited no activity in 
the enzyme assays, but in the antimicrobial pre-screening a strong antifungal and 
antibacterial activity particularly against multiresistant Streptococcus and Candida 
albicans were observed. 
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Nebularic acid A (32) (C14H20O3) was obtained as colourless oil by open column 
chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 95:5 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 25.1 min. Upon spraying with vanillin/sulphuric acid a strong 
violet spot was obtained on the TLC plate, suggesting a terpenoid. 
 
ESI-MS: m/z 237 [M+H]+, 259 [M+Na]+ 
HR-ESIMS (found [M+H]+; 237.1480 calcd.  
for C14H21O3: 237.1485)   
UV (MeOH): λmax 246 nm 
IR (film): 2925, 2846, 1743, 1633, 1432, 1410, 1258,  
1186 cm-1 
 
1H NMR (CDCl3, 300 MHz):  δ 1.4-1.8 (m, 2H, H-1), 1.6-1.8 (m, 2H, H-2), 1.1-1.5 (m, 
2H, H-3), 1.78 (m,1H, H-5), 2.50-2.65 (dd, J = 3.8, 18.0 Hz, 2H, H-6), 8.02 (s, 1H, H-
9), 1.14 (s, 3H, H-13), 0.88 (s, 3H, H-14), 0.92 (s, 3H, H-15)   
 
13C NMR (CDCl3, 75 MHz): δ 36.8 (t, C-1), 18.1 (t, C-2), 40.7 (t, C-3),  33.0 (s, C-4), 
49.4 (d, C-5), 35.2 (t, C-6), 204.3 (s, C-7), 123.5 (s, C-8), 175.4 (d, C-9), 38.3 (s, C-
10), 164.0 (s, C-12), 17.1 (q, C-13), 20.9 (q, C-14), 32.6 (q, C-15)   
       
Nebularone (33) (C13H20O) was obtained as colourless oil by open column 
chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 95:5 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 25.5 min. Upon spraying with vanillin/sulphuric acid a strong 
violet spot was obtained on the TLC plate, suggesting a terpenoid. 
 
ESI-MS: m/z 193 [M+H]+, 215 [M+Na]+  
HR-EISMS (found [M+H]+; 193.1524 calcd.  
for C13H21O: 193.1587) 
UV (MeOH): λmax 246 nm 
IR (film): 2925, 2846, 1676, 1457, 1390, 1371, 1259, 1102 cm-1 
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1H NMR (CDCl3, 300 MHz):  δ 1.30-1.61 (m, 2H, H-1), 1.55-1.70 (m, 2H, H-2), 1.21-
1.50 (m, 2H, H-3), 1.72 (dd, J = 3.7, 13.9, 1H, H-5), 2.35 (m, 2H, H-6), 5.72 (d, J = 
9.8 Hz, 1H, H-8), 6.59 (d, J = 9.8 Hz, 1H, H-9), 1.07 (s, 3H, H-13), 0.87 (s, 3H, H-14), 
0.91 (s, 3H, H-15)   
 
13C NMR (CDCl3, 75 MHz) : δ 38.0 (t, C-1), 18.5 (t, C-2), 41.5 (t, C-3),  33.0 (s, C-4), 
50.4 (d, C-5), 22.3 (t, C-6), 201.5 (s, C-7), 125.4 (d, C-8), 162.6 (d, C-9), 36.8 (q, C-
10), 18.2 (q, C-13), 20.8 (q, C-14), 32.1 (q, C-15)   
 
Nebularic acid B (C14H20O4) was obtained as colourless crystals by open column 
chromatography on Sephadex LH 20 and silica gel unsing CHCl3/MeOH 95:5 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 22.0. Upon spraying with vanillin/sulphuric acid a strong violet 
spot was obtained on the TLC plate, suggesting a terpenoid. 
 
ESI-MS: m/z = 253 [M+H]+, 251 [M-H]-  
HR-EISMS (found [M-H]-; 251.1262, calcd.  
for C14H19O4: 251.1264) 
UV (MeOH): λmax 246 nm 
IR (film): 2925, 2846, 1730, 1633, 1432, 1410, 1258, 1186 cm-1 
 
1H NMR (CDCl3, 300 MHz):  δ 1.4-1.8 (m, 2H, H-1), 1.58-1.78 (m, 2H, H-2), 1.22-1.58 
(m, 2H, H-3), 1.65 (m,1H, H-5), 2.16-2.35 (dd, J = 3.8, 18.0 Hz, 2H, H-6), 3.00 (s, 1H, 
H-9), 1.13 (s, 3H, H-13), 0.85 (s, 3H, H-14), 0.89 (s, 3H, H-15)  
 
13C NMR (CDCl3, 75 MHz): δ 37.3 (t, C-1), 19.2 (t, C-2), 42.4 (t, C-3),  33.5 (s, C-4), 
42.5 (d, C-5), 36.5 (t, C-6), 205.1 (s, C-7), 62.2 (s, C-8), 69.5 (d, C-9), 35.2 (s, C-10), 
172.7 (s, C-12)   17.1 (q, C-13), 21.3 (q, C-14), 33.0 (q, C-15) 
  
Nebularilactone A (35) (C15H22O3) was obtained as colourless oil by open column 
chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 95:5 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 20.5. Upon spraying with vanillin/sulphuric acid a strong violet 
spot was obtained on the TLC plate, suggesting a terpenoid. 
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ESI-MS: m/z  = 253 [M+H]+, 251 [M-H]- 
HR-ESIMS (found [M-H]-; 251.1642 calcd.  
for C15H22O3: 251.1650) 
UV(MeOH): λmax 246 nm 
IR (film): 2925, 2846, 1730, 1430, 1409, 1258, 1186 cm-1 
 
1H NMR (CDCl3, 300 MHz): δ 3.39 (dd, J = 4.7, 10.8 Hz, 1H, H-1), 1.63 (m, 2H, H-2), 
1.32-1.52 (m, 2H, H-3), 1.34 (m, 1H, H-5), 2.20-2.40 (m, 2H, H-6), 6.85 (dd, J = 3.4, 
7.0 Hz, 2H, H-7), 2.82 (s, 1H, H-9), 4.15-4.50 (dt, J = 9.6 Hz, 2H, H-11) 0.78 (s, 3H, 
H-13), 0.94 (s, 3H, H-14), 0.90 (s, 3H, H-15) 
  
13C NMR (CDCl3, 75 MHz): δ 71.4 (d, C-1), 26.0 (t, C-2), 34.1 (t, C-3),  32.7 (s, C-4), 
43.4 (d, C-5), 25.1 (t, C-6), 135.2 (s, C-7), 127.5 (s, C-8), 42.7 (d, C-9), 38.2 (s, C-
10), 67.1 (s, C-11). 170.3 (s, C-12), 13.6 (q, C-13), 21.3 (q, C-14), 32.8 (q, C-15) 
 
Nebularilactone B (36) (C15H22O3) was obtained as clourless oil by open column 
chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 95:5 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 20.59. Upon spraying with vanillin/sulphuric acid a strong violet 
spot was obtained on the TLC plate, suggesting a terpenoid 
 
ESI-MS: m/z = 253 [M+H]+, 251 [M-H]-  
HR-ESIMS (found [M-H]-; 251.1642 calcd.  
for C15H22O3: 251.1650) 
UV (MeOH): λmax 246 nm 
IR (film): 2925, 2846, 1730, 1430, 1409, 1258, 1186 cm-1 
 
1H NMR (CDCl3, 300 MHz)  δ 3.51 (brs, J = 4.8, 10.9 Hz, 1H, H-1), 1.59-1.98 (m, 2H, 
H-2), 1.26-1.76 (m, 2H, H-3), 1.75 (m, 1H, H-5), 2.15-2.43 (m, 2H, H-6), 6.85 (dd, 1H, 
H-7), 3.58 (m, 1H, H-9), 4.05-4.4.48 (dt, J = 9.4 Hz, 2H, H-11), 0.78 (s, 3H, H-13), 
0.93 (s, 3H, H-14), 0.94 (s, 3H, H-15)  
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13C NMR (CDCl3, 75 MHz) δ 79.8 (d, C-1), 28.3 (t, C-2), 40.0 (t, C-3),  32.5 (s, C-4), 
48.7 (d, C-5), 24.7 (t, C-6), 135.2 (s, C-7), 127.6 (s, C-8), 50.1 (d, C-9), 39.5 (s, C-
10), 69.2 (s, C-11) 170.1 (s, C-12),   7.28 (q, C-13), 21.5 (q, C-14), 32.5 (q, C-15) 
 
N-Acetyltyramine (46) (C10H13NO2) was obtained as a clourless powder by open 
column chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 70:30 
as eluent. Further purification was done by HPLC using gradient (water/acetonitrile 
95:5 to 5:95; 30 min) Rt = 13.1 min. Upon spraying with vanillin/sulphuric acid a 
greenish- brown spot was obtained on the TLC plate. 
 
 
ESI-MS: 180 [M+H]+, 202 [M+Na]+  
UV (MeOH): λmax 214, 276 nm 
IR (film): 3329, 2933, 1629, 1594, 1566, 1514, 1361, 1245 cm-1 
 
1H NMR (CDCl3, 300 MHz):  δ 3.14(m, 2H,  H-1), 2.50 (m, 2H, H-2), 6.93 (d, J = 8.3, 
1H, H-4), 6.66 (d, J = 8.3 Hz, 1H,  H-5), 6.66 (d, J = 8.3 Hz, 1H, H-7), 6.93 (d, J = 8.3, 
1H, H-8), 1.76 (s, 3H, H-2’), 7.84 (brs, 1H, NH) 
 
13C NMR (CDCl3, 75 MHz): δ 40.5 (t, C-1), 34.3 (t, C-2), 129.4 (s, C-3), 115.0 (d, C-
4), 129.3 (d, C-5), 155.6 (s, C-6), 129.3 (d, C-7), 115.0 (d, C-8), 168.9 (s, C-1’), 22.5 
(q, C-2’)  
   
Diatretyne (47) (C8H3NO2) was obtained as yellowish needles by open column 
chromatography on Sephadex LH 20 and Silica gel using CHCl3/MeOH 85:15 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 19.6 min . Upon spraying with vanillin/sulphuric acid no spot was 
obtained on the TLC plate. At 254 nm it absorbed light very strongly. 
 
 
ESI-MS: 144 [M-H]-  
UV (MeOH): λmax 230, 239, 268, 284, 302, 322 nm 
IR (film): 1684, 1609, 1419, 1319, 1263, 1209, 965, 908 cm-1 
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1H NMR (DMSO-d6, 300 MHz): δ 6.66 (d, J = 16.1 Hz, 1H, H-2), 6.83 (d, J = 16.1 Hz, 
1H, H-3) 
 
13C NMR (DMSO-d6, 75 MHz): δ 167.0 (s, C-1), 140.5 (d, C-2), 121.2 (d, C-3), 78.0 
(s, C-4), 78.5 (s, C-5), 66.7 (s, C-6), 56.9 (s, C-7), 105.4 (s, C-8) 
 
5.5.4 Aspergillus sp. HKI 0472 
The strain was isolated from a soil sample (compost) collected in Bafoussam, a 
region situated in west of Cameroon and showed to have a good agreement with the 
misroscopic features of Aspergillus sp. It was deposited in the strain collection of the 
Leibniz-Institute for Natural product Research and Infection Biology, HKI, Jena 
Germany, under the number HKI 0472. 
 
5.5.4.1 Fermentation 
the producer strain Aspergillus sp. was cultivated as surface cultures at 25oC in 500 
ml Erlemeyer bottles containing 100 ml liquid malt medium. Each bottle was 
inoculated with a 1 cm2 area of a 20 days agar culture. After 28 days of cultivation at 
25 oC, the mycelium cake was harvested from 20 l of culture and extracted twice with 
10 l of ethyl acetate. The culture broth was extracted three times with 10 l of ethyl 
acetate. The combined extracts were dried and evaporated. The residue (3.2 g) was 
subjected to silica gel chromatography (silica gel 60, Merck, 0,063~0.1 mm, column 4 
x 60 cm), using stepwise CHCl3, and CHCl3–MeOH (9:1, 8:2, 1:1, v / v) as eluents. 
Final purification, which was achieved by preparative HPLC (Sperisorb ODS-2 RP18, 
5 µm (Promochem), 250 x 25 mm, acetonitrile/0.1% TFA (83:17 v / v), 10 ml/minute, 
UV-detection 210 nm) yielded 20 mg of funalenine and 10 mg and 15 mg of the 
known TMC-256A1 and asperxanthone, respectively.   
 
5.5.4.2 Pre-screening 
Chemical screening by TLC revealed a considerable number of compounds. 
Furthermore numerous UV absorbing bands were observed, and most of the 
compounds were coloured greenish-brown after been sprayed with Emmerie-Engel’s 
reagent, indicating the presence of phenolic compounds. In the biological screening, 
the crude extract exhibited a remarkable activity towards 3α-hydroxysteroid 
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dehydrogenase, suggesting the presence of anti-inflammatory compounds. In the 
antimicrobial pre-screening no significant activity was detected.  
 
Funalenine (48) (C15H12O6) was obtained as yellow crystals by open column 
chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 70:30 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 20.1 min. Upon spraying with vanillin/sulphuric acid or Emmerie-
Engel’s reagent a strong greenish- brown spot was obtained on the TLC plate.  
 
ESI-MS: m/z 289 [M+H]+, 287 [M-H]-  
HR-ESIMS (found [M-H]-; 289.0709 calcd.  
for C15H11O6: 287.09590 ) 
UV (MeOH): λmax 214, 282, 364, 412 nm  
IR (film): 3192, 2923, 1586, 1380, 1349, 1267, 1147,  
1028, 900, 822 cm-1 
 
1H NMR (DMSO-d6, 300 MHz):  δ 6.32 (s, 1H, H-5), 6.04 (s, 1H, H-8), 3.67 (s, 3H, H-
10), 2.68 (s, 3H, H-11), 18.39 (s, 1H, OH), 18.42 (s, 1H, OH) 
 
13C NMR (DMSO-d6, 75 MHz): δ 169.9 (s, C-1), 130.4 (s, C-2), 169.0 (s, C-3), 106.9 
(s, C-3a), 171.3 (s, C-4), 116.4 (d, C-5), 143.7 (s, C-6), 106.7 (s, C-6a), 163.3 (s, C-
7), 98.9 (d, C-8), 173.3 (s, C-9), 102.7 (d, C-9a), 127.5 (s, C-9b) 58.7 (q, C-10), 25.0 
(q, C-11) 
 
TMC-256A1 (50) (C15H12O5) was obtained as yellow crystals by open column 
chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 70:30 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 21.5. Upon spraying with vanillin/ sulphuric acid or Emmerie-
Engel’s reagent a strong yellow spot was obtained on the TLC plate.  
 
ESI-MS: m/z 273 [M+H]+, 271 [M-H]-  
UV (MeOH): λmax 220, 270, 410 nm 
IR (film): 3100, 1607, 1571, 1430, 1359, 1271,  
1113, 1084, 856 cm-1 
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1H NMR (DMSO-d6, 300 MHz):  δ 6.11 (s, 1H, H-3), 6.45 (d, J = 1.9 Hz, 1H, H-7) 6.61 
(d, J = 1.9 Hz, 3H, H-9), 6.99 (s, 1H, H-10), 2.34 (s, 3H, H-11), 14.8 (s, 1H, OH) 
 
13C NMR (DMSO-d6, 75 MHz): δ 168.3(s, C-2), 106.5 (d, C-3), 183.5 (s, C-4) 102.8 
(s, C-4a), 162.2 (s, C-5), 106.5 (s, C-5a), 160.5 (s, C-6), 97.4 (d, C-7), 159.9 (s, C-8), 
101.0 (d, C-9), 140.8 (s, C-9a), 99.7 (d, C-10), 152.4 (s, C-10a), 55.5 (q, C-11), 20.0 
(q, C-12) 
 
Asperxanthone (Flavasperone; TMC-256C2; Norrubrofusarin dimethyl ether) 
(51) (C16H14O5) was obtained as a yellow powder by open column chromatography  
on Silica gel using CHCl3/MeOH 90:10 as eluent. Further purification was done by 
HPLC using gradient (water/acetonitrile 95:5 to 5:95; 30 min) Rt = 27.6. Upon 
spraying with vanillin/ sulphuric acid a greenish- brown spot was obtained on the TLC 
plate.  
 
ESI-MS: 287 [M+H]+, 285[M-H]-  
UV (MeOH): λmax 240, 282, 367 nm 
IR (film): 1672, 1617, 1577, 1525, 1459, 1436, 1388,  
1329, 1210, 876, 824 cm-1 
 
1H NMR (CDCl3, 300 MHz):  δ 6.35 (d, J = 1.9 Hz, 1H, H-4), 6.52 (d, J = 1.9 Hz, 1H, 
H-6) 6.90 (s, 1H, H-7), 6.27 (s, 1H, H-10), 3.92 (s, 3H, H-11), 3.88 (s, 3H, H-12), 2.45 
(s, 3H, H-14) 
 
13C NMR (CDCl3, 75 MHz): δ 155.7 (s, C-2), 104.8 (s, C-2a), 159.0 (s, C-3), 96.9 (d, 
C-4) 161.4 (s, C-5), 97.9 (d, C-6), 141.1(s, C-6a), 105.7 (d, C-7), 156.5 (s, C-8), 
108.7 (s, C-8a), 182.8 (s, C-9), 110.1 (d, C-10), 166.5 (s, C-11), 55.8 (q, C-12), 55.4 
(q, C-13), 20.4 (q, C-14) 
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5.5.5 Inonotus sp. (fruiting body) 
The fruiting body of inonotus sp. was collected in Vietnam. Its identification was 
verified by Prof. Trinh Tam Kiet from the Mycological Research Centre, Hanoi State 
University, 334 Nguyen Trai Street, Hanoi, Vietnam, where a specimen was 
deposited. 500 g of fresh fruiting bodies were cut in to small pecies, dried and 
crushed. The resulting powder was extracted three times with ethanol, chloroform / 
methanol (3 x 2l 3 days each). The combined extract (3 g) of a brown solid, which 
was found to have a strong anti-inflammatory effect in the 3α-hydroxysteroid 
dehydrogenase (3α-HSD) assay, was subjected to silica gel chromatography (silica 
gel 60, Merck, 0,063~0.1 mm, column 4 x 60 cm), using stepwise CHCl3-MeOH ( 9:1, 
8:2, 1:1 v / v) as eluents. Bioassay-guided fractionation and monitoring by mass 
spectrometry led to the detection of six active substances with m/z = 217, 291, 244, 
244 and 177 in the negative mode. The yields were, 20 mg of inonotic acid 
methylester, , 4 mg of inotilone, 500 mg of hispidin A, 15 mg of iso-hispidin and 6 mg 
of (E)-4-(3,4-dihydroxyphenyl)but-3en-2-one. 
 
Inonotic acid methylester (52) (C14H14O6) was obtained as yellow oil by open 
column chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 95:5 
as eluent. Further purification was done by HPLC using gradient (water/acetonitrile 
95:5 to 5:95; 30 min) Rt = 20.5 min. Upon spraying with vanillin/ sulphuric acid or 
Emmerie-Engel’s reagent a strong greenish- brown spot was obtained on the TLC 
plate.  
 
ESI-MS: m/z 279 [M+H]+, 277 [M-H]-  
HR-ESIMS (found [M-H]-; 277.0682 calcd.  
for C14H13O6: 277.0707) 
UV (MeOH): λmax 261, 380 nm  
IR (film): 3094, 1733, 1632, 1567, 1513, 1435, 1282, 1022, 974 cm-1 
 
1H NMR (DMSO-d6, 300 MHz): δ 3.55 (s, 2H, H-2), 5.91 (s, 1H,  H-4), 6.50 (d, J = 
15.8 Hz, 1H, H-6), 7.45 (d, J = 15.8 Hz, 1H, H-7), 7.07 (d, J = 1.8 Hz, 1H, H-9), 6.77 
(d, J = 8.1 Hz, 1H, H-12), 7.02 (dd, J = 1.8, 8.1 Hz, 1H, H-13), 3.65 (s, 3H, H-1’) 
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13C NMR (DMSO-d6, 75 MHz): δ 167.9 (s, C-1), 45.6 (t, C-2), 191.8 (s, C-3),  100.3 
(d, C-4), 178.3 (s, C-5), 118.6 (d, C-6), 141.0 (d, C-7), 126.2 (s, C-8), 114.7 (d, C-9), 
145.6 (s, C-10), 148.4 (s, C-11),  115.7 (d, C-12), 121.5 (s, C-13), 51.8 (q, C-1’) 
 
Inotilone (53) (C12H10O4) was obtained as yellow oil by open column 
chromatography on Sephadex LH 20 and silica gel using CHCl3/MeOH 90:10 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 16 min. Upon spraying with vanillin/ sulphiric acid or Emmerie-
Engel’s reagent a strong greenish- brown spot was obtained on the TLC plate.  
 
ESI-MS: m/ z 219 [M+H]+, 217 [M-H]-  
HR-ESIMS (found [M-H]-; 217.0495 calcd.  
for C12H9O4: 217.0495) 
UV (MeOH): λmax 264, 312, 378 nm  
IR (film): 3184, 1682, 1588, 1435, 1287, 1014, 951 cm-1 
 
1H NMR (DMSO-d6, 300 MHz): δ 5.82 (s, 1H, H-4), 6.49 (s, 1H, H-6), 7.35 (d, J = 2.0 
Hz, 1H, H-8), 6.80 (d, J = 8.2 Hz, 1H, H-11), 7.17 (dd, J = 2.0, 8.2 Hz, 1H, H-12), 
2.39 (s, 3H,  H-13) 
 
13C NMR ( DMSO-d6, 75 MHz): δ 180.4 (s, C-2), 105.4 (d, C-3), 186.6 (s, C-4), 144.3 
(s, C-5) 111.9 (d, C-6), 122.9 (s, C-7), 117.9 (d, C-8), 145.4 (s, C-9), 148.1 (s, C-10),  
115.9 (d, C-11), 124.7 (s, C-12), 15.6 (d, C-13) 
 
(E)-4-(3,4-dihydroxyphenyl)but-3en-2-one (56) (C10H10O3) was obtained as  yellow 
crystals by open column chromatography on Sephadex LH-20 and Siliica gel using 
CHCl3/MeOH 80:20 as eluent. Further purification was done by HPLC using gradient 
(water/acetonitrile 95:5 to 5:95; 30 min) Rt = 15.0 min. Upon spraying with vanillin/ 
sulphuric acid or Emmerie-Engel’s reagent a strong greenish-brown spot was 
obtained on the TLC plate.  
 
ESI-MS: m/ z 179 [M+H]+, 177 [M-H]-  
UV (MeOH): λmax 248, 361, nm  
IR (film): 3459 1597, 1533, 1442, 1357, 1276, 1110, 964, 803 cm-1 
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1H NMR (CD3OD, 300 MHz): δ 2.32 (s, 3H, H-1), 6.53(d, J = 16.1 Hz, 1H, H-3), 7.52 
(d, J = 16.1 Hz, 1H, H-4), 7.07 (d, J = 1.9 Hz, 1H, H-6), 6.78 (d, J = 8.2 Hz, 1H, H-9), 
6.98 (dd, J = 1.9, 8.2 Hz, 1H, H-10) 
 
Hispidin (57) (C13H10O5) was obtained as yellow crystals by open column 
chromatography on Sephadex LH-20 and silica gel using CHCl3/MeOH 80:20 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 15.9 min. Upon spraying with vanillin/sulphuric acid or Emmerie-
Engel’s reagent a strong greenish- brown spot was obtained on the TLC plate.  
 
ESI-MS: m/ z 245 [M+H]+, 244 [M-H]-  
UV (MeOH): λmax 258 and 379 nm  
IR (film): 3093, 1594, 1544, 1373, 1284, 1260,  
1150, 1015 and 957 cm-1 
 
1H NMR (DMSO-d6, 300 MHz): δ 5.26 (d, J = 2.1 Hz, 1H, H-3), 6.14 (d, J = 2.1 Hz, 
1H,  H-5), 6.63 (d, J = 15.9 Hz, 1H, H-7), 7.13 (d, J = 15.9 Hz, 1H, H-8), 7.01 (d, J = 
2.1 Hz, 1H, H-10), 6.75 (d, J = 8.4 Hz, 1H, H-13), 6.93 (dd, J = 2.1, 8.4 Hz, 1H, H-14) 
 
13C NMR (DMSO-d6, 75 MHz): δ 162.3 (s, C-2), 89.1 (d, C-3),  170.3 (s, C-4), 100.4 
(d, C-5), 159.7 (s, C-6), 116.3 (d, C-7), 134.5 (d, C-8), 126.7 (s, C-9), 114.0 (d, C-10), 
145.5 (s, C-11),  147.3 (s, C-12), 115.7 (d, C-13), 120.2 (d, C-14) 
 
iso-Hispidin (58) (C13H10O5) was obtained as yellow crystals by open column 
chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 80:20 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 14.0 min. Upon spraying with vanillin/sulphuric acid or Emmerie-
Engel’s reagent a strong greenish- brown spot was obtained on the TLC plate.  
 
ESI-MS: m/z 245 [M+H]+, 244 [M-H]-  
HR-ESIMS (found [M-H]-; 245.0464 calcd.  
for C15H15O6: 245.0445) 
UV (MeOH): λmax 248, 361 nm  
IR (film): 3095, 1649, 1590, 1494, 1411, 1276, 1202, 1050, 1000 cm-1 
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1H NMR (DMSO-d6, 300 MHz): δ 4.42 (d, J = 1.2 Hz, 1H, H-3), 5.59 (d, J = 1.2 Hz, 
1H,  H-5), 6.12 (d, J = 15.8 Hz, 1H, H-7), 6.87 (d, J = 15.8 Hz, 1H, H-8), 6.94 (d, J = 
1.5 Hz, 1H, H-10), 6.70 (d, J = 8.1 Hz, 1H, H-13), 6.82 (dd, J = 1.5, 8.1 Hz, 1H, H-14) 
 
13C NMR (DMSO-d6, 75 MHz): δ 165.4 (s, C-2), 86.5 (d, C-3),  179.1 (s, C-4), 109.0 
(d, C-5), 156.1 (s, C-6), 118.5 (d, C-7), 130.8 (d, C-8), 127.4 (s, C-9), 113.5 (d, C-10), 
145.6 (s, C-11),  146.5 (s, C-12), 115.7 (d, C-13), 119.2 (d, C-14) 
 
5.5.6 Pholiota squarrosa (fruiting body) 
The fruiting body of Pholiota squarrosa was collected in Jena (Germany) and its 
identification was verified by Dr. Martin Roth, from the Leibniz-Institute for Natural 
Product and Infection Biology, HKI, Pilot Plant for Natural Products, where a 
specimen was deposited. 25 g of fresh fruiting bodies were cut in to small pieces, 
dried and crushed. The resulting powder was extracted three times, chloroform 
/methanol: 1:1 (3 x 2 l 3 days each). The combined extract (2.5 g) of a brown solid, 
which was found to have a strong anti-inflammatory effect in the 3α-hydroxysteroid 
dehydrogenase (3α-HSD) assay, was subjected to silica gel chromatography (silica 
gel 60, Merck, 0,063~0.1 mm, column 4 x 60 cm), using stepwise CHCl3-MeOH (9:1, 
8:2, 1:1 v / v) as eluents. Bioassay-guided fractionation and monitoring by mass 
spectrometry led to the detection of the unique active substance with m/z = 487 in the 
negative mode. The yield was 4 mg of squarrosidine. 
 
Squarrosidine (65) (C27H20O9) was obtained as yellow oil by open column 
chromatography on Sephadex LH-20 and silica gel using CHCl3/MeOH 85:15 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 23.5. Upon spraying with vanillin/ sulphuric acid or Emmerie-
Engel’s reagent a strong greenish-brown spot was obtained on the TLC plate.  
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ESI-MS:m/z 489 [M+H]+, 487 [M-H]-  
HR-ESIMS (found [M-H]-; 487.1065 calcd.  
for C27H19O9: 487.1024) 
UV (MeOH): λmax 219, 258, 369 nm  
IR (film): 3204, 1661, 1601, 1556, 1513, 1414, 1273, 1022, 987 cm-1 
 
1H NMR (DMSO-d6, 300 MHz): δ 5.85 (s, 1H, H-5), 6.52 (d, J = 15.9 Hz, 1H,  H-7), 
6.97 (d, J = 15.9 Hz, 1H, H-8), 6.96 (d, J = 1.8 Hz, 1H, H-10), 6.72 (d, J = 8.1 Hz, 1H, 
H-13), 6.88 (dd, J = 1.8, 8.1 Hz, 1H, H-14), 5.84 (s, 1H, H-5’), 6.62 (d, J = 15.9 Hz 
1H, H-7’), 7.06 (d, J = 15.9 Hz, 1H,  H-8’), 7.43 (d, J = 8.7 Hz, 1H, H-10’), 6.76 (d, J  
= 8.7 Hz, 1H, H-13’), , 7.43 (d, J = 8.7 Hz, 1H, H-14’), 3.33 (s, 1H, H-1’’) 
 
13C NMR (DMSO-d6, 75 MHz): δ 164.4 (s, C-2), 101.2 (s, C-3),  172.5 (s, C-4), 105.2 
(s, C-5), 155.4 (s, C-6), 117.3 (d, C-7), 131.5 (d, C-8), 127.2 (s, C-9), 113.6 (d, C-10), 
146.5 (s, C-11),  145.4 (s, C-12), 115.6 (d, C-13), 119.5 (d, C-14), 164.2 (s, C-2’), 
101.2 (s, C-3’), 172.5 (d, C-4’), 105.2 (d, C-5’),  155.4 (s, C-6’), 117.4 (d, C-7’), 131.1 
(d, C-8’), 126.7 (s, C-9’), 128.5 (d, C-10’), 115.6 (d, C-11’),  158.1 (s, C-12’), 115.6 (d, 
C-13’), 128.5 (d, C-14’), 18.9 (s, C-1’’) 
 
5.5.7 Phellinus pini DSM 5238 
The fungus was cultivated under the condition of surface fermentation at 25 oC in 500 
ml Erlenmeyer flasks containing 300 ml liquid malt medium. After cultivation for 28 
days at 25 oC the mycelium cake from the culture medium (40 l) was extracted twice 
with ethyl acetate (25 l) and methanol (each 10 l). The culture broth was thoroughly 
extracted with ethyl acetate. The organic layer was combined and concentrated 
under reduced pressure. The resulting dark brown oil was washed with n-hexane to 
remove fatty acid  and the residue was dissolved in a small volume of CHCl3 and 
subjected to column chromatography (silica gel 60, Merk, 0.063 - 0.1 mm, column 4 х 
60 cm), using stepwise CHCl3 and CHCl3-MeOH (9:1, 1:1, v/v) as eluents. Active 
components were isolated on the basis of bioassays. Final purification was achieved 
by preparative HPLC using a Spherisorb ODS-2 Rp18 column (250 х 25 mm, 5 µm, 
Promochem, and acetonitrile-H2O (83:17, v / v) as eluent (flow rate 10 ml/min, UV-
detection at 300 nm), yielding pinillidine (8 mg), pinillic acid (4 mg), hypholomine B (7 
mg) and hispidin (100 mg). 
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Pinillidine (72) (C28H22O10) was obtained as yellow oil by open column 
chromatography on Sephadex LH-20 ans Silica gel using CHCl3/MeOH 80:20 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt = 22.3 min. Upon spraying with vanillin/sulphuric acid or Emmerie-
Engel’s reagent a strong greenish- brown spot was obtained on the TLC plate.  
 
 
 
 
 
 
ESI-MS: m/z 517 [M+H]-  
UV (MeOH): λmax 256, 388 nm  
IR (film): 3189, 2921, 1649, 1584, 1557, 1494, 1375 cm-1 
 
1H NMR (DMSO-d6, 300 MHz): δ 6.13 (s, 1H,  H-5), 6.64 (d, J = 16.0 Hz, 1H, H-7), 
7.16 (d, J = 16.0 Hz, 1H, H-8), 7.01 (d, J = 1.9 Hz, 1H, H-10), 6.74 (d, J = 8.3 Hz, 1H, 
H-13), 6.93 (dd, 1.9,  J = 8.3, 8.4 Hz, 1H, H-14), δ 6.13 (s, 1H,  H-5’), 6.64 (d, J = 
16.0 Hz, 1H, H-7’), 7.16 (d, J = 16.0 Hz, 1H, H-8’), 7.01 (d, J = 1.9 Hz, 1H, H-10’), 
6.74 (d, J = 8.3 Hz, 1H, H-13’), 6.93 (dd, J = 1.9, 8.3 Hz, 1H, H-14’), 4.55 (q, 1H, H-
15’), 1.45 (d, J= 7.5, 3H, H-16’) 
 
13C NMR (DMSO-d6, 75 MHz): δ 164.2 (s, C-2), 105.2 (d, C-3),  166.5 (s, C-4), 105.2 
(d, C-5), 156.6 (s, C-6), 116.1 (d, C-7), 133.7 (d, C-8), 126.8 (s, C-9), 114.0 (d, C-10), 
145.5 (s, C-11),  147.1 (s, C-12), 115.7 (d, C-13), 120.1 (d, C-14), 164.2 (s, C-2’), 
105.2 (d, C-3’),  166-5 (s, C-4’), 105.2 (d, C-5’), 156.6 (s, C-6’), 116.1 (d, C-7’), 133.7 
(d, C-8’), 126.8 (s, C-9’), 114.0 (d, C-10’), 145.5 (s, C-11’),  147.1 (s, C-12’), 115.7 (d, 
C-13’), 120.1 (d, C-14’) 25.5 (d, C-15’), 16.5 (q, C-16’) 
 
Pinillic acid (73) (C17H14O5) was obtained as yellow powder by open column 
chromatography on Sephadex LH-20 and Silica gel using CHCl3/MeOH 80:20 as 
eluent. Further purification was done by HPLC using gradient (water/acetonitrile 95:5 
to 5:95; 30 min) Rt 21.3 min. Upon spraying with Emmerie-Engel’s reagent a strong 
greenish- brown spot was obtained on the TLC plate.  
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ESI-MS: m/z 297 [M-H]- 
HR-ESIMS (found [M-H]-; 297.0755 calcd.  
for C17H13O5: 297.0758) 
UV (MeOH): λmax 230, 290, 330 nm  
IR (film): 3198, 2925, 1681, 1613, 1581,  
1507, 1436, 1170, 815 cm-1 
 
1H NMR (CD3OD, 300 MHz): δ 6.34 (d, J = 15.9 Hz, 1H, H-2), 7.59 (d, J = 15.9 Hz, 
1H,  H-3), 7.18 (d, J = 2.0 Hz, 1H, H-5), 6.93 (d, J = 8.7 Hz, 1H, H-8), 7.12 (d, J = 2.0, 
8.7 Hz, 1H, H-9), 4.04 (dd, J = 8.8, 11.5 Hz, 1H, H-a1’), 4.36 (dd, J = 2.3, 11.5 Hz, 
1H, H-b1’), 5.04 (dd, J = 2.3, 8.8 Hz, 1H, H-2’), 7.28 (d, J = 8.5 Hz, 1H,  H-4’), 6.83 
(d, 8.5, 1H, H-5’), 6.83 (d, J = 8.5 Hz, 1H, H-7’), 7.28 (d, J = 8.5 Hz, 1H, H-8’) 
 
13C NMR (CD3OD, 75 MHz): δ 170.7 (s, C-1), 117.4 (d, C-2),  146.0 (d, C-3), 129.4 
(s, C-4), 117.6 (d, C-5), 145.7 (s, C-6), 146.7 (s, C-7), 118.4 (d, C-8), 123.1 (d, C-9),  
70.5 (t, C-1’), 76.2 (d, C-2’), 128.5 (s, C-3’), 129.1 (d, C-4’), 116.4 (d, C-5’),  159.1 (s, 
C-6’), 116.4 (d, C-7’), 129.1 (d, C-8’) 
 
Hypholomine B (75) (C26H18O10) was obtained as yellow oil by open column 
chromatography on Sephadex LH-20 and silca gel using CHCl3/MeOH 70:30 eluent. 
Further purification was done by HPLC using gradient (water/acetonitrile 95:5 to 5:95; 
30 min) Rt = 18.3. Upon spraying with vanillin/sulphuric acid or Emmerie-Engel’s 
reagent a strong greenish- brown spot was attained on the TLC plate.  
 
ESI-MS: m/z 489 [M+H]-, 979 [2M-H]- 
UV (MeOH): λmax  256, 388 nm  
IR (film): 3070, 1602, 1549, 1430, 1284, 1173, 988 cm-1 
 
 
 
 
1H NMR (DMSO-d6, 300 MHz): δ 6.59 (s, 1H, H-5), 6.98 (d, J = 15.9 Hz, 1H,  H-7), 
7.29 (d, J = 15.9 Hz, 1H, H-8), 7.05 (d, J = 1.9 Hz, 1H, H-10), 6.73 (d, J =  8.3 Hz, 
1H, H-13), 6.98 (dd, J = 1.9, 8.3 Hz, 2H, H-14), 5.81 (d, J = 6.0 Hz, 1H, H-15), 4.29 
OH
O
O
O
HO
Ha
Hb
46
2
7
8
9
5
2'
4'
5'
6'
7'
3
8'
1'
13'
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(d, J = 6.1 Hz, 1H, H-16), 6.09 (d, J = 2.0 Hz, 1H,  H-18), 5.29 (d, J = 2.0, 1H, H-20), 
6.92 (d, J = 8.3 Hz, 1H, H-22), 6.77 (d, J = 8.3 Hz, 1H, H-25), 6.88 (d, J = 2.0, 8.3 Hz, 
1H, H-26) 
 
13C NMR (DMSO-d6, 75 MHz): δ 162.0 (s, C-2), 98.1 (s, C-3),  171.4 (s, C-4), 94.7 (d, 
C-5), 163.2 (s, C-6), 138.2 (d, C-7), 136.2 (d, C-8), 126.5 (d, C-9), 114.1 (d, C-10),  
145.6 (s, C-11), 147.8 (s, C-12), 115.5 (d, C-13), 120.8 (d, C-14), 90.4 (d, C-15),  
50.9 (d, C-16), 158.9 (d, C-17), 101.2 (d, C-18), 170.0 (s, C-19), 89.3 (s, C-20), 163.4 
(s, C-21), 129.5 (d, C-22), 117.3 (d, C-23),  145.5 (s, C-24), 146.3 (d, C-25), 115.8 (d, 
C-26),  121.6 (d, C-27) 
 
5.5.8 Piptoporus betulinus (fruiting body) 
The fruiting body of Piptoporus betulinus was isolated from the forest district near 
Jena (Thuringia, Germany). One kilogram of fresh fruiting bodies was cut into small 
pieces, dried and crushed. The resulting powder was extracted three times with 
ethylacetate, chloroform and methanol (3 x 2 l 3 days each). The ethyl acetate 
extract (3 g) of a brown solid, which was found to have a strong anti-inflammatory 
effect was subjected to silica gel chromatography (silica gel 60, Merck, 
0,063~0.1mm, column 4 x 60 cm), using stepwise CHCl3-MeOH ( 9:1, 8:2, 1:1 v / v) 
as eluents. Bioassay-guided fractionation using a 3α-hydroxysteroid dehydrogenase 
(3α-HSD) assay and monitoring by mass spectrometry led to the detection of four 
active substances with m/z = 529, 587, 645, 483 in positive mode.  
Yield: 10 mg of polyporenic acid A, 8 mg of 3α-acetylpolyporenic acid A, 15 mg of 
(25S)-(+)-12αhydroxy-3α-methylcarboxyacetate-24-methyllanosta-8,24(31)-diene-26-
oic acid, 40 mg of (25S3’S)-(+)-12α-hydroxy-3α-(3’-hydroxy-4’methoxycarbonyl-3’-
methylbutyryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid and 30 mg of 
polyporenic acid C. 
 
Polyporenic acid A (75) (C31H50O4) was obtained as colourless oil by open column 
chromatography  on silca gel using CHCl3/MeOH 80:20 as eluent. Further purification 
was done by HPLC using gradient (water/acetonitrile 95:5 to 5:95; 50 min) Rt = 23.9. 
Upon spraying with vanillin/sulphuric acid a violet spot was obtained on the TLC 
plate, suggesting a terpernoid. 
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[α]D20 +69 (MeOH, c = 1 mg/ml) 
ESI-MS: m/z 487 [M+H]+, 509 [M+Na]+  
UV (MeOH): λmax 264 nm 
IR (film): 3400, 2932, 1706, 1570,  
1456, 1373, 1204, 1056, 890 cm-1 
 
1H NMR (CD3OD, 300 MHz): δ 1.48-167 (m, 2H, H-1), 1.61-1.69 (m, 2H,  H-2), 4.65 
(brs, J = 7.2 Hz, 1H, H-3), 1.49-1.61 (m, 1H, H-5), 1.49 (m, 2H, H-6), 2.02 (m, 2H, H-
7), 2.03 (m, 2H, H-11), 4.00 (d, J = 8.1 Hz, 1H, H-12), 2.25 (m, 2H, H-15), 1.35-2.10 
(m, 2H, H-16), 2.02 (m, 1H,  H-17), 0.66 (s, 3H, H-18), 1.01 (s, 3H, H-19), 1.40 (m, 
1H, H-20), 1.06 (d, J = 6.5 Hz, 3H, H-21), 1.24-1.65 (m, 2H, H-22), 2.02 (m, 2H, H-
23), 3.16 (q, J = 7.0 Hz, 1H, H-25), 1.25 (d, J = 7.0 Hz, 3H, H-27), 0.88 (s, 3H, H-28), 
0.96 (s, 3H, H-29), 1.10 (s, 3H, H-30), 4.89 (brs, 2H, H-31) 
 
13C NMR (CD3OD, 75 MHz): δ 31.2 (t, C-1), 26.7 (t, C-2), 76.6 (d, C-3),  38.5 (s, C-4), 
45.4 (d, C-5), 19.2 (t, C-6), 27.2 (t, C-7), 135.9 (s, C-8), 134.7(s, C-9), 37.9 (s, C-10), 
34.3 (t, C-11),  73.7 (d, C-12), 50.7 (s, C-13), 50.6 (s, C-14), 33.1 (t, C-15), 28.9 (t, C-
16), 43.9 (d, C-17), 16.9 (q, C-18), 19.3 (q, C-19),  37.6 (d, C-20), 18.0 (q, C-21), 
35.6 (t, C-22), 33.2 (t, C-23), 151.6 (s, C-24), 48.3 (d, C-25), 178.7 (s, C-26), 17.1 (q, 
C-27), 22.7 (q, C-28), 28.9 (q, C-29), 25.1 (q, C-30), 110.0 (t, C-31) 
 
3α-Acetylpolyporenic acid A (76) (C33H52O5) was obtained as colourless oil by 
open column chromatography on silca gel using CHCl3/MeOH 85:15 as eluent. 
Further purification was done by HPLC using gradient (water/acetonitrile 95:5 to 5:95; 
50 min) Rt = 33.6 min. Upon spraying with vanillin/sulphuric acid a violet spot was 
obtained on the TLC plate, suggesting a terpernoid. 
 
[α]D20 +30 (MeOH, c = 1 mg/ml) 
ESI-MS: m/z 529 [M+H]+, 551 [M+Na]+  
HR-ESIMS (found [M+Na]+; 551. calcd.  
for C33H52O5 Na: 3701551.4288) 
UV (MeOH): λmax 264 nm 
IR (film): 2939, 1709, 1457, 1374,  
1245, 1181, 1010, 892 cm-1 
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1H NMR (CDCl3, 300Hz): δ 1.49 (m, 2H, H-1), 1.61-1.69 (m, 2H,  H-2), 4.65 (brs, J = 
7.2, 1H, H-3), 1.49-1.61 (m, 1H, H-5), 1.49 (m, 2H, H-6), 2.02 (m, 2H, H-7), 2.09-2.63 
(m, 2H, H-11), 4.00 (d, J = 8.1 Hz, 1H, H-12), 1.19-1.67 (m, 2H, H-15), 1.35-2.10 (m, 
2H, H-16), 2.02 (m, 1H,  H-17), 0.60 (s, 3H, H-18), 0.96 (s, 3H, H-19), 1.40 (m, J = 
7.2 Hz, 1H, H-20), 1.00 (d, J = 6.5 Hz, 3H, H-21), 1.24-1.65 (m, 2H, H-22), 2.02 (m, 
2H, H-23), 3.16 (q, J = 7.0, 1H, H-25), 1.30 (d, J = 7.0 Hz, 3H, H-27), 0.85 (s, 3H, H-
28), 0.90 (s, 3H, H-29), 1.00 (s, 3H, H-30), 4.93-4.97 (brs,  2H, H-31), 2.06 (s, 3H, H-
2’) 
 
13C NMR (CDCl3, 75 MHz): δ 30.5 (t, C-1), 23.2 (t, C-2), 78.0 (d, C-3),  36.7 (s, C-4), 
45.1 (d, C-5), 17.9 (t, C-6), 25.9 (t, C-7), 134.7 (s, C-8), 132.9 (s, C-9), 36.7 (s, C-10), 
32.5 (t, C-11),  73.4 (d, C-12), 49.5 (s, C-13), 49.6 (s, C-14), 31.9 (t, C-15), 27.7 (t, C-
16), 43.1 (d, C-17), 16.1 (q, C-18), 18.7 (q, C-19),  35.9 (d, C-20), 17.8 (q, C-21), 
34.2 (t, C-22), 31.8 (t, C-23), 148.1 (s, C-24), 45.1 (d, C-25), 178.7 (s, C-26), 16.2 (q, 
C-27), 21.7 (q, C-28), 27.5 (q, C-29), 24.5 (q, C-30), 111.0 (t, C-31), 171.0 (s, C-1’), 
21.3 (s, C-2’) 
 
(25S)-(+)-12α-hydroxy-3α-methylcarboxyacetate-24-methyllanosta-8,24(31)-
diene-26-oic acid (77) (C35H54O7) was obtained as colourless oil by open column 
chromatography  on silca gel using CHCl3/MeOH 85:15 as eluent. Further purification 
was done by HPLC using gradient (water/acetonitrile 95:5 to 5:95; 50 min) Rt = 33.8 
min. Upon spraying with vanillin/sulphuric acid a violet spot was obtained on the TLC 
plate, suggesting a terpernoid. 
 
[α]D20 +19 (MeOH, c = 1 mg/ml) 
ESI-MS: m/z 587 [M+H]+, 609 [M+Na]+  
HR-ESIMS (found [M-H]-; 609.3756 calcd.  
for C35H54O7Na: 609.4446) 
UV (MeOH): λmax 264 nm 
IR (film): 2940, 1731, 1456,  
1374, 1152, 1017, 974, 753 cm-1 
 
1H NMR (CDCl3, 300Hz): δ 1.50 (m, 2H, H-1), 1.62-1.90 (m, 2H,  H-2), 4.70 (brs, J = 
7.2 Hz, 1H, H-3), 1.44 (m, 1H, H-5), 1.44-1.60 (m, 2H, H-6), 2.01 (m, 2H, H-7), 2.10-
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2.60 (m, 2H, H-11), 4.00 (d, J = 8.0 Hz, 1H, H-12), 1.19-1.65 (m, J = 6.9 Hz, 2H, H-
15), 1.37-1.65 (m, 2H, H-16), 2.01 (m, 1H,  H-17), 0.60 (s,  3H, H-18), 0.97 (s, 3H, H-
19), 1.40 (m, J = 7.2 Hz, 1H, H-20), 1.00 (d, J = 6.5 Hz, 3H, H-21), 1.24-1.65 (m, 2H, 
H-22), 2.01-2.20 (m, 2H, H-23), 3.15 (q, J = 7.0 Hz, 1H, H-25), 1.32 (d, J = 7.0 Hz, 
3H, H-27), 0.92 (s, 3H, H-28), 0.86 (s, 3H, H-29), 1.07 (s, 3H, H-30), 4.93-4.97 (brs, J 
= 6.9 Hz, 2H, H-31), 3.38 (s, 3H, H-2’), 3.70 (s, 3H, H-4’) 
 
13C NMR (CDCl3, 75 MHz): δ 30.4 (t, C-1), 23.1 (t, C-2), 79.7 (d, C-3),  36.8 (s, C-4), 
45.4 (d, C-5), 17.9 (t, C-6), 25.9 (t, C-7), 134.8 (s, C-8), 132.8 (s, C-9), 36.6 (s, C-10), 
32.5 (t, C-11),  73.4 (d, C-12), 49.5 (s, C-13), 49.6 (s, C-14), 31.9 (t, C-15), 27.7 (t, C-
16), 43.1 (d, C-17), 16.1 (q, C-18), 18.7 (q, C-19),  35.9 (d, C-20), 17.8 (q, C-21), 
34.2 (t, C-22), 31.8 (t, C-23), 148.1 (s, C-24), 45.1 (d, C-25), 179.0 (s, C-26), 16.2 (q, 
C-27), 21.6 (q, C-28), 27.5 (q, C-29), 24.4 (q, C-30), 111.4 (t, C-31), 166.0 (s, C-1’), 
41.7 (s, C-2’), 167.2 (s, C-3’), 52.3 (s, C-4’) 
 
(25S.3’S)-(+)-12α-hydroxy-3α-(3’-hydroxy-4’methoxycarbonyl-3’-
methylbutyryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid (78) (C38H60O8) 
was obtained as a colourless oil by open column chromatography  on silca gel using 
CHCl3/MeOH 90:10 as eluent. Further purification was done by HPLC using gradient 
(water/acetonitrile 95:5 to 5:95; 50 min) Rt = 45.2. Upon spraying with 
vanillin/sulphuric acid a violet spot was obtained on the TLC plate, suggesting a 
terpernoid. 
 
[α]D20 +17 (MeOH, c = 1 mg/ml) 
ESI-MS: m/z 667 [M+Na]+, 1311 [2M+Na]+ 
UV (MeOH): 264 nm 
IR (film): λmax 3377, 2938, 1709, 1454, 1376,  
1202, 1023 cm-1 
 
 
 
1H NMR (CDCl3, 300 MHz): δ 1.50 (m, 2H, H-1), 1.62-1.90 (m, 2H,  H-2), 4.70 (brs, J 
= 7.2 Hz, 1H, H-3), 1.44 (m, 1H, H-5), 1.44-1.60 (m, 2H, H-6), 2.01 (m, 2H, H-7), 
2.10-2.60 (m, 2H, H-11), 4.00 (d, J = 8.0 Hz, 1H, H-12), 1.19-1.65 (m, 2H, H-15), 
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1.37-1.65 (m, 2H, H-16), 2.01 (m, 1H,  H-17), 0.60 (s, 3H, H-18), 0.97 (s, 3H, H-19), 
1.40 (m, 1H, H-20), 1.00 (d, J = 6.5 Hz, 3H, H-21), 1.24-1.65 (m, 2H, H-22), 2.01-
2.20 (m, 2H, H-23), 3.15 (q, J = 7.0 Hz, 1H, H-25), 1.32 (d, 7.0 Hz, 3H, H-27), 0.92 
(s, 3H, H-28), 0.86 (s, 3H, H-29), 1.07 (s, 3H, H-30), 4.93-4.97 (brs, 2H, H-31), 2.6-
2.7 (dd, overlapped, 2H, H-2'), 1.34 (s, 3H, H-4’), 2.6-2.7 (dd, overlapped, 2H, H-5'), 
3.69 (s, 3H, H-7’) 
 
13C NMR (CDCl3, 75 MHz): δ 30.5 (t, C-1), 23.3 (t, C-2), 78.6 (d, C-3),  36.7 (s, C-4), 
45.4 (d, C-5), 17.9 (t, C-6), 25.9 (t, C-7), 134.8 (s, C-8), 132.8 (s, C-9), 36.6 (s, C-10), 
32.7 (t, C-11),  73.2 (d, C-12), 49.6 (s, C-13), 49.6 (s, C-14), 31.9 (t, C-15), 27.7 (t, C-
16), 43.0 (d, C-17), 16.2 (q, C-18), 18.7 (q, C-19),  36.0 (d, C-20), 17.8 (q, C-21), 
34.2 (t, C-22), 31.8 (t, C-23), 148.8 (s, C-24), 45.0 (d, C-25), 179.1 (s, C-26), 16.2 (q, 
C-27), 21.7 (q, C-28), 27.3 (q, C-29), 24.5 (q, C-30), 110.8 (t, C-31), 172.0 (s, C-1’), 
45.0 (s, C-2’), 69.7 (s, C-3’), 27.3 (s, C-4’), 44.8 (s, C-5’), 171.8 (t, C-6’), 51.7 (s, C-
7’),  
 
Polyporenic acid C (79) (C31H46O4) was obtained as a colourless powder by open 
column chromatography  on silca gel using CHCl3/MeOH 85:15 as eluent. Further 
purification was done by HPLC using gradient (water/acetonitrile 95:5 to 5:95; 50 
min) Rt = 27.5 min. Upon spraying with vanillin/sulphuric acid a violet spot was 
obtained on the TLC plate, suggesting a terpernoid. 
 
[α]D20 –6 (MeOH, c = 1 mg/ml) 
ESI-MS: m/ z 483 [M+H]+, 987 [2M+H]+  
IR (film): 3402, 2965, 2932, 1717, 1678, 1450,  
1252, 1109, 1016, 883 cm-1 
 
 
1H NMR (DMSO-d6, 300 MHz): δ 1.60 (m, 2H, H-1), 2.20-2.8 (m, 2H,  H-2), 1.41 (dd, 
J = 4.1, 11.4 Hz, 1H, H-5), 2.01-2.20 (m, 2H, H-6), 5.47(brs, 1H, H-7), 5.40 (brs, 1H, 
H-11), 1.77-2.07 (m, 2H, H-12), 1.37-2.02 (m, 2H, H-15), 3.90 (brs, 1H, H-16), 1.88 
(m, 1H,  H-17), 0.56 (s, 3H, H-18), 1.10 (s, 3H, H-19), 2.23 (m, 1H, H-20), 1.60-1.95 
(m, 2H, H-22), 1.94 (m, 2H, H-23), 2.20 (m, 1H, H-25), 0.98 (d, J = 6.7 Hz, 3H, H-26), 
0.98 (d, J = 6.7 Hz, 3H, H-27), 0.95 (s, 3H, H-28), 0.95 (s, 3H, H-29), 1.07 (s, 3H, H-
30), 4.70 (d, J = 18.3 Hz, 2H, H-31) 
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13C NMR (DMSO-d6, 75 MHz):  δ 35.9 (t, C-1), 34.2 (t, C-2), 215.0 (s C-3),  46.7 (s, 
C-4), 50.3 (d, C-5), 23.0 (t, C-6), 119.9 (d, C-7), 141.9 (s, C-8), 144.0 (s, C-9), 36.7 
(s, C-10), 116.5 (d, C-11),  35.1 (t, C-12), 43.6 (s, C-13), 48.1 (s, C-14), 43.1 (t, C-
15), 75.0 (d, C-16), 55.9 (d, C-17), 16.1 (q, C-18), 21.9 (q, C-19),  46.7 (d, C-20), 
176.9 (s, C-21), 29.9 (t, C-22), 31.8 (t, C-23), 154.9 (s, C-24), 33.1 (d, C-25), 21.61 
(q, C-26), 21.6 (q, C-27), 25.3 (q, C-28), 25.6 (q, C-29), 21.5 (q, C-30), 106.6 (t, C-
31) 
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Zusammenfassung 
 
 
 
Zusammenfassung 
Die vorliegende Arbeit hatte zum Ziel neue natürliche Pilzsekundärmetabolite 
aufzufinden, die auf klinisch relevante Targets (Entzündungen und Infektionen) 
und/oder gegen Mikroben- bzw. Viren wirken.    
 
Entzündungshemmende Verbindungen 
Gelenkrheumatismus ist eine chronische Entzündungskrankheit, die bis zu 1% der 
Bevölkerung betrifft, mit einer Häufigkeit von 3:1 bei Frauen mehr als bei Männern 
auftritt und keine bekannte Therapie hat. Es gibt zwar bereits eine Anzahl von 
Wirkstoffen mit kleinem Molekulargewicht zur Behandlung der Symptome, diese 
zeigen aber nur begrenzte Wirkung  und viele Nebenwirkungen. Die auf der 
Hemmung der Schlüsselenzyme (3α-Hydroxysteroid dehydrogenase (3α-HSD), 
Cyclooxygenase I (COX-1) and Cyclooxygenase II (COX-2)) basierende Therapie, 
die auf die Biosynthese der Prostaglandine wirkt, hat sich als relativ sicher und 
wirksam bei zahlreichen Entzündungskrankheiten erwiesen. Im Gegensatz zum 
Gelenkrheumatismus entsteht Gichtrheumatismus durch die Kristallisierung der 
Harnsäure (UA) in den Gelenken. Die Therapien dieser Form von Rheuma basieren 
entweder auf der Zunahme der Harnausscheidung der UA oder auf der Blockierung 
der letzten Biosyntheseschritte von UA durch  Xanthin-Oxidase-Hemmungen (XO-
Hemmung). Der einzige klinisch verwendbare XO-Inhibitor Allopurinol verursacht 
schwere Nebenwirkungen. Deswegen ist es erstrebenswert, eine spezielle, auf diese 
Enzyme gerichtete Wirkstoffe (mit kleinem Molekulargewicht) zu entwickeln, die als 
Leitstruktur für neue Entzündungsmittel und Rheumamedikamente dienen können. 
Um dieses Ziel zu erreichen, wurden nach einer 3α-HSD-Analyse sechs Pilzstämme,  
Epicoccum sp HKI 0470, Aspergillus sp HKI 0472, Inonotus sp, Pholiota squarrosa, 
Phellinus pini DSM 5238 und Piptoporus, betulinus, ausgewählt. 
  
Epicoccum sp. HKI 0470 
Neben den bereits bekannten Verbindungen Epicoccamide (27), Epicoccine (28) und 
Orevactaene (31), wurden aus Epicoccum sp. HKI 0470 zwei neue Metabolite 
Epicoccone B (29) and Epicoccalone (30) isoliert. 
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Während 29, 30 und 31 nur geringe Hemmungswirkung auf die 3α-HSD zeigten, 
wurde bei 30 Serin-Protease-Hemmung (α-Chymotrypsin) beobachtet. Es muss an 
dieser Stelle festgestellt werden, dass es einen Zusammenhang zwischen der Serin-
Protease-Hemmung, der Regulierung der Entzündung, dem Aufbau der 
Abwehrkräfte im Falle einer Infektion der Wiederherstellung des Gewebes und der 
Synthese zusätzlicher Kernzellen gibt. 
 
Aspergillus sp. HKI 0472 
Aus dem Stamm Aspergillus sp. HKI 0472 wurden drei Verbindungen isoliert: 
Funalenine (48), TMC-256C2 (50) und TMC-256A1 (51). Während TMC-256C2 (50) 
und TMC-256A1 (51) keine entzündungshemmende Wirkung zeigten, erwies sich 
das neue Funalenin mit dem ungewöhnlichen Aufbau als wirksames 
entzündungshemmendes Mittel. Es hemmt 3α-HSD, COX-1 und COX-2 mit den IC50 
Werten von 52 µM bzw. 36 µM und 45 µM. 
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Inonotus sp. (Fruchtkörper) 
Beim Vorscreening zeigte der Essigester Extrakt der Pilzart Inonotus sp. eine starke 
entzündungshemmende Wirkung. Die Bereinigung durch Bioanalyse führte zu der 
Isolierung von 5 Verbindungen von denen drei neu waren: Inonotic säuremethylester 
ester (52), Inotilon (53), und Isohispidin (58). Die bereits bekannten Verbindungen 
sind (E)-4-(3,4-Dihydroxyphenyl)but-3-en-2-one (56) und Hispidin (57).  
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Alle diese Verbindungen zeigten eine starke COX-Hemmungswirkung speziell bei 
COX-2. Es soll hier hervorgehoben werden, dass 53 und 57 selektiv das COX-2-
Enzym mit Konzentrationen hemmen, die genauso niedrig sind, wie die der 
vermarkteten selektiven Inhibitoren Meloxicam und Nimesulide. In allen Fällen bis auf 
53 wurde eine starke 3α-HSD-Hemmungswirkung festgestellt, sowie eine schwache 
Inhibition von XO, bis auf 57, wo eine Hemmung festgestellt wurde, die mit der des 
Standards Allopurinol vergleichbar ist.  
 
Pholiota squarrosa (Fruchtkörper) 
Die neue Verbindung mit dem Namen Squarrosidin (65) ist der einzige Metabolit, der 
aus dem Pilz Pholiota squarrosa anhand der von der Bioaktivität geleiteten 
Chromatographie isoliert werden konnte. Die Verbindung ist ein Bishispidin-Derivat 
mit einer seltenen Methylenbrücke. 65 zeigt starke 3α-HSD, COX-1, COX-2 und XO-
Hemmungswirkung mit einem IC150 Wert von 8.1, 0.02, 0.04 bzw. 8.1 µM.  
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Phellinus pini DSM 5238 
Drei Verbindungen wurden aus dem filamentösen Pilz Phellinus pini DSM 5238 
isoliert. Es sind Pinillidin (72) (eine bekannte Struktur, deren analytische Daten aber 
in der Fachliteratur noch nicht vorliegen), Pinillic säure (73), ein neuer Metabolit, und 
das bereits bekannte Hypholomin B (74). Während 73 keine entzündungshemmende 
Wirkung zeigte, stellen 72 und 74 potente Inhibitoren der 3α-HSD und XO. dar. 
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Piptoporus betulinus (Fruchtkörper) 
Die Fraktionierung des Essigester Extrakts des Piptoporus betulinus führte zur 
Isolierung von 5 Lanostanoid-artigen Triterpenen, von denen zwei neu sind: 
Acetylpolyporenicsäure A (76) und (25S)-(+)-12α-Hydroxy-3α-methylcarboxyacetat-
24-methyllanosta-8,24(31)-dien-26-oik säure acid (77)). Die bereits bekannten 
Verbindungen sind Polyporenicsäure A (75), (25S.3’S)-(+)-12α-Hydroxy-3α-(3’-
hydroxy-4’-methoxycarbonyl-3’-methylbutyryloxy)-24-methyllanosta-8,24(31)-dien-26-
oik säure (78) und Polyporenic säure C (79). 76 und 77 zeigten bemerkenswerte 
Hemmungswirkungen bei 3α-HSD. Bemerkenswert ist die Tatsache, dass 76 eine 
noch stärkere Wirkung zeigte als das Referenzmittel (Indomethacin). 
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Die vorliegende Untersuchungsreihe, die zum Zweck hatte, neue 
entzündungshemmende Verbindungen zu finden, führte zur Isolierung von 22 
Verbindungen, von denen 10 neu sind. Von diesen Verbindungen erwiesen sich 7 als 
vielversprechende entzündungshemmende Wirkstoffe: Funalenine (48), Inonotic 
säuremethyester (52), Inotilon (53), Isohispidin (58), Squarrosidin (65), 
Acetylpolyporenic säure A (76) und (25S)-(+)-12α-Hydroxy-3α-methylcarboxyacetat-
24-methyllanosta-8,24(31)-dien-26-oik säure (77). Zudem wurden Hispidin (57), (E)-
4-(3,4-dihydroxyphenyl)but-3-en-2-one (56), Pinillidine (72) und Hypholomine B (74) 
zum ersten Mal als entzündungshemmende Wirkstoffe beschrieben. 
 
Infektionshemmende Verbidungen 
Trotz der Erfolge bei der Behandlung einiger Infektionskrankheiten bleibt die Suche 
nach neuen Arzneimitteln gegen Viren und Mikroben ein wichtiges Gebiet, da es für 
viele Infektionskrankheiten keine wirksame Behandlung gibt. Das auftreten von 
resistenten Mutanten erfordert die Entdeckung neuer Arzneimittel. Um neue 
antibakterielle Verbindungen zu identifizieren, wurden zwei Pilzarten Trichoderma 
crassum HKI 0471 und Lepista nebularis HKI 0411 mittels antifungalen und 
antibakteriellen Vorscreenings ausgewählt. 
 
Trichoderma crassum HKI 0471 
Drei bereits bekannte Metabolite, β-Viridin (13), α-Viridin (14) und CAF 603 (19) 
wurden aus Trichoderma crassum HKI 0471 isoliert. Diese Metabolite zeigten eine 
starke antifungale Wirkung gegen Candida albicans ATCC 18804 und 
Sporobolomyces salmonicolor SBUG 549. 
Zusammenfassung 
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Lepista nebularis HKI 0411 
Neben zu der neuen antiviralen Metabolite (Nebularic säure A (32)), wurden auch 
starke antimikrobielle Metabolite (Diatretyne (47)) aus Lepista nebularis (HKI 0411) 
isoliert. 
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32 zeigt eine starke Wirkung gegen Viren und den Cosackievirus mit einem IC50 Wert 
von 6 µM, und Diatretyne (47) zeigt eine deutliche Wirkung gegen Pilze und 
bakterielle Entwicklung bei Candida albicans ATCC 18804 (MIC = 25 µg/ml), multi-
resistente Streptococcus aureus (MIC = 1.56 µg/ml) und Mycobacterium vaccae (MIC 
= 6.25 µg/ml). Diatretyn zeigt auch zytotoxische und antiproliferative Wirkung. 
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